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Clostridioides difficile infection (CDI) is the leading cause of infective antibiotic-
associated diarrhoea and is responsible for significant patient morbidity and 
mortality. Despite appropriate antimicrobial therapy, CDI recurs in 
approximately 20-30 % of cases, suggesting that C. difficile can occupy a 
protective niche whereby antimicrobial therapy is ineffective. Biofilms represent 
such a potential niche. We sought to determine the role of biofilms in recurrent 
CDI (rCDI) and how the sessile community can affect C. difficile biofilm 
formation. 
A triple stage chemostat model of the human colon was used to predict the 
efficacy of a simulated faecal microbiota transplantation (FMT) and two 
different dosing regimens of a spore consortium, SER-109, to prevent rCDI and 
to define a role for biofilms in rCDI. Planktonic and biofilm communities were 
individually analysed using culture-based techniques and bacterial taxonomic 
sequencing. Bile acid levels were monitored to investigate potential 
mechanisms of efficacy. A biofilm batch culture assay was used to investigate 
the influence of biofilm-associated microbiota on C. difficile biofilm formation.  
Results show that FMT and a triple dose of SER-109 successfully prevented 
rCDI, potentially due to reducing the levels of primary bile acids through 
conversion to secondary bile acids. Despite the ability of microbiome therapies 
to prevent rCDI, they failed to eradicate C. difficile from the biofilm, suggesting 
a risk of future CDI. The biofilm-associated C. difficile was able to seed the 
planktonic phase, resulting in C. difficile germination and proliferation, which 
proved to be sufficient to induce CDI. Biofilm batch culture experiments indicate 
that commensal biofilm populations can reduce or increase C. difficile biofilm 
formation and growth, which required the presence of viable cells.  
We conclude that biofilms provide a protective niche for C. difficile, which 
facilitates CDI recurrence, and that patients undergoing microbiome-based 
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Chapter 1 Introduction  
1.1   Clostridium difficile  
1.1.1 History  
Clostridium difficile was first isolated from the stool of healthy neonates by Hall 
and O’Toole in 1935. Originally named ‘Bacillus difficilis’ due to the difficulty 
experienced when isolating and culturing the organism, they found that the 
bacterium was highly pathogenic to animals (Hall and O'Toole, 1935). Hall and 
O’Toole suggested the pathogenicity of this obligate anaerobe was mediated 
through the action of a toxin, which was later confirmed by Snyder in 1937 
(Snyder, 1937) who further described it as a Gram-positive, spore forming 
bacillus that produced a heat labile exotoxin. They also observed that this 
bacterium was found as part of the commensal flora of roughly 10 % of infants, 
carried asymptomatically. However, the link between C. difficile and human 
disease was not established for another four decades.   
The earliest reports of pseudomembranous colitis (PMC) occurred in 1983 
when Finney, a surgeon at Johns Hopkins Hospital, described a case of 
‘pseudodiphtheritic enteritis’ of the ileum and colon of a patient (Finney, 1983). 
Subsequently, various reports of a similar nature emerged with the cause 
attributed to staphylococcal enterocolitis, vascular insufficiency and neonatal 
necrotizing enterocolitis (Gorbach, 2014). The association between diarrhoea 
and colitis with antibiotic treatment became apparent in 1973 with cases of 
pseudomembranous colitis linked to prior use of lincomycin (Scott et al., 1973) 
and clindamycin (Tedesco et al., 1974). This was further demonstrated using a 
hamster model of clindamycin-associated colitis, revealing the role of a toxin-
producing species of Clostridium (Bartlett et al., 1977). Studies on the stool of 
patients with PMC revealed the cause to be a bacterial produced toxin, which 
effects could be neutralised by gas-gangrene antitoxin (Larson et al., 1977, 
Larson and Price, 1977, Bartlett et al., 1978). This neutralising effect was later 
attributed to Clostridium sordellii antitoxin, and hence C. sordellii was believed 
to be the aetiological agent in PMC; however, it could not be recovered from 
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the stool of patients (Rifkin et al., 1977). C. difficile was later isolated in large 
quantities from patients with antibiotic-associated colitis and was demonstrated 
to produce a cytotoxin that could be neutralised by C. sordellii antitoxin and 
hereby found to be the aetiological agent in antibiotic-associated diarrhoea and 
colitis (George et al., 1978a, George et al., 1978b, Bartlett et al., 1979) 
C. difficile is now recognised as the leading cause of infective antibiotic-
associated diarrhoea in the healthcare setting; however, reports of community 
acquired CDI rates are increasing (Ofori et al., 2018). Highly resilient spores 
and recalcitrance to antibiotic treatment has led to the persistence of C. difficile 
infection (CDI) in susceptible patients and healthcare facilities, leading to 
significant morbidity, mortality and economic burden worldwide. Although 
officially renamed Clostridioides difficile in 2016 (Lawson et al., 2016), 
Clostridium difficile is still the preferred name in current literature and therefore 
will be referred to as such in this thesis.  
1.1.2 Clinical manifestations and risk factors  
CDI can present in a variety of disease states, ranging from mild self-limiting 
diarrhoea to life threatening complications and death. The wide range of clinical 
manifestations of CDI is a result of host-specific factors (immune status, age 
and underlying medical conditions) and virulence of the infecting strain. CDI is 
responsible for between 15-25 % of antibiotic-associated diarrhoea (AAD) 
(Bartlett and Gerding, 2008) and in the majority of cases symptoms appear a 
few days after antibiotic use; however, onset may occur concurrently with 
antibiotic treatment or several weeks following a treatment course (Mogg et al., 
1979). Initial symptoms include watery diarrhoea, raised white blood cell 
counts, raised temperature and fever, hypoalbuminaemia and abdominal 
discomfort that can rapidly progress to extensive colonic inflammation (Mogg et 
al., 1979, Bartlett et al., 1980). C. difficile is the leading cause of PMC, an 
advanced stage of CDI, in which lesions of immune cells, necrotic tissue and 
mucous form plaques that combine in a pseudomembrane, accompanied by 
fever and leucocytosis (Farooq et al., 2015). In some cases, fulminant colitis 
occurs, manifesting as acute toxic colitis with colonic and abdominal distension, 
leading to toxic megacolon, colonic perforation, toxic shock and death (Dallal et 
al., 2002). Conversely, C. difficile may be carried without causing clinical 
symptoms (asymptomatic carriage).  
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One of the most significant risk factors for the development of CDI is the use of 
antibiotics (Spencer, 1998). Antibiotics with the highest risk of predisposing to 
CDI include ampicillin, amoxicillin, third-generation cephalosporins, clindamycin 
and fluoroquinolones (de Lalla et al., 1989, Pepin et al., 2005, Vardakas et al., 
2012, Leffler and Lamont, 2015). The tendency of certain antibiotics to 
contribute to the development of CDI could be due to the effect they have on 
the hosts’ microbiome and no activity against C. difficile, with increased 
microbiota disruption linked to increased rates of CDI (Pultz and Donskey, 
2005). Advanced age was also highlighted as one of the major risk factors in 
the development of CDI (McFarland et al., 1999). A prospective population-
based analysis in Sweden showed that CDI incidence increased 10 fold over 
60 years of age (Karlstrom et al., 1998). Other risk factors for the development 
of CDI include severe underlying conditions, hospitalisation (especially 
admittance to the intensive care unit), long-term care facility residence, 
gastrointestinal (GI) surgery, inflammatory bowel disease, use of gastric acid 
suppressants, immunosuppression and immunodeficiency (Brown et al., 1990, 
Fekety and Shah, 1993, McFarland et al., 1999, Rupnik et al., 2009, 
Vesteinsdottir et al., 2012, Tariq et al., 2017) 
1.1.3 CDI recurrence 
Despite appropriate antimicrobial therapy, CDI can recur in approximately 20 – 
30 % of cases (Kelly and LaMont, 2008, Cornely et al., 2012b). In addition, the 
risk of further recurrent CDI (rCDI) increases with each subsequent episode 
(McFarland et al., 1994, McFarland et al., 2002), reaching up to 40 – 60 % 
(Figure 1-1). rCDI has a significant impact on patients and healthcare 
resources (Kelly and LaMont, 2008, Wilcox et al., 2017a), with a higher risk of 
mortality compared to first episode CDI (36 % vs 26 %, p < 0.001) (Olsen et al., 
2015). rCDI is defined as an additional episode of CDI occurring within 8 weeks 
of a previous episode (Debast et al., 2014). The majority of recurrences were 
found to be caused by the same strain isolated in the original episode of CDI, 
with studies suggesting that in over 80 % of cases, the original strain was 
responsible for recurrences rather than reinfection with a different strain 
(Figueroa et al., 2012). More recently, an extended period of 20 weeks instead 
of the current 8 weeks was proposed to distinguish rCDI with the same strain 
from reinfection with a different strain (Durovic et al., 2017).  
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It is believed that rCDI is linked to prolonged intestinal dysbiosis caused by the 
antibiotics used to treat the initial infection (Kelly and LaMont, 2008). 
Recurrence rates were similar in patients treated with either metronidazole or 
vancomycin for their initial episode; whereas fidaxomicin has a significantly 
lower risk of recurrence, most likely due to the relative narrow spectrum of 
activity causing less disruption to the microbiota and its anti-sporulation effects 
(Kelly and LaMont, 2008, Louie et al., 2011, Cornely et al., 2012a, Zhanel et al., 
2015). The host’s immune response has also been implicated in the risk of 
developing rCDI, with increased levels of antibodies against either toxin A or 
toxin B resulting in a protective effect against rCDI (Kyne et al., 2001, Gupta et 
al., 2016). A human monoclonal antibody against C. difficile toxin B 
(bezlotoxumab) used as an adjunctive therapy alongside standard-of-care 
therapy, showed a 38 % lower rate of rCDI than that associated with standard-
of-care therapy alone (Wilcox et al., 2017b). Interestingly, the human 
monoclonal antibody against C. difficile toxin A (actoxumab) showed no 
protective effect against rCDI and had no additional benefit when added in 
combination with bezlotoxumab, suggesting a stronger role for toxin B in CDI in 
humans. 
 
Figure 1-1. The C. difficile recurrence escalator. In patients with CDI, there 
is an increased risk of further disease recurrence with each subsequent 
episode of rCDI. Initially, there is a 25-30 % risk of recurrence; however, 
after one episode of rCDI, the risk of another episode increases to 40 % 




1.1.4 Epidemiology  
The epidemiology of C. difficile in the UK has changed dramatically in the last 
10-15 years. During 2003-2004, the first known large outbreak of CDI occurred 
at the Stoke Manderville Hospital (Buckinghamshire Healthcare NHS Trust), 
with 174 CDI cases and 19 deaths followed by another outbreak during 2004-
2005 of 160 cases with 19 deaths, attributed to the hyper-virulent C. difficile 
ribotype 027 (Smith, 2005). This increased incidence and mortality rate of CDI 
highlighted the need for closer monitoring of CDI cases and improved infection 
prevention measures as poor practice in infection control was implicated in both 
outbreaks. As such, mandatory surveillance and reduction targets for CDI were 
implemented as well as the C. difficile Ribotyping Network (CDRN) to type 
isolates in order to identify outbreaks and map C. difficile epidemiology. 
Epidemiological studies since the introduction of C. difficile monitoring and 
surveillance programmes have demonstrated a shifting pattern in ribotype 
incidence (Freeman et al., 2010). During the years of 2007-2008, 2008-2009 
and 2009-2010, ribotype 027 predominated; however, incidence decreased 
dramatically (55 %, 36 % and 21 %, respectively) (Wilcox et al., 2012), in line 
with a decrease in overall mortality. This was also accompanied by a reduction 
in cephalosporin and fluoroquinolone use, indicating improved antibiotic 
stewardship and prescribing practices that were preventative for CDI.  
During 2007-2010, the predominant circulating ribotypes in England included, 
in order of prevalence, ribotypes 027, 106, 001, 014/020, 015, 002, 078, 005, 
023, 016 (Wilcox et al., 2012). Looking at the period from 2008 – 2018, there 
was a reduction in the prevalence of ribotypes 027, 001 and 106, with 
compensatory increases in other ribotypes, giving England a more 
heterogeneous distribution of ribotypes, with predominant ribotypes including 
002, 014/020, 015, 005, 023 and 078, levels of which have remained relatively 
stable for the last approximately 3 years (Public Health England, CDRN 2015-
2018 report). The shift from the predominant 027 ribotype to a more diverse 
occurrence of ribotypes reflects the improved infection prevention and antibiotic 
prescribing practises and highlights the increasing rate of community onset CDI 
(Davies et al., 2016) in the UK. A total decrease of 77.9 % in CDI rates from 
2007/2008 – 2018/2019 was reported; however, this decrease was mainly seen 
in the hospital setting as community-onset cases are on the increase and 
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reportedly constitute 66% of cases, increasing from 57.3 % in 2011/2012 
(Public Health England, 2019). 
The European, multicentre, prospective, biannual, point-prevalence study of 
Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID), 
looked at the distribution of C. difficile isolates in Europe which included 19 
European countries. They identified125 distinct ribotypes with considerable 
inter-country variation in distribution of ribotypes. 027 (19 %) was the 
predominant strain, followed by 001/072 (11 %) and 014/020 (10 %) and the 
following contributing ≤ 5 % prevalence: 002, 140, 010, 078, 176 and 018  
(Davies et al., 2016). Across Europe, the prevalence of the 027 ribotype has 
increased over three fold since 2008 with Germany, Hungary, Poland and 
Romania being most affected, accompanied by a decrease in ribotype diversity 
(Davies et al., 2016).  
1.1.5 Pathogenesis  
CDI is mediated through the faecal-oral transmission of spores. C. difficile 
spores are ubiquitous in the environment, especially in healthcare settings 
(Weber et al., 2013). Spores are incredibly resilient and highly resistant to 
environmental pressures including high temperatures and standard disinfection 
procedures (Fawley et al., 2007, Edwards et al., 2016, Dyer et al., 2019). 
Environmental contamination with C. difficile spores, particularly in a hospital 
setting, is mediated through shedding of spores from symptomatic CDI patients 
as well as direct transfer to health care workers (Kim et al., 1981, Kaatz et al., 
1988, McFarland et al., 1989, Best et al., 2010, Landelle et al., 2014), 
facilitating the transmission and recurrence of CDI (Figure 1-2). After ingestion, 
spores can survive the acidic pH of the gastric tract, allowing them to pass into 
the large intestine (Paredes-Sabja et al., 2014).  If the conditions in the 
intestine are conducive, spores are able to germinate into a vegetative 
morphotype which then proliferate and produce toxin, resulting in active CDI. 
Certain strains of C. difficile are non-toxigenic and lack the genes required to 
express the toxins.    
The ability of C. difficile spores to germinate and colonise the colon is largely 
dependent on the host microbiota and associated metabolome (Buffie et al., 
2015, Theriot and Young, 2015) The intestinal tract is home to a myriad of 
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microbial populations, and the conservation of these communities is vital in 
maintaining host health. In a healthy host, the microbiota is able to protect the 
host against the incursion of pathogens by establishing colonisation resistance 
and competing for space and nutrients. If there is disruption to the host 
microbiota, for example antibiotic-induced dysbiosis, this can create an 
environment conducive to CDI (Theriot et al., 2016). The propensity of C. 
difficile spores to germinate is largely dependent on the presence of certain 
primary bile acids. Primary bile acids, cholic acid and chenodeoxycholic acid, 
are derivatives of cholesterol synthesised by the liver and facilitate the 
absorption of lipids and lipid-soluble vitamins in the intestine. The majority of 
these bile acids are reabsorbed by the intestine; however, roughly 5 % of these 
non-reabsorbed primary bile acids undergo 7 α-dehydroxylation by resident 
anaerobic populations to form the secondary bile acids deoxycholic acid and 
lithocholic acid (Chiang, 2009). In vitro, primary bile acids such as taurocholate 
together with co-germinants such as glycine, stimulate C. difficile spore 
germination through interactions with the CspC receptor located on the spore 
coat or outer membrane (Sorg and Sonenshein, 2008, Francis et al., 2013). 
Conversely, gut microbiota-derived secondary bile acids inhibit spore 
germination and vegetative growth of C. difficile cells. Intestinal dysbiosis, 
commonly caused by the use of antimicrobials, results in depletion of the 
populations responsible for the conversion of primary to secondary bile acids, 
leading to the accumulation of primary bile acids in the intestine, stimulating C. 
difficile germination and outgrowth. In a study assessing levels of bile acids, it 
was found that primary bile acids were significantly elevated in patients with 
CDI and rCDI whereas secondary bile acids were elevated in healthy controls 
(Allegretti et al., 2016).  
Germination of C. difficile spores is then followed by colonisation and 
outgrowth, mediated by various adhesion and colonisation factors. C. difficile 
expresses a vast array of virulence factors that aid in survival through the 
stomach, adhesion to mucosal surfaces and colonisation of the host. 
Colonisation is facilitated by evasion of the hosts innate defences and the 
expression of various colonisation factors including fibronectin-binding proteins, 
cell surface layer proteins and polysaccharides, cell-wall proteins and flagella 
(Vedantam et al., 2012). Not all patients colonised with C. difficile are 
8 
 
symptomatic, but may contribute to the transmission of the disease (Leffler and 
Lamont, 2015). The symptoms of CDI are mainly attributed to the production 
toxins. These toxins cause damage to the hosts epithelial cell cytoskeleton, 
causing disruption to the to the tight junctions between the cells resulting in 
fluid loss and a loss of gut barrier integrity (Czepiel et al., 2019).  
 
 
                 
Figure 1-2. C. difficile transmission and pathogenesis in the human 
gastrointestinal tract. The three main sources of C. difficile spores are 
indicated and include health care settings, animal reservoirs and the 
environment. The life cycle of C. difficile is illustrated as well as the 




1.1.6 Virulence factors  
1.1.6.1 Toxins  
The symptoms of CDI are caused by the production of toxins. C. difficile can 
produce up to three toxins, namely enterotoxin toxin A (Tcd A), cytotoxin toxin 
B (TcdB) and the binary toxin (CDT).  
Toxin A and toxin B  
TcdA and TcdB belong to the family of large clostridial glucosylation toxins 
which target the actin cytoskeleton of the hosts’ epithelial cells through 
inactivation of guanosine triphosphatases (GTPases). Historically, TcdA was 
viewed as the more potent of the two toxins, with administration of purified toxin 
to rabbit and rodent models eliciting a more toxic effect than that of TcdB 
(Lyerly et al., 1985, Mitchell et al., 1986, Triadafilopoulos et al., 1987). The 
reverse was seen in models using human colonic tissue which suggests 
differences in receptor binding in animal and human models and it was found 
that TcdB alone is able to induce the phenotype of CDI (Riegler et al., 1995).  
TcdA (308 kDa) and TcdB (270 kDa) are highly related, with 48 % identity and 
63 % similarity in amino acid sequence (von Eichel-Streiber et al., 1992, Jank 
and Aktories, 2008, Pruitt et al., 2010). Both toxins are comprised of four major 
functional domains; an amino-terminal glucosyltransferase domain (GTD) that 
modifies host Rho-GTPases, a cysteine autoprotease domain (APD), a pore-
forming and delivery domain and a combined repetitive oligopeptides (CROPs) 
domain for receptor binding (Figure 1-3) (Jank and Aktories, 2008, Chumbler et 




Figure 1-3. Structure of C. difficile toxins A (tcdA) and B (TcdB). (a) Gene 
sequence of C. difficile toxin A (TcdA) and toxin B (TcdB), illustrating four 
domains including the glucosyltransferase (GTD - domain A), the 
combined repetitive oligopeptides (CROPS, domain B), an autoprotease 
(domain C) and the delivery/binding (domain D). (b) The crystal structure 
of domains A, C and D of TcdA and (c) a model of the full toxin.  Image 
from Aktories et al. (2017).  
 
Mechanism of action 
Once the toxins are secreted, they enter the colonic epithelium via PACSIN2-
mediated endocytosis (TcdA) (Chandrasekaran et al., 2016) and clathrin-
mediated endocytosis (TcdB) (Papatheodorou et al., 2010). Receptor binding is 
mainly associated with the CROPs domain which is able to bind carbohydrate 
residues. Although similar, the CROPs domains for TcdA and TcdB differ in 
spatial and sequential arrangements, indicating that receptors for the toxins are 
different (Chaves-Olarte et al., 1997). TcdA receptors identified include 
GalNAc-(1,3)-β-Gal-(1,4)-β-GlcNAc; Lewis I, X and Y glycan sequences; and 
glycoprotein gp96 (Tucker and Wilkins, 1991, Teneberg et al., 1996, Smith et 
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al., 1997, Na et al., 2008). Domains other than CROPs have been associated 
with binding the toxins, as TcdA and TcdB lacking a CROPs domain are still 
capable of cytotoxic effects, however with less potency (Olling et al., 2011). 
The receptors identified for TcdB to date include three protein receptors; the 
poliovirus receptor-like protein 3 (PVRL3) which is expressed on the surface of 
colon epithelial cells; chondroitin sulphate proteoglycan 4 (CSPG4) which is 
expressed in the intestinal sub epithelium, indicating that CSPG4 binding 
occurs once the epithelium is damaged; and the Frizzled (FZD) receptor 
involved in the Wnt signalling pathway (LaFrance et al., 2015, Yuan et al., 
2015, Tao et al., 2016). Acidification of the endosome results in a structural 
change in the delivery domain, resulting in the translocation of the GTD and 
APD domains across the membrane (Pruitt et al., 2010). The APD domain then 
binds eukaryotic inositol-hexakisphosphate (InsP6) which releases the GTD 
domain into the cytosol through cysteine protease activity (Egerer et al., 2007, 
Shen et al., 2011).  
Once internalised, the GTD domain transfers glucose from uridine diphosphate 
(UDP) glucose onto Rho proteins at threonine 35 [Rac and cell division control 
protein 42 (CDC42)] and threonine 37 (Rho A,B and C) (Just et al., 1995a, Just 
et al., 1995b). Rho proteins are GTP-binding proteins and regulate the cell 
cytoskeleton and transcription as well as cell-cycle progression and apoptosis 
(Jaffe and Hall, 2005). Glucosylation of Rho proteins interferes with the ability 
of Rho to interact with their effector molecules. Cytopathic effects include 
alterations in the cytoskeleton through the redistribution of actin and the loss of 
stress fibres leading to alterations in tight junctions, cell shrinkage and 
disruption to barrier function (Ottlinger and Lin, 1988, Hecht et al., 1992, Nusrat 
et al., 1995, Nusrat et al., 2001). TcdA and TcdB, through the activation of 
caspase enzymes and inactivation of RhoA, can induce apoptosis (Hippenstiel 
et al., 2002, Gerhard et al., 2008).  
In addition to direct cytopathic effects, TcdA and TcdB also provoke a 
significant inflammatory response that leads to tissue damage and necrosis 
through the induction of pro-inflammatory cytokine IL-1β. Once the toxins are 
recognised in the cell, the assembly of a multi-protein complex called the 
inflammosome is initiated, which is involved in activating inflammation (Ng et 
al., 2010). They also activate hypoxia-inducible factor 1 (HIF-1α), a 
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transcription factor that regulates the expression of genes involved in the 
immune response (Hirota et al., 2010). At high concentrations, TcdB is able to 
induce the assembly of the Nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase complex (NOX) which leads to the generation of reactive 
oxygen species (ROS) and tissue necrosis (Farrow et al., 2013).    
Regulation of toxin expression 
Toxin expression is regulated bidirectionally by environmental and metabolic 
signals (Bouillaut et al., 2015). Inhibition of toxin production occurs via the 
carbon catabolite control protein A (CcpA) and the global transcriptional 
regulator CodY (Dineen et al., 2010) in conditions of high nutrient availability 
and intracellular levels of GTP, including the presence of glucose or amino 
acids such as cysteine or proline (Dupuy and Sonenshein, 1998, Karlsson et 
al., 2000, Antunes et al., 2012). The presence of short-chain fatty acids such as 
butyrate and sub-inhibitory concentrations of certain antimicrobials are known 
to stimulate toxin production (Karlsson et al., 2000, Mani et al., 2002, Aldape et 
al., 2013). Expression of motility-associated sigma factor SigD; sporulation-
associated Spo0A; and quorum signalling also influence toxin gene expression 
(El Meouche et al., 2013, Mackin et al., 2013, Darkoh et al., 2015). Genes 
encoding these toxins are located in a chromosomal region known as the 
pathogenicity locus (PaLoc) (Figure 1-4) which is 19.6 kb in length and 
comprised of five open reading frames (Hammond and Johnson, 1995). In non-
toxigenic strains, this region is replaced by a 115 bp non-coding sequence 
(Braun et al., 1996). The five genes located on the PaLoc include tcdA and 
tcdB which encode toxin A and toxin B respectively; regulatory genes tcdR and 
tcdC; and the gene encoding membrane lysis protein tcdE. All the genes are 
transcribed in the same direction, with the exception of tcdC which is orientated 




Figure 1-4. The pathogenicity locus of C. difficile. Illustration of the 19.6 kb 
pathogenicity locus encoding a positive transcriptional regulator (tcdR), 
toxin B (tcdB), presumed membrane lysis protein (tcdE), toxin A (tcdA) 
and a putative negative transcriptional regulator (tcdC). Image from Kelly 
and LaMont (2008). 
 
tcdR encodes an alternative RNA polymerase sigma factor that is critical for the 
initiation of tcdA and tcdB expression and acts as a positive regulator of toxin 
production (Mani and Dupuy, 2001, Mani et al., 2002). tcdE encodes a 
bacteriophage holin-like protein that facilitates the extracellular release of both 
toxins by forming oligomers in the cytoplasmic membrane (Tan et al., 2001, 
Govind and Dupuy, 2012). The function of tcdC is not fully understood but 
appears to be involved in repression of toxin production. It was noted that high 
levels of TcdC and low levels of TcdA, B, D and E were found during early 
exponential phase, with the reverse seen during stationary phase, suggesting 
that TcdC negatively regulates the transcription of the other genes 
(Hundsberger et al., 1997). The identification of an 18 bp deletion in the tcdC 
gene of the epidemic 027 ribotype which led to a functional disruption of the 
protein, was speculated to be responsible for the hyper production of toxins A 
and B (Warny et al., 2005, MacCannell et al., 2006). The proposed mechanism 
of TcdC mediated toxin repression involves the destabilising the TcdR-
containing RNA polymerase holoenzyme hereby interfering with its ability to 
recognise the promotors for tcdA and tcdB (Matamouros et al., 2007). Further 
studies into the action of TcdC have provided conflicting results (Carter et al., 
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2011, Bakker et al., 2012, Cartman et al., 2012), with a C. difficile strain 630 
containing a mutant tcdC gene not displaying significantly different toxin levels 
when compared to the wild type (Bakker et al., 2012), and a C. difficile 027 
ribotype strain complemented with a fully functional tcdC gene, failed to affect 
toxin levels (Cartman et al., 2012).    
Binary C. difficile transferase toxin  
The binary C. difficile transferase toxin (CDT) is found in approximately 17-23 
% of C. difficile strains, notably in 027 and 078 ribotype strains (Eckert et al., 
2015) and belongs to the binary actin ADP-ribosylating toxin family (Barth et al., 
2004). Presence of CDT in clinical isolates is associated with higher rates of 
disease recurrence and mortality (Gerding et al., 2014). CDT is encoded by two 
genes, cdtA (48 kDa) and cdtB (98.8 kDa) that are located on the binary toxin 
locus (CdtLoc, 4.3 kb) and transcribe the enzymatic and binding/translocation 
region of the toxin, respectively (Perelle et al., 1997, Gonçalves et al., 2004). A 
response regulator gene, cdtR, is located upstream of the Cdt A and B operon 
and acts as a positive regulator of CDT production (Carter et al., 2007). CDT 
negative strains contain a 2.3 kb deletion in this locus (Stare et al., 2007). The 
host cell receptor for CDT was identified as the lipolysis-stimulated lipoprotein 
receptor (LSR) (Papatheodorou et al., 2011). The mechanism of toxin entry is 
not fully understood; however as the translocation component of this toxin 
shares similarity with the iota toxin of C. perfringens, it is believed that the 
binding/translocation domain interacts with LSR where it accumulates in lipid 
rafts, followed by oligomerisation and binding of the enzymatic component. This 
complex is then internalised in endosomal compartments and acidification of 
the endosome results in pore formation and translocation into the cytosol 
(Nagahama et al., 2000, Hale et al., 2004). Translocation of the enzymatic 
portion of the toxin is dependent on host cell helper proteins including the 
chaperone protein Hsp90 (Haug et al., 2004) and cyclophilin A (Kaiser et al., 
2011). Once in the cytosol, CDT is able to irreversibly ADP-ribosylate G-actin 
monomers at arginine-177 (Gulke et al., 2001), acting as a capping protein and 
causing depolymerisation of the actin filament resulting in the destruction of the 




The ADP-ribosylation of actin by CDT influences the dynamics of the 
microtubules within the cell. Microtubules growth towards the cell membrane is 
inhibited by contact with cortical actin; however, the presence of CDT disrupts 
the capture function of cortical actin, resulting in long protrusions developing 
from the cells (Siegrist and Doe, 2007). The destruction of the cytoskeleton and 
development of microtubule protrusions have been shown to increase bacterial 
adherence and attachment to the cell, and therefore may have a role in 
colonisation (Schwan et al., 2009).  
1.1.6.2 Spores 
During nutrient limitation, C. difficile forms spores that are metabolically 
dormant, aero tolerant and highly resilient to environmental pressures including 
high temperatures and standard disinfection procedures, allowing C. difficile to 
survive and persist in the environment (Sorg and Sonenshein, 2008, Lawley et 
al., 2009b). Deakin et al., (2012) demonstrated that a sporulation deficient 
strain of C. difficile was unable to persist in the environment or transmit 
between hosts. Environmental reservoirs of C. difficile spores include direct and 
indirect (hands and shoes) transfer of spores from symptomatic patients in the 
health care setting, asymptomatic human carriers in the community and 
hospital setting, zoonotic origins and the food chain (Brown and Wilson, 2018, 
Ofori et al., 2018, Sheth et al., 2019).  
Spore architecture is largely conserved between bacterial species. In the centre 
lies a partially dehydrated core containing supercoiled DNA bound in acid 
soluble proteins to protect the DNA and block transcription (Nicholson et al., 
1990, Setlow and Setlow, 1993, Moeller et al., 2009). High concentrations of 
calcium dipicolinic acid are also found in the spore core and contributes to heat 
resistance in Bacillus subtilis (Setlow et al., 2006). This core is surrounded by 
an inner membrane, a germ cell wall and the spore cortex, the latter containing 
modified peptidoglycan to facilitate hydrolysis by cortex lytic enzymes (CLE) 
during germination (Meador-Parton and Popham, 2000, Chirakkal et al., 2002). 
The spore coat surrounds the cortex and some strains contain an outer 
exosporium layer which plays a role in adhesion and interaction with the host 
(Díaz-González et al., 2015).  
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C. difficile spores are resistant to gastric acid and can survive the passage 
through the upper GI tract to the small intestine. Here, they come in contact 
with germinants that act on receptors located in the inner spore membrane, 
leading to the efflux of monovalent cations and CaDPA and subsequent 
rehydration of the spore core. Activation of CLEs leads to degradation of the 
peptidoglycan wall to enable active metabolism of the spore core and facilitates 
the switch to a vegetative morphotype. Increased sporulation rates have been 
implicated in the virulence and severity of the epidemic ribotype 027 (Åkerlund 
et al., 2008, Merrigan et al., 2010); however, this has been disputed with 
studies finding no significant difference in sporulation rates when compared to 
other non-epidemic ribotypes (Burns et al., 2010, Sirard et al., 2011). Burns et 
al., demonstrated high variability in sporulation rates between and within 
ribotype groups (Burns et al., 2011), highlighting the difficulty in drawing 
conclusions between sporulation and disease severity.      
1.1.6.3 Resistance to the hosts innate defences  
Mucosal surfaces are particularly vulnerable to infection, therefore the mucosal 
immune system is a vital defence against pathogens. The tightly packed 
epithelial layer of the intestinal tract secretes antimicrobial peptides into the 
mucous layer, providing a layer of physical and biochemical defence against 
invading pathogens. In order to colonise host mucosal surfaces in the gut, 
bacteria must overcome the antimicrobial agents generated by the hosts’ innate 
immune response, including lysozyme and cationic antimicrobial peptides 
(CAMPs). 
Lysozyme is as a peptidoglycan hydrolase secreted at high levels in mucosal 
surfaces, causing disruption to the bacterial cell wall through cleavage of 
peptidoglycan at the MurNAc and GlcNAc linkage in the bacterial cell wall. To 
prevent peptidoglycan hydrolysis, C. difficile is able to modify the peptidoglycan 
in its cell wall to inhibit the action of lysozyme. This is accomplished by N-
acetylglucosamine deacetylation of peptidoglycan, mediated by the 
deacetylase PdaV and regulated by expression of csfV gene, encoding the 
extracytoplasmic sigma factor V (Peltier et al., 2011, Ho et al., 2014). CAMPs 
are another antimicrobial agent, including cathelicidin antimicrobial peptide and 
α-definsins. CAMPs mainly target the bacterial cell membrane; however, 
several different mechanisms of action have been suggested, based on the 
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individual peptide structure (Bechinger and Gorr, 2017). Resistance of C. 
difficile to CAMPs include the D-alanyl esterification of teichoic acid; mediated 
by the dlt operon, which results in an increased positive charge of the 
membrane (McBride and Sonenshein, 2011a); and the expression of ABC 
transporters, the CprABC transporter recognises multiple substrates and is 
capable of removing CAMPs from the cell (McBride and Sonenshein, 2011b). 
1.1.6.4 Adhesins  
Adhesion and subsequent colonisation of the GI tract is a precursor to the 
development of disease. C. difficile has been shown to adhere to different cell 
lines and extracellular matrix (ECM) proteins in vitro (Karjalainen et al., 1994, 
Naaber et al., 1996, Drudy et al., 2001, Cerquetti et al., 2002) and in vivo 
(Borriello et al., 1988b, Spigaglia et al., 2013). Borriello et al (1988) 
demonstrated enhanced adherence of a virulent toxigenic C. difficile strain 
when compared to a non-virulent toxigenic strain, highlighting the importance of 
adherence to virulence (Borriello et al., 1988b). Adhesion is mediated by 
bacterial adhesins that are located on the cell surface. C. difficile possesses a 
proteinaceous cell surface layer (S-layer), which is composed of surface layer 
proteins (SLPs) connected in a crystal lattice formation. The S-layer is mainly 
composed of SlpA proteins and the cell wall protein (CWP) family.  
Cysteine proteases, Cwp84 and Cwp13, are responsible for the assembly of 
the S-layer by the cleavage and processing of the precursor molecule SlpA (de 
la Riva et al., 2011). Cwp84 can also be found in the extracellular fraction and 
degrades ECM proteins in vitro, which could aid in the spread of the bacteria 
(Janoir et al., 2007). SLPs are composed of two subunits, namely the low-
molecular weight S-layer protein (LMW-SLP) and the high-molecular weight S-
layer protein (HMW-SLP) (Mauri et al., 1999).  SLPs have been shown to 
facilitate adherence to Hep-2 cells in vitro, mediated mainly by the HMW-SLP, 
with substrates collagen I, thrombospondin and vitronectin identified (Calabi et 
al., 2002). SlpA has been found to be a major contributor to bacterial 
adherence, with pre-treatment of host cells with purified SlpA or incubation of 
vegetative bacteria with anti-SlpA antisera resulting in significantly reduced 
bacterial attachment (Merrigan et al., 2013). SLPs from 027 and 078 ribotypes 
demonstrated high variability in LMW-SLP subunit, leading to an increased 
inflammatory response which could play a role in the hyper-virulence of these 
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strains (Lynch et al., 2017). Cwps are characterised by the presence of a 
conserved binding domain CWB2 that, together with polysaccharide II (PSII), 
anchors the proteins to the bacterial cell surface (Willing et al., 2015). Cwps 
display high genetic variability in response to immune pressure and hence 
contribute to the evasion of host defences (Biazzo et al., 2013). Cwp66 has 
been shown to adhere to Vero cells and its expression is upregulated in 
response to increased temperatures. With antibodies and adhesion fragments 
partially inhibiting C. difficile adherence during cell binding studies, the role of 
Cwp66 in bacterial adhesion was demonstrated (Waligora et al., 2001). CwpV, 
the largest protein of the Cwp family, is composed of a highly variable domain 
across C. difficile strains which mediates the auto-aggregation of C. difficile 
(Reynolds et al., 2011) as well as protection against phage infection (Sekulovic 
and Fortier, 2015). 
The surface-associated fibronectin-binding protein (FnBP) Fbp68 is able to bind 
soluble and immobilised fibronectin which is a major component of the ECM 
and potentially acts as a bridge to the host cells. Anti-Fbp68 antibodies were 
able to partially inhibit C. difficile attachment to fibronectin and Vero cells 
(Hennequin et al., 2003) and pre-treatment of Caco-2 cells with the fibrobectin-
binding domain of Fbp68 blocked bacterial adhesion (Lin et al., 2011), 
providing further evidence for the role in Fbp68 in C. difficile colonisation. 
Interestingly, a FnBP mutant demonstrated increased adherence to Caco-2 and 
HT29-MTX cell lines as well as equivalent faecal shedding and in mouse 
models when compared to the wild type strain (Barketi-Klai et al., 2011), 
highlighting the need for further investigation into the role of FnBPs in 
adherence and colonisation. The collagen-binding protein, CbpA, is another 
surface-associated protein capable of binding components of the ECM, namely 
collagen type I and IV. The ability to bind to collagen was indistinguishable 
between a CbpA knock-out mutant when compared to the wild type (WT) strain 
(Tulli et al., 2013), indicating that although CbpA is an adhesin, it is not a major 
adhesin in C. difficile. The lipoprotein CD08730 demonstrated adhesive 
properties to Caco-2. This property was further demonstrated when mutant 
strain and a WT strain, pre-incubated with specific antibodies, showed a 




1.1.6.5 Secreted proteases 
As the secreted component of Cwp84 was found to degrade components of the 
ECM (Janoir et al., 2007), other secreted proteases have been identified. 
These are believed to contribute to infection, with the degradation of ECM 
enabling the spread of bacteria and releasing nutrients. C. difficile produces 
hydrolytic enzymes to degrade connective tissue and include hyaluronidase, 
chronditin sulphatase, collagenase and gelatinase (Steffen and Hentges, 1981) 
and the expression of these have been linked to increased virulence (Seddon 
et al., 1990).  A zinc metalloprotease, CD630_2830 (Zmp1), was identified and 
found to be capable of cleaving fibronectin and fibrinogen and in doing so 
destabilising the fibronectin network produced by human fibroblasts (Cafardi et 
al., 2013). Zmp1 was also found to cleave certain surface adhesins, including 
the collagen-binding protein CD630_28310, providing a role in the regulation of 
adherence in C. difficile (Hensbergen et al., 2014).  
1.1.6.6 Motility 
The human intestinal tract is covered by mucus secretions that protect the 
epithelium and prevent colonisation of the cells; however, bacteria have 
developed mechanisms to circumvent this and traverse the mucus layer. The 
flagellum is a complex appendage of the cell surface and is primarily an 
organelle of motility and chemotaxis; however, other functions have been 
identified including biofilm formation, adhesion and immune system stimulation 
(Duan et al., 2013, Haiko and Westerlund-Wikström, 2013). C. difficile 
possesses peritrichous flagella; but the role of flagella in the virulence of C. 
difficile is not well understood. The work from Tasteyre et al., characterised the 
flagellum of C. difficile and found it was comprised of a flagellum subunit (FliC) 
and a flagellar cap protein (FliD) (Tasteyre et al., 2000, Tasteyre et al., 2001b). 
Purified FliC, FliD and crude flagella preparations adhered to mouse caecal 
mucus in vitro, revealing a role for flagella in adhesion. Indeed, tissue 
association in the mouse caecum of a non-flagellated strain was 10-fold lower 
than that of a flagellated strain (Tasteyre et al., 2001a).  
Flagellar gene transcription occurs in a hierarchical order with early-stage 
genes encoding the basal body assembly and the flagellar alternative sigma 
factor (SigD). SigD activates late-stage flagellar genes as well as genes 
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required for post-translational modification of the flagellum (Stabler et al., 2009, 
El Meouche et al., 2013). SigD has also been linked to TcdA and TcdB 
expression through the control of tcdR transcription. Mutagenesis of sigD 
resulted in a decrease in expression of genes involved in flagellar and toxin 
regulation (Aubry et al., 2012, El Meouche et al., 2013). More recently, it was 
found that flagellum and toxin production is subject to phase variation 
(Anjuwon-Foster and Tamayo, 2017). The DNA invertible element is found 
upstream of the sigD operon, with inversion catalysed by a tyrosine 
recombinase, RecV (Anjuwon-Foster and Tamayo, 2018).    
Evidence suggesting a role for flagella in adherence and colonisation is 
contradictory, with results comparing the historic C. difficile 630 strain showing 
conflicting results to epidemic 027 R20291. In 2013, Baban et al., (2013) 
compared the C. difficile 630 and R20291 flagellated parent strain to strains in 
which the flagella were paralysed and strains where the flagella were absent. 
R20291 flagellar fliC and fliD mutants adhered less than the WT strain 
indicating that flagella were necessary for adherence and virulence in R20291 
strain but not the 630 strain. R20291 mutants with a paralysed flagellum (the 
motor proteins of the flagellum were disabled, producing a structurally present 
but immotile flagella), were able to outcompete fliC mutants in colonisation and 
adherence, indicating that the structural components of flagella are important to 
C. difficile adherence and colonisation, rather than motility (Baban et al., 2013). 
The contrasting behaviour between the strains highlighted the importance of 
testing a variety of strains before drawing conclusions. It was also noted that 
diversity between post-translational modifications of the flagella differ greatly 
between strains (Twine et al., 2009) and that mutations in these glycosylation 
modifications can affect motility, colonisation and disease recurrence in mice; 
indicating that alterations in flagella architecture play a role in virulence 
(Faulds-Pain et al., 2014). Flagella have also been demonstrated to play a role 
during in vitro biofilm formation, with fliC mutants producing less biofilm than 
the WT strain (Ðapa et al., 2013).  
In addition to flagella, C. difficile was also found to expresses type IV pili (T4P) 
that are responsible for swarming and twitching motility but are also associated 
with adhesion, cell aggregation and biofilm formation (Borriello et al., 1988a, 
Sebaihia et al., 2006, Goulding et al., 2009). The expression of T4P is highly 
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dependent on intracellular levels of the bacterial second messenger cyclic 
dimeric guanosine monophosphate (C-di-GMP). In other bacteria, c-di-GMP 
has been shown to be responsible for the switch from a free living, motile 
phenotype to a sessile, immobile phenotype. Increased levels of C-di-GMP 
reduces the expression of flagella and increases the expression of T4P, leading 
to cell aggregation and biofilm formation (Tamayo et al., 2007). A similar 
system has been demonstrated in C. difficile with increased levels of c-di-GMP 
associated with increased transcript of the T4P genes (Bordeleau et al., 2015) 
accompanied by the repression of motility and an increase in cell aggregation 
(Purcell et al., 2012). Inactivation of the major and minor subunits of pili (PilA1 
and PilJ, respectively), results in the absence of pili which significantly reduced 
cell aggregation in C. difficile (Bordeleau et al., 2015). As with flagella, major 
differences were demonstrated in pilus expression and regulation between the 
630 and R20291 strain, with R20291 expressing higher levels on T4P and is 
therefore capable of surface-associated growth and motility (Purcell et al., 
2016). The ability to switch between free-living and sessile phenotypes may 
have important implications for virulence.  
1.1.7 Current Diagnosis and Treatment 
According to European guidelines, all unexplained diarrhoea episodes are 
recommended to be investigated as possible CDI (with the exception of 
children under 3 years of age) (Crobach et al., 2016). A positive laboratory 
diagnosis includes a positive result of glutamate dehydrogenase (GDH) and a 
positive toxin result, or a positive nucleic acid amplification test (NAAT) 
together with a positive toxin result, from a stool sample. Additional tests 
include a full blood count, urea and electrolytes as well as lactate and radiology 
in severe to life-threatening cases. Guidelines for the diagnosis and treatment 
of CDI and rCDI are available from the European Society for Clinical 
Microbiology and Infectious Disease (ESCMID) (Debast et al., 2014) and the 
Infectious Disease Society of America (IDSA) and the Society for Healthcare 
Epidemiology of America (SHEA) (McDonald et al., 2018b).  
In non-severe CDI cases (diarrhoea without features of severe or life-
threatening infection), oral vancomycin at 125 mg four times daily for 10 days if 
symptoms subside, or 14 days should symptoms persist. In severe CDI, 
characterised by: raised white cell counts of > 15 x 109/L, acute kidney injury (> 
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50 % rise in serum creatinine above baseline), temperature > 38.5°C or 
evidence of severe colitis; treatment includes oral vancomycin at 125 mg four 
times daily or 200 mg fidaxomicin if antimicrobial treatment is required for other 
infections or multiple comorbidities. Life-threatening CDI, characterised by: 
hypotension, partial or complete ileus or toxic megacolon; treatment includes 
125 mg NG vancomycin four times daily plus 500 mg IV metronidazole three 
times daily. There are multiple treatment options for recurrent CDI, including 
oral fidaxomicin for 10 days or a tapered and pulsed regimen of vancomycin. In 
cases of multiple recurrences, faecal microbiota transplantation (FMT) is 
considered.  
1.1.7.1 Treatment options for CDI  
Initially metronidazole was the drug of choice to treat CDI. A number of studies 
found equivalent efficacy and recurrence rates of metronidazole to vancomycin 
for the treatment of CDI (Teasley et al., 1983, Wenisch et al., 1996), and with 
the emergence of vancomycin resistant enterococci (VRE), the use of 
vancomycin was discouraged. With the emergence of the hyper-virulent 027 
ribotype, with increased disease severity, further studies investigating the 
efficacy of metronidazole to vancomycin stratified by disease severity found 
that overall cure rates were 84 % for metronidazole and 97 % for vancomycin. 
In mild CDI cases, the cure rate was 90 % and 98 % for metronidazole and 
vancomycin, respectively (p = 0.36); whereas, in severe cases the cure rate 
was 76 % for metronidazole and 97 % for vancomycin (p = 0.02). This 
demonstrated that vancomycin was superior to metronidazole, particularly in 
the treatment of severe CDI (Zar et al., 2007). In a multinational, randomised, 
controlled trial, it was found that the clinical success of metronidazole was 
inferior to vancomycin (p = 0.02, 72.7 % vs 81.1 % and p = 0.059, 66.3 % vs 
78.5 % for severe CDI) (Johnson et al., 2014). It was also found that VRE 
frequency was similar between patients treated with metronidazole and 
vancomycin; therefore, vancomycin has replaced metronidazole as the drug of 
choice for CDI treatment (Sethi et al., 2009).  
Fidaxomicin, a more recent option in CDI treatment, was found to be more 
active against C. difficile in vitro than vancomycin, as well as proving to be 
more selective for C. difficile and sparing to the normal gut flora (Ackermann et 
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al., 2004, Finegold et al., 2004, Hecht et al., 2007). Fidaxomicin was found to 
have equal initial clinical cure efficacy to vancomycin, but was associated with 
a significantly lower recurrence rate; however, cost-effectiveness of fidaxomicin 
hinders its use as a first line treatment (Al Momani et al., 2018).  
Alternative antimicrobials demonstrating action against C. difficile include 
tigecycline, teicoplanin, ridinilazole and ramoplanin. Non-antimicrobial therapies 
include immunotherapy (monoclonal antibodies and vaccination), adsorbants to 
bind toxins and probiotics (Roshan et al., 2018). Microbiome-based 
therapeutics, including FMT and defined bacterial consortia, are discussed in 
1.2.2.   
1.1.8 Models used to study CDI 
1.1.8.1 In vivo models of CDI  
Animal models play an important role in understanding disease aetiology. They 
facilitate the study of host-pathogen interactions, immunological response to 
pathogens and evaluate the safety, toxicity and efficacy of potential drugs and 
novel treatments. In contrast to clinical studies, animal model subjects are 
readily available and provide an opportunity to standardise disease severity 
and progression. They enable the use of experimental drugs and treatment 
strategies using invasive tests and extensive tissue sampling; however, there 
are ethical considerations and study approval can be difficult and time 
consuming. The animals used are fed the same diet and typically come from an 
inbred stock, where genetic variation is minimal. This can have an impact on 
studies especially where the microbiome and/or host factors can affect the 
disease outcome. This has been shown between the disparity in outcomes 
from mouse studies and clinical trials (Best et al., 2012, Hutton et al., 2014).  
Additionally, there are inter-species differences in disease susceptibility and 
aetiology, making extrapolating results between studies and to humans difficult. 
Several different animal models have been used to study CDI including hares 
(Dabard et al., 1979), monkeys (Arnon et al., 1984), prairie dogs (Muller et al., 
1987), rabbits (Kelly et al., 1994), rats (Castagliuolo et al., 1997), quails (Butel 
et al., 1998), guinea pigs (Xia et al., 2000), pigs (Steele et al., 2010), and 
zebrafish (Hamm et al., 2006); however, the mouse (Chen et al., 2008, Lawley 
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et al., 2009a, Pawlowski et al., 2010) and hamster (Bartlett et al., 1977, Fekety 
et al., 1979, Buckley et al., 2011) model of CDI are the most common. 
Hamster models – Hamster models, in particular Golden Syrian hamsters, 
demonstrate many of the clinical characteristics seen in human CDI (Price et 
al., 1979) and have therefore been used extensively as a model for CDI 
(Sambol et al., 2001, Goulding et al., 2009, Trzasko et al., 2012, Buckley et al., 
2013, Weiss et al., 2014). In hamster models, CDI is induced with the 
administration of an antimicrobial agent that perturbs the normal gut flora, as 
seen in humans. This model has been used to elucidate many aspects of CDI 
and has improved our understanding on the mechanisms of CDI initiation, 
development, aetiology and treatment. Hamster colonisation studies have 
demonstrated colonisation resistance of the normal flora to CDI (Wilson et al., 
1981, Larson and Welch, 1993) and revealed the presence of toxin specific 
receptors on colonic epithelium (Rolfe and Song, 1993). They were also crucial 
in establishing the mechanisms of action of C. difficile toxins and their role in 
virulence and disease (Babcock et al., 2006, Lyras et al., 2009). Hamsters have 
also been used in CDI induction studies (Larson and Borriello, 1990) and in the 
evaluation of experimental treatments (Trzasko et al., 2012, Sattar et al., 2015). 
Despite the extensive use of hamsters in CDI research, there are notable 
limitations with this model. These include the development of a ‘wet-tail’ 
phenotype in hamsters instead of diarrhoea, which is a crucial feature of CDI in 
humans. CDI is also rapidly and uniformly fatal in hamsters if left untreated, 
which is not consistent with human studies (Sambol et al., 2001, Razaq et al., 
2007) and limits the duration of experiments, preventing hamsters being used 
in colonisation and recurrence studies. There are also distinct histological 
differences, with the caecum as the site of infection in hamsters whereas the 
colon is the site of infection in humans (Price et al., 1979). The lack of 
immunological tools available to study the host immune response is also a 
major drawback to this model.  
Mouse models – The use of mouse models in the study of CDI has increased in 
line with improved susceptibility models as well as the increased availability 
and variety of mouse models and mouse-related reagents. Similar to humans, 
CDI in conventional mice is induced by disrupting the flora with antibiotics 
(Lawley and Young, 2013) with untreated mice becoming asymptomatic 
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carriers of C. difficile (Lawley et al., 2009a). A number of different mouse 
models have been described (Collignon, 2010).  
Gnotobiotic/ mono axenic mice do not have an associated microbiota and 
therefore no antibiotic treatment is required to induce CDI. They have been 
used to investigate the host immune response to infection and the contribution 
of selected members of the microbiota to C. difficile colonisation resistance. 
They have also been used to identify C. difficile genes required for colonisation 
and virulence (Pawlowski et al., 2010, Reeves et al., 2012, Soavelomandroso 
et al., 2017). However, the lack of a microbiota in this model is not reflective of 
the normal condition of humans and animals; therefore, the hosts’ immune 
response to infection may not be accurate or complete and results need to be 
interpreted with caution. This is particularly true as gnotobiotic mice are known 
to have an underdeveloped immune system as the microbiota plays an 
important role in immune homeostasis (Wagner, 2008, Yamamoto et al., 2012).  
The antibiotic cocktail mouse model was originally developed to overcome 
some of the limitations of the hamster model in a species with more 
immunological tools, providing a more reflective model for CDI in humans. Mice 
are given a cocktail of antibiotics followed by clindamycin induction and C. 
difficile exposure, and the resulting CDI progression and histological findings 
closely resemble that of humans (Chen et al., 2008). This model has been used 
to study colonisation resistance and microbiome studies as well as CDI relapse 
and recurrence (Chen et al., 2008, Sun et al., 2011); however, mice treated 
with vancomycin were not as susceptible to relapse as humans and develop a 
milder form of the disease (Sun et al., 2011).  
The single antibiotic mouse model is cheaper than the cocktail model and uses 
one antibiotic, usually either clindamycin or cefoperazone, to disrupt the 
microbiota and create an environment susceptible to CDI (Theriot et al., 2011, 
Buffie et al., 2012). This model has been used to study C. difficile 
asymptomatic carriage and spore transmission (Lawley et al., 2009a); 
environmental spore contamination and disinfection (Lawley et al., 2010) and 
microbiota changes during antibiotic treatment and CDI (Buffie et al., 2012). 
One of the main limitations of this model, as with the other mouse models, is 
the difference between the mouse and human microbiota and immune factors, 
which makes extrapolating results difficult. Additionally, mice obtained from 
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different sources produce different responses to the inducing antibiotic, leading 
to reproducibility problems. Individual C. difficile strain variation leading to 
different disease outcomes is another notable limitation of these models which 
makes it difficult to draw conclusions using a single strain (Goulding et al., 
2009) as well as reproducibility issues using the same strain which requires 
dose optimisation to improve the consistency of the outcome (Reeves et al., 
2011, Sun et al., 2011). Other mouse models include the humanised microbiota 
mouse using human-derived faecal microbiota (Collins et al., 2015); and the 
chimeric mouse model with human intestinal xenografts (Savidge et al., 2003).  
1.1.8.1.1 In vitro models of CDI  
With growing ethical considerations towards animal models, it has been 
increasingly important to utilise alternative models of disease. The advantages 
of in vitro models include: greater control and flexibility over experiment 
parameters; they are generally more cost and resource effective and more 
readily available; a greater number of replicates are achievable; and they 
eliminate the ethical implications of animal models. In vitro CDI models range 
from simple batch culture to complex, multistage chemostat systems; however, 
they are unable to model the complexity of animal systems and therefore 
cannot represent host-related interactions.  
Batch culture models - Batch culture models are inexpensive and do not 
require specialised equipment or specialist knowledge, making them cost and 
time effective. They offer a large degree of flexibility over experiment 
parameters and facilitate large numbers of replicates. They also provide an 
ideal opportunity to compare different strains or substrates run in parallel. They 
have also been used extensively in gene inactivation technologies, with batch 
culture providing an easy way to determine the difference between wild type 
strains and mutants (Aubry et al., 2012, Ðapa et al., 2013, Dembek et al., 2015, 
Jain et al., 2017). Despite these advantages, there are notable limitations to 
batch culture. The short experimental duration does not reflect the behaviour of 
C. difficile or the microflora in vivo, and the depletion of nutrients coupled with 
the accumulation of waste products can influence observations (Best et al., 
2012). Borriello and Barclay (1986) described an in vitro batch culture 
colonisation resistance model. They determined that C. difficile growth and 
toxin production was inhibited when co-cultured in the faecal emulsion from 
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healthy volunteers but not in faecal emulsions from patients undergoing 
antibiotic therapy. The also determined the inhibitory effect of the faecal 
emulsion could be negated by sterilisation of the emulsion and therefore 
attributing the colonisation resistance demonstrated to the healthy microbiome 
(Borriello and Barclay, 1986). This experiment was repeated with the caecal 
contents of hamsters and found that in vitro findings correlated closely with in 
vivo hamster models (Larson and Borriello, 1990, Larson and Welch, 1993). 
Similar batch culture models using faecal emulsions from mice were also used 
to investigate the effect of different antibiotics on the microbiota and their ability 
to facilitate or inhibit C. difficile growth and toxin production (Pultz and 
Donskey, 2005). They were also used to determine the effect of 
fluoroquinolones on colonisation resistance and the subsequent selective 
pressure on different C. difficile epidemic and non-epidemic strains (Adams and 
Mercer, 2007). Horvat and Rupnik (2018), using batch culture models, 
demonstrated that dysbiotic faecal microbiota was associated with higher C. 
difficile sporulation frequency and was more affected after co-culture with C. 
difficile than healthy faecal microbiota. In addition to colonisation resistance, 
batch culture has also been shown to determine the inhibitory effects of 
putative probiotics on C. difficile growth and toxin production (Folkers et al., 
2010, Schoster et al., 2013) as well as the activity of novel therapeutics, such 
as phage cocktails, on C. difficile growth in faecal emulsions (Nale et al., 2018).  
The continuous culture model – Continuous culture models afford additional 
flexibility over batch models and facilitates the controlled manipulation of the 
system. They have longer experimental timescales due to the replenishment of 
nutrients and removal of waste which allows for a more reflective environment 
than that seen in batch culture experiments. This enables the profile of the 
microbiota and C. difficile to be investigated in response to environmental 
changes and treatment interventions. The general protocols for continuous 
models are well standardised including equipment, methodology and 
monitoring, leading to more reproducible outcomes that can be compared 
between studies. They tend to be more expensive and labour-intensive than 
batch culture systems and often require specialist equipment and training.  
Continuous culture systems can be single, double or triple staged. Single stage 
systems represent the earliest and most simple systems.  
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The first continuous culture system to study CDI was used by Onderdonk in 
1979, which was an adaptation from an earlier model (Onderdonk et al., 1976). 
This single stage model was used to evaluate the changes in C. difficile toxin 
levels in culture media and determined that increased temperature and the 
presence of sub-inhibitory levels of antibiotics resulted in an increase in toxin 
production but not an increase in C. difficile growth (Onderdonk et al., 1979). 
The complexity of these models increased with the use of caecal contents from 
hamsters to seed the model (Wilson et al., 1986). They determined that 
hamster caecal flora in both the continuous model and transplanted to 
gnotobiotic mice led to the inhibition of C. difficile growth. They later used this 
model to study nutrient competition between C. difficile and the hamster flora 
(Wilson and Perini, 1988). The use of single stage continuous culture models 
seeded with human faeces was investigated by Yamamoto-Osaki (1994) where 
the growth of C. difficile was inhibited more strongly with faeces from C. 
difficile-negative patients than C. difficile positive patients. They also 
determined that C. difficile-negative faces contained a greater diversity in 
microbial populations when compared to C. difficile-positive faces and that 
colonisation resistance to C. difficile may be mediated by the consumption of 
amino-acids by the microflora rather than the production of inhibitors 
(Yamamoto-Osaki et al., 1994).  
Two stage continuous models were later used to investigate the prebiotic effect 
of substances on Bifidobacterium-mediated inhibition of C. difficile (Hopkins 
and Macfarlane, 2003) and to further study colonisation resistance in 
environments mimicking the proximal and transverse/distal colon (Fehlbaum et 
al., 2016). The triple stage continuous model of the human gut is a more 
complex system, allowing microbiota changes to be monitored in an 
environment highly reflective of the human gut. This model was used to 
generate much of the data in this thesis and therefore will be discussed in more 
detail.  
The triple stage continuous gut model – The triple stage gut model used to 
study CDI was based on the model from Macfarlane et al. (1998) which was 
validated against the microbiological and physico-chemical evaluation of the 
intestinal contents from human sudden death victims The model consists of 
three vessels connected in a weir cascade and top fed with a complex growth 
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medium at a set flow rate. It was designed to reflect the spatial, nutritional, 
temporal and physico-chemical properties of the human gut from the proximal 
colon (vessel one), medial/transverse colon (vessel two) and the distal colon 
(vessel three) (Macfarlane et al., 1998). The model is inoculated with pooled 
faecal slurry from healthy volunteers and allowed to equilibrate for a minimum 
of two weeks. Colonisation resistance in the system is determined with the 
addition of a C. difficile spore preparation, with the failure of these spores to 
establish colonisation and proliferate confirming microbiota-mediated inhibition 
of C. difficile. This is a crucial step not considered in previous models. From 
this point the model can be used to evaluate antimicrobial propensity to: induce 
CDI (Moura et al., 2019); to determine antimicrobial efficacy as a CDI treatment 
option (Freeman et al., 2007, Baines et al., 2009, Chilton et al., 2014b); to 
investigate antibiotic dosing regimens (Chilton et al., 2015, Crowther et al., 
2016); to evaluate the efficacy of novel interventions (Chilton et al., 2016, Wang 
et al., 2020); to examine the emergence and transfer of resistance 
determinants (Saxton et al., 2008, Rooney et al., 2019) and to determine the 
relative fitness of different C. difficile strains (Baines et al., 2013, Crowther et 
al., 2015). Antibiotics instilled into the model are reflective of a clinical dosing 
regimen with doses instilled periodically over a number of days to ensure levels 
achieved are consistent with those found clinically in faeces, which is not seen 
in other models. Depending on the experiment outcomes, the model can run for 
a number of months, facilitating daily sampling of microbial populations to 
generate a profile of the microbiota and C. difficile and the subsequent 
responses to interventions (Chilton et al., 2014a, Crowther et al., 2015, Moura 
et al., 2019).  
Human Intestinal Organoids (HIOs) – organoids are miniature 3D organs grown 
in vitro from adult multipotent stem cells (Ootani et al., 2009, Sato et al., 2009, 
Sato and Clevers, 2013) or induced pluripotent stem cells (iPSC)(Spence et al., 
2011), and cultured in stromal replacement scaffolding that resembles in vivo 
structure and organisation. Organoids provide an advance in the structural and 
functional complexity of intestinal model systems whilst retaining the ability to 
modify or influence the genetic and molecular aspect of the system (Hill and 
Spence, 2016, Wallach and Bayrer, 2017). They form a stable environment in 
which intestinal tissue function and therapeutic targets can be studied as well 
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as the study of host-pathogen interactions. The ability to self-renew enables 
increased research throughput when compared to techniques requiring 
continuously sourced starting material. Organoids sourced from human 
material are more applicable to pharmacological research than animal in vivo 
models and in vitro batch or continuous models and have been used to study 
host-bacterial pathologies, such as CDI. One of the main limitations for the use 
of organoids in CDI research included the inability to co-culture the human cell 
lines with obligate anaerobic microorganisms; however, it was shown that C. 
difficile could persist for at least 12 hours in the organoids, suggesting the 
presence anoxic microenvironments suitable for the survival of obligate 
anaerobic microorganisms (Leslie et al., 2015). Microinjections of C. difficile 
directly into the lumen of the organoid demonstrated C. difficile colonisation 
followed by HIO epithelial cell disruption and the loss of para-cellular barrier 
function. Similar effects were seen with purified TcdA and absent with a non-
toxigenic strain (Leslie et al., 2015). HIOs have also been used to study the 
effect of C. difficile on epithelial cell mRNA expression, with the finding that C. 
difficile can inhibit the expression of the sodium-hydrogen exchanger 3 (NHE3), 
creating an environment more suitable to C. difficile growth (Engevik et al., 
2015). HIOs were used to define a role for inflammasomes in CDI pathogenesis 
with the finding that C. difficile toxins induced the expression of caspases 3/7 
which lead to apoptosis, a critical early stage host defence against CDI 
(Saavedra et al., 2018). Using HIOs as a toxicity model, cell death was 
demonstrated upon exposure to C. difficile toxins and Melphalan chemotherapy 
(Apewokin et al., 2017). Pharmacologic studies using HIOs against CDI have 
also been considered, with the antibiotic Bacitracin preventing TcdB-mediated 
disruption of the epithelial cells and the maintenance of cell barrier function 
(Zhu et al., 2019). Although HIOs offer a clear advantage over other models to 
study CDI, there are still significant limitations and are discussed in numerous 
reviews (Zachos et al., 2016, Wallach and Bayrer, 2017, Fair et al., 2018). One 
of the main limitations is that the organoid lacks certain elements seen in the 
complete organ and only represent intestinal epithelial cells with potentially 
important contributions from immune, neural and mesenchymal cells not 
considered this system; however, the use of iPSC negates some of these 
restrictions as the HIOs contains both epithelial and mesenchymal cells but 
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require longer to generate (Spence et al., 2011). There are also practical 
limitations as HIOs are grown in a 3D shape which makes access to the apical 
surface difficult resulting in complications of manipulating cells for simple 
procedures such as microscopy, DNA and mRNA isolation and 
immunocytochemistry (Zachos et al., 2016, Wallach and Bayrer, 2017, Fair et 






1.2 The intestinal microbiota  
The indigenous microbiota of the intestinal tract is a diverse microbial 
community with dynamic interactions that influence the host in healthy and 
disease states. The microbiota is composed of over 1014 microorganisms (Gill 
et al., 2006) with a collective genome that has more than 100 times the number 
of genes as the human genome. The microbiota play a significant role in 
regulating host immunity, maintaining colonocyte homeostasis, metabolism and 
providing colonisation resistance against pathogen invasion (Bien et al., 2013, 
Thursby and Juge, 2017). Colonisation resistance was first described by van 
der Waaij et al. (1971) after observations that mice were only colonised by 
challenges of Enterobacteriaceae after antibiotic-induced disruption to the 
microbiota. They also noted that anaerobic bacteria were fundamental in 
colonisation resistance and once antibiotic treatment was removed, 
colonisation resistance gradually re-established (van der Waaij et al., 1971). 
Colonisation resistance protects the host against outgrowth of opportunistic 
pathogens, endogenous pathogens found in low numbers in the GI tract was 
well as exogenous pathogens. Colonisation resistance mediated by a heathy 
microbiota includes: competition for nutrients and space, with exogenous 
organisms unlikely to find uncontested niches and available substrates; 
metabolic mechanisms including bile acid and short chain fatty acid 
metabolism; as well as active antagonism in the form of bacteriocins and 
antimicrobial proteins (Sorbara and Pamer, 2019). The distribution of 
microorganisms in the intestinal tract is heterogeneous and therefore the 
mechanisms of colonisation resistance vary according to the spatial 
organisation of the microenvironments.  
Whole-genome shotgun sequencing has revealed a plethora of species 
isolated from the GI tract with 93.5 % belonging to the phyla Proteobacteria, 
Firmicutes, Bacteroidetes and Actinobacteria (Hugon et al., 2015). The specific 
composition of the gut microbiota is highly variable between regions of the gut 
and between individuals; however, it displays a high degree of functional 
redundancy and is shaped by both environmental factors and host genetics. 
Abundant microenvironments of the intestine provide distinct niches for 
microbes to occupy, with the composition of mucosal communities varying from 
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luminal contents (Zoetendal et al., 2002, Lavelle et al., 2015). Microbial 
characterisation of an in vitro model simulating luminal and mucosal 
populations revealed a predominance of Bacteriodetes and Proteobacteria in 
the luminal content whilst Firmicutes, in particular butyrate-producing 
Clostridium cluster XIVa, preferentially colonised the mucin layer (Van den 
Abbeele et al., 2013). Perturbation of a healthy microbiota exposes previously 
unavailable niches and substrates, providing an opportunity for pathogen 
expansion. 
1.2.1 Intestinal dysbiosis 
There are a number of different definitions for intestinal dysbiosis, but here it 
will be described as an imbalance of the microflora and its function (Carding et 
al., 2015, Lynch and Pedersen, 2016). Intestinal dysbiosis can be caused by a 
number of factors including drug exposure (in particular antimicrobial agents), 
stress, radiation and dietary changes.  A number of disease states have been 
linked to intestinal dysbiosis such as  inflammatory bowel disease (IBD) 
(Baumgart and Carding, 2007), metabolic disorders (Ley et al., 2006, Cani et 
al., 2008), central nervous system related diseases (Lyte et al., 2006), 
carbapenamase-producing Enterobacteriaceae (CPE) colonisation (Evain et 
al., 2019) and intestinal infections like CDI (Milani et al., 2016). One of the 
greatest risk factors of CDI is the use of broad spectrum antibiotics as their use 
results in dramatic changes to the intestinal microbiota with a decrease in 
microbial species and functional diversity, creating an environment favourable 
to colonisation by pathogens, such as C. difficile (Khoruts and Sadowsky, 
2016). Initial colonisation of C. difficile is vital for pathogenesis and therefore 
the loss of colonisation resistance in the intestinal tract exposes niches 
previously unavailable to C. difficile colonisation, facilitating outgrowth and toxin 
production. The propensity of an antimicrobial agent to induce CDI is likely 
related to the effect it has on the host microbiota and C. difficile itself. It was 
found that antimicrobial agents with a broad spectrum increase the risk of 
inducing CDI when compared to an agent with a narrow spectrum in mice 
(Pultz and Donskey, 2005). Antibiotic treatment of CDI further perturbs the 
microbiota, leading to disease relapse, which is reflected in high rates of rCDI 
(Cornely et al., 2012a, Marsh et al., 2012). The microbiota of patients with 
recurrent CDI is characterised by reduced community diversity and subsequent 
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reduced community structure and function, characterised by a reduction in the 
phylum of Bacteroidetes and Firmicutes, with an increase in Proteobacteria 
(Chang et al., 2008, Khoruts et al., 2010). Intestinal dysbiosis also leads to 
metabolic changes in the gut, such as faecal bile acid metabolism. Broad 
spectrum antibiotics significantly diminish bacterial populations responsible for 
secondary bile acid metabolism, which are known to inhibit C. difficile spore 
germination. This leads to the accumulation of primary bile acids such as 
taurocholate and cholate, both being potent C. difficile germinants (Sorg and 
Sonenshein, 2008). 
1.2.2 Microbial based therapies  
1.2.2.1 Faecal microbiota transplantation (FMT) 
Faecal microbiota transplantation (FMT) is a treatment that involves the 
transplantation of minimally manipulated faeces from a healthy donor to a 
recipient with the intent of restoring normal gut microbiota composition and 
function. FMT has been recommended to treat multiply recurrent CDI (Debast 
et al., 2014). FMT was first described in the 1958 as a treatment for 
pseudomembranous colitis (Eiseman et al., 1958) and later in the 1983 for CDI 
(Schwan et al., 1983). A systematic review reported the weighted pooled rate 
(WPR) clinical cure after a single FMT infusion as 76.1 % (Tariq et al., 2018). It 
was found that cure rates were lower in randomised trials than open-label 
studies (WPR: 67.7 % vs 82.7 %), most likely due to patient selection and 
differences in primary outcomes and study definitions. The randomised trials 
reported similar cure rates to observational studies after multiple FMT infusions 
(Tariq et al., 2018). The exact mechanisms underlying the success of FMT are 
not fully understood; however, the bacterial diversity and functional profile of 
patient faeces was found to have increased after FMT instillation, reflecting the 
composition of the donor stool (van Nood et al., 2013, Youngster et al., 2014, 
Kelly et al., 2016).  
1.2.2.1.1 Donor screening, preparation and instillation of stool 
Donor eligibility and screening varies between studies; however, in general the 
donor must be healthy, between 18-50 years of age, have normal bowel 
movements and to have not taken antimicrobial agents for at least three 
months, sometime six months, preceding the donation. It is also preferable if a 
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co-habiting relative of the recipient is able to donate due to the likelihood of a 
similar microbiota composition due to linked environments. A medical interview 
and physical examination is conducted and donors excluded if they have a 
known communicable disease or other systemic or metabolic disease. Donor 
faeces are screened for parasites and pathogens and general blood work 
conducted. Routes of administration include the upper GI tract through a 
nasogastric or nasojejunal tube or gastroscopy (Gough et al., 2011, van Nood 
et al., 2013); and the lower GI tract using retention enemas (Gough et al., 
2011) or colonoscopy (Youngster et al., 2014, Cammarota et al., 2015, Kelly et 
al., 2016).  
1.2.2.1.2 FMT for the treatment of recurrent CDI 
Clinical cure rates of 76.1 % (WPR) after a single FMT for rCDI were reported 
in a systematic review, with lower rates seen in studies including both recurrent 
and refractory CDI than those with rCDI only (WPR: 63.9 % vs 79 %, p < 0. 
001) (Tariq et al., 2018). It was also found that colonoscopy and oral route were  
more effective as faecal delivery routes than an enema (Tariq et al., 2018). A 
randomised open-label controlled trial by van Nood et al. (2013) studied three 
treatment regimes, (1) vancomycin (500 mg 4x daily for 4-5 days) followed by 
bowel lavage and infusion of FMT through a nasoduodenal tube after antibiotic 
treatment, n=17, (2) vancomycin (500 mg 4x daily for 14 days), n=13 (3) 
vancomycin (500 mg 4x daily for 14 days) with bowel lavage on day 4 or 5, 
n=13. The outcome of the study revealed a 81 % resolution rate for the FMT 
group (94 % resolution after multiple infusions) and 31 % resolution for the 
vancomycin only group and 23 % resolution rate for vancomycin treatment 
followed by bowl lavage. Based on these results, the trial was terminated and 
the FMT treatment offered off-protocol to the patients in the other arms of the 
study, achieving an 83 % resolution rate. A pilot study was conducted by 
Youngster et al. (2014) to determine the effectiveness of using a frozen faecal 
inoculum from unrelated donors for rCDI. A 70 % resolution rate after one FMT 
treatment was reported and an overall resolution rate of 90 % after retreatment. 
This demonstrated that using an infusion of unrelated frozen donor stool was 
efficacious in treating rCDI. A follow up study looking at the oral instillation of a 
suspension of double encapsulated frozen faecal matter was conducted with an 
overall resolution rate of 91 % with one or two treatments (Youngster et al., 
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2016). Another randomised, open-label controlled trial was conducted by 
Cammarota et al. (2015) to evaluate the efficacy of vancomycin treatment 
followed by FMT instillation verses an extended vancomycin treatment in 
treating rCDI. Vancomycin treatment followed by FMT instillation returned an 
overall cure rate of 90 %, whereas vancomycin only had a 26 % cure rate, 
further illustrating the effectiveness of FMT therapy on rCDI.  
In a retrospective series, Kelly et al. (2014) investigated the effectiveness and 
safety of FMT in immunocompromised (IC) patients. IC patients have 
previously been excluded from FMT studies due to safety concerns; however, 
the overall resolution rate was reported as 89 % with no deaths or documented 
infections that occurred as a result of FMT treatment, suggesting that FMT 
treatment appears to be a safe and effective treatment for rCDI in IC patients. 
Importantly, two cases of bacteraemia (one of whom died) linked to the transfer 
of an extended-spectrum beta-lactamase (ESBL) producing Escherichia coli 
following FMT from the same donor have raised major safety concerns (safety 
alert, FDA). 
The mechanisms underlying the success of FMT are likely multifactorial and 
not fully understood; however, restoration of bile acid metabolism and short-
chain fatty acid (SCFA) levels through the reconstitution of a more diverse 
microbiota have been implicated (McDonald et al., 2018a, Seekatz et al., 2018, 
Mullish et al., 2019). In contrast, a study using sterile filtrates were effective in 
the treatment of CDI, indicating that bacterial components and metabolites may 
be sufficient to reduce the risk of CDI while the normal gut flora is re-
established (Ott et al., 2017). Interestingly, analysis of bacteriophages in the 
filtrate indicated a role for the virome in the efficacy of FMT (Ott et al., 2017). 
16S ribosomal RNA (rRNA) was used to determine diversity in patients before 
and after FMT and the respective donors. The microbial community diversity 
was consistently low prior to FMT displaying marked dysbiosis characterised by 
a reduction in the phyla Firmicutes and Bacteroidetes with an increase in 
Proteobacteria. Post-FMT showed a significant increase in diversity within two 
weeks, becoming indistinguishable from donor samples and characterised by 
an increase in Firmicutes; in particularly the genus Blautia, Faecalibacterium, 
Roseburia, Ruminococcus; and Bacteroidetes; in particularly Bacteroides and 
Parabacteroides. This was accompanied by the reduction in Proteobacteria; 
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both Gammaproteobacteria and Betaproteobacteria, in particularly 
Enterococcus, Escherichia and Klebsiella (van Nood et al., 2013, Youngster et 
al., 2014, Kelly et al., 2016, Kellingray et al., 2018, Staley et al., 2019). 
Adverse events after FMT were generally minor and included patients reporting 
diarrhoea, abdominal cramps and pain, bloating, constipation, fever, nausea, 
vomiting, belching and flatulence; however, serious adverse effects have been 
reported, including death linked directly to FMT from aspiration pneumonia 
(Baxter et al., 2015, Baxter and Colville, 2016, Wang et al., 2016, Bang et al., 
2017), and the transfer of an ESBL producing E. coli (safety alert from the 
FDA). This highlights the safety concerns of FMT and the need to further 
develop more defined and standardised microbiome-based therapeutics. 
1.2.2.2 Other microbiome-based therapies  
The success of FMTs have demonstrated that the microbiome can be 
modulated for an advantageous outcome in CDI; however, the lack of 
standardisation and potential safety concerns have prompted great interest in 
defined microbiome based therapies. Using information gathered from FMT 
experiments, researchers have been able to identify selected populations that 
may be responsible for the efficacy of the FMT and have strived to create a 
more defined bacterial consortium or indeed an alternative method of FMT 
delivery, offering a more standardised procedure.  
Targeted restoration of the microbiota has been shown to resolve rCDI in mice 
(Lawley et al., 2012), generating much interest in the field of targeted 
microbiome therapies in humans. Rebiotix’s RBX2660 works in a similar way to 
an FMT and is an enema microbiota suspension prepared from a large faecal 
slurry comprised of 75 stool donations from 17 donors. In a randomised, 
double-blind, placebo controlled study, 1 dose of RBX2660 proved more 
effective than the placebo (p < 0.05) with an overall response rate of 88.8 % 
(Dubberke et al., 2018). Further to this study, RBX7455 was produced, which is 
a lyophilized, orally-administered therapy based on the RBX2260 enema 
formulation. RBX7455 is in Phase 1 proof-of-concept trial for rCDI with an 
overall success rate of 90 %, with patients remaining recurrence free at 6 
months post treatment (Khanna et al., 2018, Khanna et al., 2019). Another 
example of lyophilized orally-administered therapies based on faecal-derived 
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microbiota is the CP101 formulation from Finch Therapeutics. For the treatment 
of rCDI, CP101 achieved an 88 % success rate with confirmation of phylum-
level engraftment of CP101 such that recipients’ microbiota composition shifted 
to that of CP101 (Staley et al., 2017a, Staley et al., 2017b).  
A different approach is being taken by Seres Therapeutics in an attempt to 
produce an effective treatment for rCDI using a more defined bacterial 
consortium rather than a faecal suspension. SER-109, an oral capsule of a 
defined mix of spores sourced from faecal donors, achieved 95 % clinical 
resolution of rCDI in Phase 1 trials (Khanna et al., 2016); however, phase 2 
results were in contrast to this with no significant reduction in rCDI. In a post-
trial analysis, it was proposed that the lack of SER-109 efficacy in the Phase 2 
trial could be due to suboptimal dosing and patient selection issues, with rCDI 
diagnosed using PCR-based means, which, if not coupled with toxin testing, 
could incorrectly classify diarrhoea (in the presence of C. difficile colonisation) 
as active rCDI (press release, Seres Therapeutics).  SER-109 has entered 
Phase 3 trials based on these observations. Another Seres Therapeutics 
product, SER- 262, was based on 12 strains of bacterial spores from SER-109 
that engrafted in SER-109 patients. SER-262 is produced from in vitro 
fermentation, eliminating the need for faecal donors, reducing the safety 
concerns surrounding FMTs and a standardised procedure and composition. 
SER-262 is in Phase 1 clinical trials (ClinicalTrials.gov Identifier: 
NCT02830542). Most microbiome-based therapeutics are based on human 
faecal specimens and therefore focused on luminal contents alone. Indeed, 
post-treatment engraftment and microbial composition only looks at luminal 
populations. The mucosal microbial communities, due to inaccessibility, have 
been overlooked. Considering the link between biofilms and chronic, relapsing 
infections (Bjarnsholt, 2013), the need to study the composition of the biofilm 




1.3 Biofilms  
The association of biofilms with chronic infection has been well demonstrated 
(Donlan and Costerton, 2002, Hall-Stoodley and Stoodley, 2009, Bjarnsholt, 
2013), therefore biofilm formation could play an important role in CDI, in 
particularly CDI recurrence, where the biofilm could protect C. difficile cells from 
host defences and antimicrobial therapy, as well as preventing its removal from 
the gut with the luminal flow. C. difficile has been shown to form robust biofilms 
in vitro (Dawson et al., 2012, Donelli et al., 2012, Ðapa et al., 2013, Semenyuk 
et al., 2014) and in vivo (Buckley et al., 2011, Semenyuk et al., 2015) in mouse 
and hamster models. A biofilm is regarded as a complex community of 
microbial cells embedded in a self-produced matrix of extracellular polymeric 
substances (EPS) (Costerton et al., 1995, de Vos, 2015, Coenye et al., 2020). 
The matrix is mainly comprised of polysaccharides, extracellular DNA and 
proteins; however, non-cellular materials may also be found depending on the 
environment in which the biofilm formed (Percival et al., 2011). They are 
ubiquitous in nature and are believed to be the predominant mode of bacterial 
growth. The clinical implications of biofilms have been extensively reviewed 
(Donlan, 2001a, Hall-Stoodley et al., 2004) with an estimated 65 % of all 
hospital infections being associated with biofilms (Costerton et al., 1999, 
Potera, 1999, Donlan, 2001b). Biofilms present in hospital wards on medical 
devices and equipment act as reservoirs for pathogens leading to the spread of 
infection. Biofilms protect pathogens from the hosts’ immune response and act 
as a barrier to certain antimicrobial agents, contributing to disease persistence 
and recurrence (Costerton et al., 1995, Bjarnsholt, 2013) resulting in significant 
patient morbidity and mortality as well as economic burden.  
The study of anaerobic bacteria in intestinal biofilms is poorly understood due 
to the invasive nature of mucosal sampling and the lack of suitable in vitro 
models, therefore the role of biofilms in CDI has not been fully elucidated. Due 
to the inaccessibility of the mucosal communities in healthy individuals, the 
majority of the data on these populations comes from biopsy samples from 
patients with GI disorders with results potentially influenced by antimicrobial 
therapy and colonic washing prior to the procedure. In these studies, it has 
become clear that microbial populations adherent to the colonic mucosa are 
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heterogeneous in their distribution along the colon, taking advantage of 
microhabitats and selective metabolic niches. The community profile of the 
sessile populations were revealed to be significantly different from those 
obtained from faecal specimens (Zoetendal et al., 2002, Macfarlane and Dillon, 
2007). Although not anatomically reflective, in vitro biofilm studies of 
microorganisms isolated from the GI tract provide data on potential biofilm 
forming capabilities and mechanisms.  
1.3.1 Biofilm formation and development  
The ability of C. difficile to form a biofilm in vitro was first demonstrated by 
Donelli et al. (2012) using crystal violet staining and Field Emission Scanning 
Electron Microscopy (FESEM). Further studies revealed that the amount of 
biofilm produced was strain dependent, with hyper virulent strains forming a 
larger biofilm (Ðapa et al., 2013, Piotrowski et al., 2017). Many studies have 
since focused on the mechanisms underpinning C. difficile biofilm formation in 
vitro using a combination of microscopy and biofilm batch cultures. During in 
vivo studies, C. difficile has been shown to adhere to the epithelial mucosa in 
hamster (Borriello et al., 1988b) and mouse models (Spigaglia et al., 2013). In 
vivo evidence for biofilm formation of C. difficile was demonstrated by clumps 
or aggregates of C. difficile cells associated with damaged tissue, the epithelial 
barrier and within the mucus layer (Lawley et al., 2009a, Spencer et al., 2014, 
Soavelomandroso et al., 2017). Semenyuk et al. (2015) demonstrated that C. 
difficile was present as a minority member of a multispecies community located 
in the outer mucus layer in the caecum and colon of a mouse model, providing 
evidence of interactions of C. difficile with multispecies biofilms. Evidence of C. 
difficile biofilm formation in the human GI tract has not yet been demonstrated; 
however, cells have been shown to adhere to human intestinal epithelial lines 
in vitro (Drudy et al., 2001, Spigaglia et al., 2013) and Lyra et al. (2012) 
detected C. difficile together with common GI tract microorganisms in a 
mucosal biopsy sample. This evidence suggests the potential for C. difficile to 
form biofilms or be incorporated into existing biofilms in the GI tract.  
The transition from unicellular planktonic organisms to diverse surface-bound 
multicellular communities requires a highly regulated developmental pathway in 
response to bacterial and environmental signals. Through advances in 
molecular and imaging techniques, many of the mechanisms of biofilm 
41 
 
formation have been identified. Although complex, biofilm development follows 
a regulated path and is generally accepted as consisting of four stages (Palmer 
and White, 1997, Sauer et al., 2002) namely initial reversible attachment, 
irreversible attachment, co-aggregation/maturation and dispersal/detachment 
(Figure 1-5). These stages form part of a biofilm life-cycle with detached cells 
reverting back to a planktonic phenotype. Bacteria within each stage are 
phenotypically distinct from cells in other developmental stages (Sauer et al., 
2002) and it is possible for all four stages to occur simultaneously in mature 
biofilms. The cells within biofilms display altered gene expression profiles in 
each stage, creating a community of cells fundamentally different from 
planktonic cells, capable of rapidly responding and adapting to changing 
internal and external conditions (Donlan, 2002).  
 
 
Figure 1-5 Developmental model of biofilm formation. Through microscopic 
analysis of predominantly Gram negative bacteria, Pseudomonas 
aeruginosa in particular, this developmental model was established. It 
illustrates the formation of a biofilm as a life-cycle, with transitions through 
distinct developmental stages. These stages include the attachment of 
planktonic (i) bacteria to a surface (ii), aggregation and microcolony 
formation (iii), biofilm maturation to a macrocolony (iv) and dispersal or 
dissemination back to a planktonic state (v).  Image from Monds and 





1.3.1.1 The biofilm life-cycle 
The establishment of a biofilm is a multifactorial process consisting of phases 
that contain both conserved and species-specific events. The first step in 
biofilm formation is attachment to a surface. Zobell (1943) first proposed that 
adherence was a two-step sequence involving initial reversible attachment 
followed by irreversible attachment. In order for bacteria to attach to a surface, 
they need to be in close proximity to the surface and this is mediated by 
Brownian motion, gravitation, diffusion or intrinsic motility of the organism. 
Biofilm formation is initiated through the non-specific interaction of planktonic 
bacteria with a substratum in response to environmental conditions. Non-
specific binding involving hydrophobic and electrostatic interactions often 
occurs between a bacteria and an abiotic surface, whereas specific molecular 
mechanisms characteristic to the surface of the cell are involved in adhesion to 
living tissue (Percival et al., 2011) such as hydrophobicity, the presence of 
flagella, fimbriae, lipopolysaccharide (LPS) and the production of EPS (Donlan, 
2002). Using phase-contrast microscopy, O'Toole and Kolter (1998a) 
determined that planktonic cells attach as a dense monolayer to the 
substratum, followed by microcolony formation. This initial attachment is 
reversible as some cells may only attach transiently. Motile bacteria generally 
have a competitive advantage, using flagella to overcome some of the 
repulsive forces and align the bacteria in close proximity to the surface. A 
mutant defective for flagella biosynthesis in Pseudomonas aeruginosa was 
unable to make stable interactions with an abiotic surface resulting in few 
adherent cells (O'Toole and Kolter, 1998a) and a significant reduction in biofilm 
formation under flow conditions when compared to the flagellated wild type 
(Sauer et al., 2002). The role of flagella in biofilm formation is not restricted to 
initial binding, with investigations indicating an architectural role for flagella in 
biofilms with consequences throughout the biofilm life-cycle in E. coli (Domka et 
al., 2007, Serra et al., 2013). In C. difficile, a flagella mutant produced less 
biofilm that the wild type strain; however, this effect was only seen in later 
stages of biofilm development indicating a role for flagella in C. difficile biofilm 
maturation (Ðapa et al., 2013).  
Irreversible attachment is characterised by specific interactions of the 
microorganism with the conditioning film, which is formed by the adsorption of 
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molecules to the substrate that influences adhesion (Lorite et al., 2011). These 
interactions are facilitated by the presence of cell-surface adhesions, such as 
pili, and stimulate various signalling pathways regulated by intra and 
extracellular signals leading to biofilm formation (O'Toole and Kolter, 1998b). A 
role for T4P in stabilising interactions with the surface and other cells was 
demonstrated when a P. aeruginosa mutant defective for T4P biosynthesis was 
able to form a sparse monolayer of planktonic cells adhered to the surface but 
failed to aggregate and form microcolonies (O'Toole and Kolter, 1998a). T4P-
mediated twitching motility was also found to be necessary for cells to migrate 
along a surface to recruit other cells into aggregates, indicating a role for T4P 
early on in the developmental pathway. A C. difficile pilin pilA1 mutant, 
defective for T4P production, formed an initial biofilm with significantly reduced 
mass and thickness when compared to the wild type. Biofilm forming ability was 
restored upon complementation, indicating a role for T4P in early C. difficile 
biofilm formation (Maldarelli et al., 2016, Purcell et al., 2016). RNA sequencing 
also revealed an altered gene expression profile for T4P when C. difficile was 
grown in a biofilm, compared to planktonic growth (Maldarelli et al., 2016). 
Ðapa et al. (2013) also found a role for a mature S-layer in early C. difficile 
biofilm formation while investigating a mutated cwp84 gene. The cwp84 gene 
encodes a surface protease that is involved in maturation of the S-layer in C. 
difficile. The cwp84 deletion mutant showed no defect in planktonic growth in 
strain R20291; however, a dramatic reduction in biofilm accumulation was seen 
(Ðapa et al., 2013). The opposite was seen in strain 630 as this mutant 
displayed an increase in biofilms formation (Pantaleon et al., 2015). Both 
strains encode different proteins that are involved in S-layer maturation and 
therefore express different protein arrays on the immature S-layer (Biazzo et 
al., 2013), indicating that the contribution of the S-layer to biofilm formation is 
strain specific.  
During biofilm maturation, cell clusters become progressively layered with the 
majority of the cells displaced from the substratum. Characteristic of the 
maturation stage is biofilm differentiation resulting in a complex architecture 
consisting of mature community encased in EPS. The greatest difference in 
protein expression is seen in the maturation stage when compared to 
planktonic cells with approximately 50 % of proteins upregulated in a mature P. 
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aeruginosa biofilm with 36 % of the detectable proteins displaying a 6 fold or 
higher change in regulation (Sauer et al., 2002). It was also found that protein 
patterns were significantly different from the reversible binding stage with the 
de novo expression of over 100 proteins.  
In the final stage of biofilm development, cell clusters undergo alterations in 
their structure as a result of the dispersion/detachment of bacteria from the 
interior to the bulk phase. Dispersion facilitates the recolonization of biofilms 
when there is nutrient limitation or an accumulation of waste products. Dawson 
et al. (2012) demonstrated the ability of C. difficile biofilms to detach from an 
abiotic surface as a free-floating aggregate, which could have consequences in 
CDI. The dispersion of bacteria from biofilms has vast implications for clinical 
settings (Nickel et al., 1994, Lindsay and von Holy, 2006, Percival and 
Suleman, 2014) and public health (Zottola and Sasahara, 1994, Lau and 
Ashbolt, 2009), with links to infection dissemination and persistence. Stoodley 
et al. (2001) investigated the detachment of cells from a mixed species biofilm 
comprised of P. aeruginosa, Pseudomonas fluorescens, Klebsiella pneumoniae 
and Stenotrophomonas maltophilia, and reported the dissemination of large cell 
clusters containing enough cells to exceed the minimum infective dose of many 
biofilm-forming pathogens. Cells from a biofilm may be dispersed passively 
through erosion and sloughing or actively in response to quorum sensing (QS) 
signals and/or nutrient levels or shedding from actively growing cells. 
Detachment of biofilm aggregates offer a fitness advantage in establishing new 
biofilms over planktonic cells in environments with high competition for 
nutrients. 
The release  of cells is facilitated by the degradation of the EPS believed to be 
initiated by the concentration of an inducer molecule resulting in the expression 
of matrix-degrading enzymes (Stoodley et al., 2002). Examples of matrix 
polymer-degrading enzymes include the surface protein releasing enzyme 
(SPRE) of Streptococcus mutans (Lee et al., 1996) and alginate lyase of P. 
aeruginosa (Boyd and Chakrabarty, 1994) with overexpression leading to the 
disruption of the EPS and the subsequent release of cells from the biofilm. Cell-
density-dependent regulation and QS homoserine lactones have also been 
implicated in cell dispersal through the activation of matrix-degrading enzymes 
(Allison et al., 1998, Stoodley et al., 2002).  
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1.3.1.2 Biofilm structure  
The extracellular matrix of a biofilm is composed of water, environmental 
components such as host molecules, and self-produced EPS consisting of: 
polysaccharides, proteins, nucleic acids and lipids (Di Martino, 2018). The 
function of the EPS is to provide mechanical stability to biofilms and mediates 
their adhesion to surfaces whilst proving protection against biocides, antibiotics, 
host immune responses and UV radiation (Flemming and Wingender, 2010). 
The formation of the EPS matrix creates a unique environment that facilitates 
the transition to a biofilm mode of growth. The exact composition of the EPS is 
dependent on the environment in which it forms and the organisms present, 
therefore varies greatly in its physical and chemical properties. The EPS is able 
to incorporate large amounts of water into its structure through hydrogen 
bonding which protects the embedded cells from desiccation and is responsible 
for over 90 % of the dry mass of a biofilm (Donlan, 2002). The EPS is able to 
immobilise biofilm cells and keeps them in close proximity to enable 
interactions to occur such as cell-to-cell communication through quorum 
sensing, horizontal gene transfer and the development of synergistic 
cooperation (Flemming and Wingender, 2010). The matrix is able to retard the 
diffusion of extracellular enzymes enabling cells to metabolise particulate 
nutrients, serving as an external digestive system, allowing nutrients to be 
sequestered and utilised. It also keeps the contents of lysed cells available as a 
source of nutrients and serves as a genetic archive.  
The EPS facilitates the formation of extensive 3D networks with differing 
chemical gradients, generating biodiversity by forming a range of different 
habitats within a single biofilm. It provides physical structures that separate 
micro-domains harbouring different biochemical environments that are modified 
in response to changing external and internal conditions (Lawrence et al., 
2007). The structure of the EPS is also influenced by the interaction of non-
microbial particles from the host or the environment, which may become 
embedded in the matrix. This is evident during infective endocarditis when 
microcolonies develop in a matrix of EPS, fibrin and platelets leading to the 
development of a fibrin capsule that protects the bacteria from the host immune 
response (Durack, 1975).  
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The presence and purpose of extracellular DNA (eDNA) within the EPS has 
been extensively reviewed by Montanaro et al. (2011) and Okshevsky and 
Meyer (2015). Altruistic autolysis of small sub-populations and fratricidal 
differentiation of attacker and target cells are the main mechanisms responsible 
for the release of DNA into the matrix. The presence of eDNA in the matrix 
plays an important role in the initial attachment of bacteria and stabilises the 
matrix structure. It also acts as a dynamic gene pool facilitating the rapid 
spread of virulence and antibiotic resistance genes through horizontal gene 
transfer to naturally competent organisms. DNA is also anionic and therefore 
has the ability to chelate cations and restricts the diffusion of cationic 
antimicrobial agents. Investigations on the composition of EPS of C. difficile 
has revealed the presence of eDNA, polysaccharides and proteins (Ðapa et al., 
2013, Semenyuk et al., 2014). Differential polysaccharide staining of C. difficile 
biofilms revealed different polysaccharide compositions on the surface of cells 




Figure 1-6 Confocal laser-scanning analysis of stained C. difficile 
biofilms. C. difficile strains B16 (top panels), J9 (middle panels) and BY1 
(bottom panels) were stained with the polysaccharide stain concanavalin 
A-Texas Red (left panels) and the nucleic acid stain Syto-9 (middle 
panels) (middle, Syto-9, green) and imaged separately (left and middle 
panels) and together (right panels). Image from Semenyuk et al., 2014.  
 
1.3.1.3 Genetic determinants for C. difficile biofilm formation  
C-di-GMP can regulate cellular pathways through a number of mechanisms 
including regulation of gene expression through directly binding to riboswitches 
or modulation of transcription factors or allosteric regulation of enzymes 
(Sudarsan et al., 2008, Valentini and Filloux, 2016). Levels of c-di-GMP are 
regulated by the enzymes diguanylate cyclase (DGC) responsible for its 
synthesis, and c-di-GMP specific phosphodiesterase (PDE) responsible for its 
breakdown (Simm et al., 2004). In a study by Bordeleau et al. (2011), C. difficile 
was found to express an unusually high assortment of functional DGCs and 
PDEs, indicating that c-di-GMP was an important and well conserved signalling 
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system. They also found that increased levels of c-di-GMP resulted in reduced 
flagella expression whilst increasing the expression of adhesins (Bordeleau et 
al., 2011). Ectopic expression of genes regulating c-di-GMP levels 
demonstrated reduced motility and cell aggregation associated with high c-di-
GMP levels (Purcell et al., 2012). Later it was found that c-di-GMP levels 
regulate T4P expression, flagella motility and toxin synthesis (Purcell et al., 
2016). When examining one of the PDEs involved in c-di-GMP regulation, it 
was found that it was allosterically regulated by GTP and that its transcription 
was controlled by the nutrient-regulated transcriptional regulator CodY, linking 
c-di-GMP levels to nutrient availability (Purcell et al., 2017). CodY is a global 
regulatory protein that regulates cellular activity in response to nutrient levels in 
the environment (Dineen et al., 2010). In this way, biofilm formation is linked to 
nutrient availability through the action of CodY on c-di-GMP levels.  
Another transcriptional regulator that plays a significant role in C. difficile biofilm 
formation is Spo0A. Spo0A is more commonly known as a sporulation 
regulatory element; however, depending on the phosphorylation state of 
Spo0A, it has been shown to influence biofilm formation. This was 
demonstrated when Spo0A mutants formed a significantly reduced biofilm in 
vitro (Dawson et al., 2012, Ðapa et al., 2013). The Spo0A signalling pathway 
has been shown to play an important role in sporulation, cannibalism and 
biofilm formation, with the degree of phosphorylation determining the cell fate in 
Bacillus subtilis (Aguilar et al., 2010). In B. subtilis, Spo0A is able to regulate 
the activity of the transcriptional regulator SinR through activation of the 
expression of its antagonist SinI (Newman et al., 2013). SinR represses the 
expression of biofilm-related genes and therefore when Spo0A activates the 
expression of sinI, this results in the inhibition of SinR and subsequent 
expression of biofilm-related genes. Homologues of sinR and sinI have been 
found in C. difficile (Edwards et al., 2014) and have been linked to sporulation, 
toxin production and motility (Girinathan et al., 2018, Ciftci et al., 2019). A SinR-
like regulator in C. difficile (CD2214 and/or CD2215) control many genes 
associated with biofilm formation, with mutants in both causing an increase in 
biofilm formation (Poquet et al., 2018). With sporulation and biofilm formation 
closely associated, the presence of sporulation in biofilms could have 
significant implications for disease persistence and dissemination. Semenyuk 
49 
 
et al. (2014) found that sporulation efficiency in in vitro biofilms formed from 
human clinical isolates had a sporulation efficiency of between 46 – 65 %, 
suggesting high levels of sporulation in these biofilms.  
 
1.3.2 Characteristics of biofilms 
1.3.2.1 Interactions within the biofilm 
The GI tract is home to plethora of microorganisms who likely co-exist in a 
multispecies biofilm. Intra and interspecies interactions within multispecies 
biofilms are fundamental in shaping the overall structure, spatial organisation 
and regulation of gene expression of the different cells of the biofilm. Social 
phenotypes influence evolutionary fitness through cooperative and competitive 
interactions (Kim et al., 2008, Liu et al., 2016, Nadell et al., 2016), which is 
fundamental in shaping the overall structure and function of the biofilm. Spatial 
organisation within biofilms can act to balance competitive and cooperative 
interactions leading to community stability (Kim et al., 2008). This has distinct 
advantages over planktonic cells including protection against antimicrobial 
agents, host immune system, desiccation and protozoan predation (Burmølle et 
al., 2014).  
A key determinant in biofilm success and survival is the diversity of the species 
found therein. Population diversity increases the likelihood of survival when the 
biofilm is subjected to adverse conditions, with certain subpopulations 
demonstrating increased fitness when exposed to selected conditions. This 
may also be true in mono-species biofilms. Phenotypic heterogeneity in 
metabolism, physiology and gene expression create subpopulations with 
different biological roles within the biofilm, allowing rapid response to changes 
in the environment. Using FESEM micrographs, the presence of C. difficile 
vegetative cells were found growing in dense mats on an abiotic surface, 
interspersed with sporulating cells, spores and cell debris encased in a 
filamentous EPS matrix (Dawson et al., 2012, Donelli et al., 2012), with biofilm 
thickness increasing over time (Figure 1-7). Z-stack imaging and live/dead 
straining revealed multiple structured layers of cells composed largely of live 
cells (Ðapa et al., 2013). In a triple stage model of the human colon simulating 
CDI, dormant C. difficile spores and vegetative cells were found associated 
50 
 
with the multispecies biofilm throughout the experiment (Crowther et al., 
2014a), and Semenyuk et al. (2014) demonstrated the presence of two distinct 
exosporium morphotypes and toxin-producing vegetative cells during biofilm 
formation, further illustrating the heterogeneity found in C. difficile biofilms. 
 
Figure 1-7 Scanning electron microscopy of C. difficile biofilms. C. difficile 
biofilms were visualised after 3 days incubation (top panels) and 6 days 
incubation (bottom panels) at x 3000 magnification (left panels) and x 10, 
000 magnification (middle panels). The white boxes indicate areas 
enlarged (right panels) and the white arrows indicate connections between 
cells and assumed biofilm. Image from Dawson et al., 2012. 
 
Rapid diversity was seen in Pseudomonas aeruginosa biofilms with the 
development of heritable variants, suggesting genetic changes (Boles et al., 
2004). This diversity affected a number of cellular functions including motility, 
nutritional requirements, production of a secreted product and the generation of 
at least three different biofilm phenotypes. The presence of these diverse 
subpopulations enhanced the survival of the biofilm when exposed to 
environmental stresses. Similar results were seen in biofilms of Serratia 
marcescens (Koh et al., 2007), Pseudomonas fluorescens  and Burkholderia 
cenocepacia (Martin et al., 2016). The latter study used spatially structured 
environments to demonstrate the evolution of microbial subpopulations from 
clonal ancestors with distinct ecotypes. The community was shaped by a range 
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of social and environmental interactions including antagonism (social 
exploitation), niche complementation and cooperation (cross-feeding). 
Planktonic cultures did not generate the variants seen in biofilm cultures (Martin 
et al., 2016).  
The diversity seen in the above experiments did not necessarily give a specific 
subpopulation increased fitness. It is more likely that the subpopulations 
specialisation enhances biofilm survival and sustainability under selected 
conditions and benefits the community as a whole. This self-generated diversity 
acts to safeguard the microbial community to ensure survival in adverse 




Figure 1-8 Theoretical simulation of the development of phenotypic 
heterogeneity within biofilms in response to environmental pressure. 
This theoretical model is based on observations from predominantly Gram 
negative bacteria. It demonstrates the initial binding of cells to a surface in 
response to appropriate signals (a) followed by cell division to form 
isolated colonies (b). These colonies continue to expand and eventually 
merge, forming microcolonies (c). This generates different 
microenvironments and includes areas of oxygen and carbon limitation 
(pink cells). The cells in the pink zone adapt to this environment, 
generating phenotypic heterogeneity in the microcolony. (d) Further 
heterogeneity is seen as the biofilm continues to grow, including cells 
producing increased levels EPS (white) and exposure of cells to shear 
forces (green), leading to the establishment of a mature biofilm with 
distinct local adaptation and heterogeneity.  Image from Monds and 
O’Toole, 2009.  
 
1.3.2.2 Interspecies interactions 
Physical interactions can be either direct through cell-to-cell interactions or 
indirect mediated by the growth or presence of another organism (Klayman et 
al., 2009). An example of competitive direct interactions was demonstrated by 
Xie et al. (2000) when they reported that attachment of the oral pathogen 
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Porphyromonas gingivalis was specifically inhibited by the presence of the 
commensal Streptococcus cristasus. Contact-dependent downregulation of the 
FimA gene of P. gingivalis encoding components of fimbriae was mediated by 
the surface protein arginine deiminase (ArcA) of S. cristasus  (Xie et al., 2007). 
Klayman et al. (2009) demonstrated indirect interactions within biofilms 
between Escherichia coli and P. aeruginosa. They established that E. coli 0157 
was unable to produce a biofilm when inoculated alone; however, was able to 
co-adhere in a co-inoculum with P. aeruginosa. They also noticed that E. coli 
inoculated after the establishment of a P. aeruginosa biofilm resulted in a 10 
fold increase in E. coli adherence.   
Co-metabolism and syntrophy are examples of cooperation within biofilms. It 
involves resource sharing and can be in the form of reliance on a by-product as 
a nutrient source. This can be seen in the relationship between the sulphate-
reducing bacteria (SRB) Desulfovibrio vulgaris and other members of the 
biofilm community. SRBs can interact syntrophically with other bacteria in the 
biofilm in the absence of sulphate. Interactions with the hydrogen consuming 
methanogenic Methanococcus maripaludis are also beneficial when they 
consume the H2 by-product of D. vulgaris that is potentially inhibitory at certain 
concentrations (Brileya et al., 2014). This excretion and consumption of by-
products may influence the physiochemical properties of the biofilm, generating 
new niches for further colonisation.    
1.3.2.3 Quorum sensing  
Quorum sensing (QS) is the regulation of gene expression mediated by the 
release of signalling molecules in response to cell density. This cell-to-cell 
communication facilitated by chemical messengers is able to co-ordinate the 
mechanism of biofilm formation and the social behaviour of mixed bacterial 
communities. It has been demonstrated to be pivotal in biofilm development,  
maturation and dispersal for both Gram positive bacteria (such as 
Staphylococcus aureus and B. subtilis) and Gram negative bacteria (such as P. 
aeruginosa and P. fluorescens) (Yarwood et al., 2004, O'Loughlin et al., 2013, 
Papenfort and Bassler, 2016, Verbeke et al., 2017, Kalamara et al., 2018) as 
well as being implicated in the regulation of virulence determinants (Percival et 
al., 2011). The close proximity of cells within a biofilm provides ideal 
spatiochemical conditions to facilitate QS mediated genetic regulation. Bacterial 
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cells produce extracellular signalling molecules and at high cell densities they 
are able to accumulate and activate membrane receptors. This leads to the 
expression of genes involved in cooperative behaviour as well as a QS 
molecule feedforward loop (Rutherford and Bassler, 2012). QS signalling 
molecules can either be species specific or may cross species boundaries and 
consist of N-acyl-homoserine lactones (AHLs), autoinducing peptides (AIPs) 
and autoinducer-2 (AI-2). AHL systems are found primarily in Gram negative 
organisms (Gambello and Iglewski, 1991) and AIPs in Gram positive organisms 
(Li et al., 2001, Percival et al., 2011). Both Gram positive and negative 
organisms produce and sense AI-2 signals (Bassler et al., 1994). The AI-2 
signalling system is composed of three genes; luxP which encodes a 
periplasmic binding proteins, luxQ encodes a histidine kinase, and luxS which 
encodes an autoinducer synthase that produces the signal named AI-2. AI-2 is 
capable of operating across species boundaries and is therefore considered a 
universal signal and is associated with multispecies biofilms (Bassler et al., 
1997, Xavier and Bassler, 2003, Burmølle et al., 2014). A luxS homologue was 
found in C. difficile that produces an active AI-2 molecule (Carter et al., 2005), 
which was demonstrated to regulate virulence gene expression (Lee and Song, 
2005). Using luxS mutants, biofilm formation was significantly impaired (Ðapa 
et al., 2013, Slater et al., 2019). Interestingly, a C. difficile luxS mutant 
produced a larger biofilm in co-culture with the gut commensal Bacteroides 
fragilis, when compared to co-cultures with the C. difficile wild type, indicating 
that the mechanisms of AI-2 mediated biofilm formation in mixed species 
biofilms is not fully understood.   
1.3.2.4 Biofilm tolerance to antimicrobial agents  
One of the most medically important characteristics of a biofilm is its intrinsic 
tolerance to antimicrobial agents, making biofilm-associated infections difficult 
to treat and almost impossible to eradicate. Biofilm cells show between 10-
1000-fold higher tolerance to antibiotics than planktonic counterparts (Ceri et 
al., 1999). Tolerance of C. difficile biofilms to antimicrobials commonly used 
against CDI has been demonstrated; however, the mechanisms of this 
tolerance has not been fully explored. High concentrations of metronidazole 
(100 µg/mL) resulted in an approximately 10 fold reduction in sessile 
communities after 20 hours initial growth, whereas 1 µg/mL was effective at 
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reducing planktonic populations by 100-fold (Semenyuk et al., 2014). A similar 
effect was seen when testing the efficacy of vancomycin against C. difficile 
biofilms, in which concentrations of 100 times the MIC failed to eliminate the 
sessile populations (Ðapa et al., 2013). This increased tolerance was negated 
when the biofilms were disrupted, suggesting that tolerance was conferred by 
the intact biofilm and not genetic changes in the cells. In a triple-stage model of 
the human colon simulating CDI, vancomycin was able to reduce planktonic 
populations to below the limit of detection whereas sessile populations were 
unaffected (Crowther et al., 2014a). Evidence of lower vancomycin 
concentrations in the biofilm was seen (average 40.4 mg/L in the biofilms vs 
54.7 mg/L in the vessel lumen) indicating reduced penetration into the biofilm 
and therefore the antimicrobial was unable to reach effective levels. Further, 
sub-inhibitory concentrations of metronidazole and vancomycin have also been 
shown to stimulate and promote biofilm formation of C. difficile in vitro (Ðapa et 
al., 2013, Vuotto et al., 2015). This highlights that low concentrations of 
antimicrobials at the beginning and the end of treatment could potentially act as 
a stress signal to C. difficile displaying susceptibility to the antimicrobial, 
resulting in a stress response and stimulating increased biofilm formation. The 
antibiotics surotomycin and fidaxomicin were more effective at killing vegetative 
cells in established biofilms when compared to vancomycin and metronidazole, 
by disrupting the biofilm structure (James et al., 2017).  
This particular area of biofilms has been extensively studied and a number of 
mechanisms have emerged that are believed contribute to the resistance 
exhibited by biofilms. The presence of eDNA in the matrix of the biofilm serves 
as a genetic pool with high levels of horizontal gene transfer occurring within a 
community leading to the generation of new genetic combinations and 
increased horizontal transfer of resistance determinants (Molin and Tolker-
Nielsen, 2003). This increased mutation frequency and the presence 
upregulated drug efflux pumps lead researches to believe that the organisms 
themselves were displaying additional resistance mechanisms.  Although this 
has been demonstrated to be true for certain bacteria (Tyerman et al., 2013), 
the vast majority of bacteria, when removed from the biofilm, display similar 
resistance to the planktonic cells (Spoering and Lewis, 2001). This implied that 
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mechanisms other than traditional resistance determinants were responsible for 
the reduced susceptibility of biofilms to antimicrobials. 
Further research has shown that several mechanisms can contribute to 
antimicrobial tolerance in biofilms. The EPS matrix can act as a physical barrier 
resulting in impaired or reduced penetration of antimicrobials into the biofilm 
(Flemming and Wingender, 2010). It was originally believed that the resistance 
conferred by the biofilm-mode of growth was due to the inability of antibiotics to 
penetrate the barrier created by the EPS matrix however, it was found that 
penetration of the biofilm varied between different types of antibiotic and 
therefore could not account for the degree of resistance displayed (Anderl et 
al., 2000, Singh et al., 2010). Shigeta et al. (1997) demonstrated that certain 
antimicrobial agents interacted chemically with the EPS matrix in addition to 
binding to anionic polysaccharides therein. This was confirmed by Walters et al. 
(2003) who showed that positively charged aminoglycosides bound to the 
negatively charged matrix and therefore retarded their penetration into the 
biofilm. Further work by Anderl et al. (2003) revealed an accumulation of 
secreted β-lactamase enzyme in surface layer which was able to deactivate β-
lactam antibiotics before they were able to reach lower regions of the biofilm. 
As the nature of the EPS is dependent on the microbes present, the effect the 
matrix has on antimicrobials varies considerably and therefore the composition 
of the biofilm and the chemical properties of the antimicrobial need to be 
considered (Stewart, 2015). The metabolic state of microorganisms within the 
biofilm also influences tolerance to antimicrobials (Schiessl et al., 2019). 
Nutrient limitation in inner regions of the biofilm causes bacterial cells to 
become less metabolically active resulting in slower growth, resembling the 
stationary phase of bacterial growth (Roberts and Stewart, 2004). Most 
antibiotics are only effective against actively dividing cells and therefore this 
stationary growth enables cells in the centre of clusters to survive antimicrobial 
exposure. The general stress response, initiated by the alternative σ-factor 
RpoS in response to cell density, results in physiological changes that act to 
protect the cell from various environmental stresses (Battesti et al., 2011). 
These include the expression of osmoprotectants and catalase.  
The highly complex architecture of biofilms leads to the generation of 
microenvironments within the biofilm displaying microscale gradients in pH, 
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oxygen concentration and nutrient and waste levels (Jensen et al., 2017, Ren 
et al., 2018). The different conditions in these microenvironments have been 
shown to interfere with the function of certain antibiotics and lead to their 
inactivation or reduced activity as demonstrated by Walters et al. (2003) when 
they noticed that oxygen limitation in lower levels antagonised antimicrobial 
action as well as the reduced efficiency of aminoglycosides in anaerobic 
conditions (Tack and Sabath, 1985). The distribution of bacteria in biofilms is 
not uniform and therefore the spatial distribution of cells and the size of clusters 
results in cells being exposed to different concentrations of antibiotic and in 
some regions the concentration achieved may not be high enough to eradicate 
the population. The presence of persister cells, a biofilm-specific phenotype, is 
induced in a subpopulation of cells that exhibits increased tolerance to 
antibiotics without undergoing genetic change (Lewis, 2008). These cells 
constitute < 1 % of the original population and persist despite continued 
exposure to antimicrobials. It is believed that the persister state results as a 
response to stress and nutrient limitation and is associated with the production 
of guanosine tetraphosphate (ppGpp) and the presence of toxin-antitoxin (TA) 
systems (Wood et al., 2013) which cause the cells to become less 
metabolically active and enter a dormant state. This dormant, almost spore-like 
state suggests a pathway of differentiation with the potential to reseed the 
community after the death of susceptible populations (Wood et al., 2013).   
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1.3.3 Methods used in biofilm culture and quantification 
The increased interest in biofilm research has led to the development of various 
methodologies to cultivate, examine and quantify biofilms. Methods for studying 
biofilms are highly variable, and a lack of standardisation has resulted in 
difficulty reproducing data between laboratories. Here, the more common 
methods of biofilm formation and quantification will be briefly discussed.  
1.3.3.1 Methods for culturing biofilms 
1.3.3.1.1 Static biofilms  
Static biofilm models include culture in wells, typically 96 or 24 per plate. These 
methods are high-throughput and relatively inexpensive, requiring little 
specialist equipment. Limitations include short duration of experiments due to 
nutrient limitation; poor reproducibility with a high degree of variability; 
biological environments not reflective of the gut; and end-point measurement 
only.   
The Microwell plate – The microwell plate is the most commonly used method 
which was initially used to asses adhesion to plastic (Christensen et al., 1985) 
and later used for the growth of biofilms by O'Toole and Kolter (1998b). 
Biofilms are grown in the wells of a microwell plate and by removing the 
planktonic phase; the sessile communities could be examined by measuring 
the attached biomass at various stages of biofilm development. They are most 
useful for screening biofilm formation capacity, especially for mutants defective 
in attachment (Valle et al., 2003) and for the test of anti-microbial compounds 
(O'Toole and Kolter, 1998b). Individual wells could also be coated with different 
molecules to investigate biofilm formation to different supports (Cucarella et al., 
2002). Another limitation of this model is the sedimentation of cells that become 
embedded in the EPS resulting in a biomass not solely from the biofilm 
process. 
The Calgary biofilm device overcomes the issue with sedimentation and 
consists of pegs attached to the lid of the microwell plate where the biofilm is 
formed when submerged into the substrate located in the wells. This allows for 
changing of the growth medium and therefore useful in MIC testing (Ceri et al., 
1999). Removal of the biofilm from the pegs is usually accomplished by 
sonication which can lead to incomplete population recovery (Müller et al., 
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2011) with detached communities not necessarily reflective of the entire sessile 
community due to differences in adhesion and detachment properties (Grand et 
al., 2011, Malhotra et al., 2019).  
The Biofilm ring test enables the study of early stages of biofilm formation 
(Chavant et al., 2007) based on the ability of bacteria to immobilize 
paramagnetic microbeads in the presence of an applied magnetic field when 
forming a biofilm. This method reduces the variability seen in other static 
methods as no intervention, such as staining or fixation, is required. The 
method is more expensive and requires specific magnetic device and scanner.  
1.3.3.1.2 Flow models  
Unlike static models, flow models allow the continuous replenishment of 
nutrients and growth media, enabling experiments to run over longer periods of 
time and facilitate the study of biofilm development and maturation. Often 
requiring specialist knowledge and equipment, flow models are generally low-
throughput with limited sampling opportunities and they tend to be expensive.   
The Robbins and Modified Robbins device are used for screening surfaces 
supporting biofilm growth and in-line flow experiments. The Robbins device is 
comprised of numerous coupons mounted to screws that are inserted into the 
flow through threaded holes in a pipe or channel. It was initially used to monitor 
biofilm formation under different flow velocities in industrial drinking water 
systems (McCoy et al., 1981) and later adapted for use in the laboratory (Nickel 
et al., 1985). These models require specialist knowledge of the flow dynamics 
of the system for optimum results. 
The Drip flow biofilm reactor consists of parallel chambers each containing a 
coupon where the biofilm forms under low shear stress (Goeres et al., 2009). 
The growth medium or cell suspension is introduced through a gauge needle 
located in the lid of each chamber and therefore can be used to simultaneously 
test different disinfectant and antimicrobial strategies (Slade et al., 2019) and to 
test biofilm formation under low shear stress. During operation, the reactor tilts 
at a specified angle from the horizontal, allowing fluid to pass over the length of 
the coupon. It is a compact design with easy operation (Agostinho et al., 2011); 
however, biofilm heterogeneity on the coupons and limited number of samples 
are limitations in this system.   
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Rotary biofilm reactors allow for the formation of biofilms under constant shear 
forces with retrievable coupon inserts of various materials for analysis. They 
are composed of a stationary chamber housing a variable speed rotating 
mechanism housing the coupons for sampling (Coenye and Nelis, 2010). The 
rotation frequency can be set independently of the feed flow rate; enabling the 
dilution rate to be adjusted independently to shear forces. Contamination is 
frequent in these reactors and the system requires specialist equipment. The 
number of individual strains analysed simultaneously is limited and therefore 
offers low-throughput analysis of various strains.  
The triple stage chemostat gut model, as discussed in section 1.1.8 and based 
on the design from Macfarlane et al. (1998) has been validated against the 
microbial and physiochemical properties of sudden death victims. It is a 
continuous model and is seeded with human faeces and the established 
environment mimics the human colon. It has been used extensively to model 
CDI and to assess the ability of a drug to induce or treat CDI with outcomes 
consistent with clinical findings (Baines et al., 2005, Freeman et al., 2005, 
Baines et al., 2006, Freeman et al., 2007, Chilton et al., 2014a). The chamber 
reflecting the distal colon was modified to incorporate glass biofilm support 
structures inserted in the lid of the vessel, enabling emersion in the gut model 
contents and facilitating the formation of biofilms that can be periodically 
sampled (Crowther et al., 2014b). This allows for the longitudinal monitoring of 
multispecies biofilms and their response to antimicrobial therapy and exposure 
to pathogens. Limitations of this model include the finite number of sampling 
rods and the requirement for specialist equipment. It is an expensive model to 
run and requires extensive manpower; therefore is low-throughput. The biofilm 
support structures were constructed of glass which is not reflective of the 
human gut. These models were used extensively in this thesis and will be 
described in more detail in Chapter 2.   
Flow chambers allow the real time, non-destructive, in-line study of biofilm 
formation and development. Flow chambers can be either open or closed 
(Lewandowski et al., 2004) with biofilms cultivated on coverslips in a chamber 
which allows for microscopic examination during biofilm development. The 
coverslips can also be coated with biological molecules to assess the effect on 
bacterial attachment (Landry et al., 2006). The addition of fluorescent dyes and 
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proteins enable the visualisation of spatial organisation and community 
structure, as well as gene expression studies with confocal microscopy 
(Sternberg et al., 1999, Haagensen et al., 2007, Pamp et al., 2009). These 
systems are low-throughput and require specialist equipment and do not allow 
direct access to the biofilm cells.  
1.3.3.2 Methods to measure biofilms 
Cell counting - The most common method used to quantify biofilms is to 
determine the colony forming units (CFU) using serial dilutions and plating the 
cells on appropriate agar. This method is inexpensive and does not require 
specialised equipment. Limitations of this method include incomplete 
homogenisation of the biofilm leading to variance, detached biofilm not 
representative of the whole biofilm, viable but nonculturable cells (VBNC) not 
detected, labour intensive and subject to counting errors and personal bias, 
and it is unable to provide information on dead cells and biofilm matrix 
components (Davey, 2011, Azeredo et al., 2017). The use of flow cytometry 
coupled with fluorophores enables the rapid and accurate determination of 
viable, dead and VBNC (Berney et al., 2007, Cerca et al., 2011, Oliveira et al., 
2015); however, this method requires specialist equipment and experienced 
personnel, it’s expensive, results may be influenced by the presence of organic 
matter in the sample (Frossard et al., 2016) and the structure and spatial 
organisation of the biofilm cannot be studied.  
Molecular – one of the more popular molecular based methods of bacterial 
detection and quantification is quantitative polymerase chain reaction (qPCR). 
qPCR provides rapid, high-throughput quantification of target and absolute 
DNA with high specificity and sensitivity (Hoffmann et al., 2009). As qPCR is 
designed to detect DNA, results may be overestimated as it does not 
discriminate between live and dead cells or eDNA found in the biofilm matrix. 
The use of RNA persistence (Birch et al., 2001) or intercalating fluorescent 
dyes, such as propidium monoazide and ethidium monoazide, (Nocker et al., 
2007, Nocker et al., 2009, Alvarez et al., 2013) together with qPCR, have been 
used to test for cell viability. Both methods come with additional limitations 
including the requirement for specialist knowledge in RNA isolation (Birch et al., 
2001) and the dependence on light-transparent matrix and membrane integrity 
for dyes (Nocker et al., 2007, Nocker et al., 2009, Sträuber and Müller, 2010).  
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Physical – the biomass of a biofilm can be quantified indirectly by measuring 
the wet or dry weight (Characklis et al., 1982), the electrochemical impedance 
(Dominguez-Benetton et al., 2012) or the acoustic impedance (Sim et al., 2013, 
Anastasiadis et al., 2014). Determining the weight of a biofilm is inexpensive 
without the need for specialist equipment; however, this method is time 
consuming and lacks accuracy. Both electrochemical and acoustic impedance 
are non-destructive methods allowing for real-time in situ measurement of 
biofilms; however, the heterogeneity of biofilms makes measurements and 
interpretations difficult.     
Chemical – The wet or dry biomass of a biofilm can be measured by the 
adsorption followed by desorption of a dye, most commonly crystal violet 
(Christensen et al., 1985). The dye is capable of staining both live and dead 
cells, as well as some matrix components (Merritt et al., 2005). This method is 
high-throughput, inexpensive and versatile, allowing the simultaneous 
examination of different conditions and microbial species. Although commonly 
used, there is no standard protocol for this assay and therefore comparisons 
between studies are difficult (Stepanović et al., 2007). It also lacks 
reproducibility and results are highly variable. The washing step of these 
assays often results in the loss of a portion of the biofilm, leading to 
underestimating the biomass as well as increasing the variability (Gómez-
Suárez et al., 2001). The metabolic activity of biofilms can also be quantified 
using colorimetric assays including the reduction of tetrazolium salts (Koban et 
al., 2012, Sabaeifard et al., 2014) and resazurin (Van den Driessche et al., 
2014).  
Microscopy – Light microscopy is the most inexpensive and simple form of 
microscopy used in biofilm research. It can be used for biofilm detection and 
quantification of early stages of biofilm formation with a counting chamber 
(Lembke et al., 2006). Samples are generally easy to prepare and require 
simple staining but do not allow for discrimination of components or structure of 
the biofilm. One of the main limitations of light microscopy is the limited 
magnification and resolution; however, this enables the imaging of larger parts 
of the biofilm and can be very useful in combination with higher magnification 
microscopes. Confocal laser scanning microscopy (CLSM) is capable of 
obtaining high-resolution images of biofilms at various depths, facilitating the 3-
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D reconstruction of the biofilms and providing information on the biofilm 
architecture, spatial organisation, composition and function (Bridier et al., 2010, 
Carvalho et al., 2012, Neu and Lawrence, 2014). With the development of 
image capture and analysis software, it is now also possible to quantify the 
bacteria in a biofilm and differentiate between live/dead cells (Sommerfeld 
Ross et al., 2014, Guilbaud et al., 2015, González-Machado et al., 2018). The 
main limitations of CLSM are the requirement for fluorophores and the limited 
number of available reporter molecules which restricts the amount of 
information obtainable. Scanning electron microscopy (SEM) is another high-
resolution/high-magnification method which has the added advantage of a wide 
range of available magnifications allowing for the examination of large fields to 
get an overall impression of the biofilm down to single cell visualisation which 
includes surface details and EPS (Asahi et al., 2015). One of the main 
limitations of SEM is the extensive and time-consuming destructive preparation 
of the sample that can cause shrinkage and can lead to damage of the 
structure of the biofilm (Alhede et al., 2012). Both CLSM and SEM are 
expensive to perform and require specialist knowledge and equipment.   
1.4 Rationale  
The link between chronic infections and biofilms has been clearly established 
(Bjarnsholt, 2013, Jamal et al., 2018), with GI tract mucosal populations 
gathering much interest in health and disease (Macfarlane and Dillon, 2007). 
rCDI displays the classic hallmarks of a biofilm-associated infection given its 
chronic nature and recalcitrance to antimicrobial therapy; however, biofilms 
have not yet been linked to the recurrence of CDI. Due to the relative 
inaccessibility of these populations in vivo and insufficient appropriate in vitro 
models, there is a paucity of information on the role of biofilms in rCDI. Here, 
we set out to define the biofilm niche that could potentially harbour C. difficile 
cells and facilitate rCDI, as well as to further characterise the interactions of C. 






1.5 Aims  
This study aims to determine whether multispecies biofilms play a role in C. 
difficile recurrence and to characterise the interactions between C. difficile and 
commensal microorganisms found in biofilms.  
 
 
1.5.1 Primary objectives  
To determine if the Leeds triple-stage model of C. difficile infection can reflect 
the outcome of microbiome-based therapeutics used clinically; 
to evaluate optimal dosing regimens for microbiome-based therapies currently 
in clinical trials using the triple-stage model of recurrent C. difficile infection; 
to identify commensal microorganisms present in a multispecies biofilm and 
characterise their interactions with C. difficile; 





Chapter 2 Materials and Methodology  
2.1 Chemicals and Agars 
All chemicals and growth media (pre-poured and powder) used were sourced 
from Sigma Aldrich, UK and Oxoid UK, respectively, unless stated otherwise.   
2.2 In vitro gut model experiments  
The in vitro gut model used in these experiments was based on Macfarlane et 
al. (1998) and has been validated against the physico-chemical and 
microbiological intestinal contents of sudden death victims. It has previously 
been used to profile the dynamics of microbiota and C. difficile population 
changes during CDI initiation, treatment and recurrence (Freeman et al., 2003, 
Baines et al., 2005, Chilton et al., 2014b, Crowther et al., 2015), with results 
reflecting those seen clinically. Data generated from different variations of the 
in vitro gut models was used in all chapters. Described here is a generic gut 
model experiment and associated tests. Each individual chapter details any 
deviation from this protocol and additional assays performed.   
2.2.1 Ethical approval  
Ethics for the investigation of pathogens and commensal bacteria using in vitro 
gut models was approved by the School of Medicine Research Ethics 
Committee (MREC 15-070). Human faeces is classified as tissue by the 
Human Tissue Act (HTA), therefore ethical approval was sought for the storage 
of donated faeces. The study received approval from East Midlands – Leicester 
South Research Ethics Committee (REC number: 16\EM\0263), IRAS project 
identification 206781, for the long term storage of donor faecal samples for the 
in vitro gut model experiments (appendix, A1).  
2.2.2 Participant recruitment and specimen collection 
Each gut model was initially started using a pooled faecal slurry made from the 
faeces from healthy donors. Potential participants were recruited from healthy 
members of the public and provided with an information sheet detailing the 
purpose of the study (appendix, A2). The information sheet provided 
instructions for sample collection and contact information of the primary 
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research scientists should any questions arise. By providing a sample, 
participants were consenting that the sample could be frozen, stored and used 
for the sole purpose of the gut model experiments and all donations were 
completely anonymous. 22 participants were recruited to provide faecal 
samples for a series of 9 gut models. Donors were required to be > 60 years 
old to reflect the age group at most risk of CDI, with no history of antimicrobial 
therapy in the preceding three months to ensure a healthy microbiota. 
Specimen kits included an AnaeroGen W-Zip Compact Generator system 
(Oxoid, Hampshire, UK) which maintained the sample in an anaerobic 
environment, for a maximum of 18 hours, before being transferred to an 
anaerobic cabinet (Whitley A95 anaerobic workstation, Don Whitley Scientific, 
UK).  
2.2.3 Screening of faeces  
To ensure the absence of C. difficile within the donor faecal material, all 
specimens were screened for the presence of GDH antigen (Goldenberg et al., 
2010, Sharp et al., 2010) using the C.DIFF CHEK-60 enzyme immunoassay 
(DS2, DYNEX Magellon Biosciences, USA) and plated directly onto Brazier’s 
CCEYL agar [cefoxitin (8 mg/L), cycloserine (250 mg/L), lysozyme (5 mg/L], 
supplemented with 2 % lysed horse blood] in triplicate and incubated 
anaerobically at 37°C for 48 hours. Any specimen testing positive for the 
presence of C. difficile was eliminated from the study.  
2.2.4 Preparation of the faecal slurry  
To provide increased consistency between a series of models, a stock of faecal 
slurry was prepared by pooling equal quantities of faeces from the 22 donors 
and diluting 1:3 in pre-reduced phosphate buffered saline (PBS) (MP 
Biomedicals, France) supplemented with 10 % (v/v) glycerol (Costello et al., 
2015), and the suspension emulsified in a stomacher (Borolabs, Aldermaston, 
UK). Large particulate matter was removed by filtration through a sterile muslin 
cloth (Bigger Trading Limited, Watford, UK). The slurry was separated into 
aliquots before being rapidly frozen using liquid nitrogen and stored at – 80°C 
(New Brunswick Scientific, Austria). When required, aliquots were defrosted at 
4°C and further diluted with pre-reduced PBS to a 10 % (v/v) final 
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concentration. The preparation of the faecal slurry was performed under 
aerobic conditions.    
2.2.5 Viability of frozen faeces  
To ensure consistency between the different model sets, the same faecal slurry 
was used to inoculate the models and therefore the slurry was frozen and 
maintained at – 80°C until required. Previous studies in our laboratory indicated 
that freezing a faecal slurry had a negligible effect on sampled bacterial 
populations (unpublished data, Buckley, AM, 2016). Prior to inoculating each 
model set, a sample of the defrosted slurry was enumerated on selected media 
as described in section 2.2.11. Statistical analysis using a Kruskall-Wallis with 
Pairwise Comparisons (IBM SPSS Statistics 23) were performed on total 
counts to determine if the fluctuations were significant. A p value of ≤ 0.05 was 
considered significant.  
2.2.6 C. difficile strain  
The C. difficile PCR ribotype 027 strain 210 (BI/NAP1/toxinotype III) used in 
this experiment was isolated during an outbreak of CDI at the Maine Medical 
Centre (Portland, ME, USA) and supplied courtesy of Dr Robert Owens 
(formally at Maine Medical Centre). This strain has been used in previous gut 
model experiments in our laboratory (Freeman et al., 2003, Baines et al., 2005, 
Freeman et al., 2007, Chilton et al., 2014a). Spore stocks were maintained at -
80°C prior to subculture on Columbia blood agar (CBA) plates (E&O, UK) and 
incubated anaerobically for 48 hours at 37°C (Whitley A95 anaerobic 
workstation, Don Whitley Scientific, UK) in preparation for spore production.  
2.2.7 Spore preparation and purification  
The spore purification protocol was adapted from Lawley et al. (2009b). A 
single colony of C. difficile was inoculated into 150 mL of pre-reduced brain-
heart infusion (BHI) broth and incubated anaerobically with agitation for 10 
days at 37°C to ensure maximum spore production. The broth was divided 
equally three ways and centrifuged at 3270 g (Allegra X-12R centrifuge, 
Beckman Coulter) for 20 mins at 5°C and the supernatants discarded. Pellets 
were re-suspended in 1mL of sterile deionised water (SDW) and 3 mL of 100 % 
(v/v) ethanol (Fisher Scientific, Loughborough, UK) each and vortexed every 10 
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mins for one hour followed by centrifugation at 16, 000g for 20 mins at 5°C. 
After discarding the supernatants, pellets were re-suspended in 10 mL PBS 
containing 1 % (v/v) sodium lauroyl sarcosinate (Sarkosyl) and incubated at 
37°C for one hour aerobically for cell lysis and then centrifuged at 16,000g for 
20 mins at 5°C and the supernatant discarded. Pellets were re-suspended in 
10 mL PBS containing 0.125 M Tris buffer (pH 8) and 10 mg/mL lysozyme 
(Sigma) and incubated at 37°C with agitation overnight. Samples were layered 
onto 10 mL of 50 % sucrose solution and centrifuged at 3270 g for 20 mins at 
5°C. After discarding the supernatants, the pellets were re-suspended in 10 mL 
PBS containing 200 mM ethylenediaminetetraacetic acid (EDTA), 300 ng/mL 
proteinase K and 1 % (v/v) Sarkosyl and incubated at 37°C for three hours and 
the sucrose centrifugation step repeated. The supernatants were discarded and 
the pellets re-suspended and washed twice in 10 mL SDW prior to pooling the 
samples and centrifuging at 3270 g for 20 mins at 5°C. Pellets were re-
suspended in 2 mL of nutrient broth supplemented with 15 % (v/v) glycerol. 
Final spore preparations were enumerated (CBA, anaerobic incubation at 
37°C) and diluted appropriately with SDW to a final concentration of 
approximately 1 x 107 CFU/mL for inoculation into the models.  
2.2.8 The in vitro gut model set up 
The model consists of three glass fermentation vessels (Soham Scientific, 
Cambridgeshire, UK) connected in a weir cascade formation, top fed with a 
complex growth medium through Saint-Gobain TYGON E-1000 tubing (Fisher) 
at a constant rate of 0.3 mL/min using a peristaltic pump (Masterflex L\S, Cole-
Parmer, UK) (Figure 2-1). Each vessel was inoculated with approximately 160 
mL of the 10 % (w/v) faecal slurry and the gut model culture media flow started. 
An anaerobic atmosphere was maintained in all three vessels with nitrogen 
sparging (Parker Domnick Hunter, VWR, Leicestershire, UK) through a vented 
filter unit (Millex, USA), and the temperature maintained at 37°C using a 
circulating water bath (Grant LTD6G, Thermo Scientific, UK) round each 
vessel. The system was controlled to reflect the physiological conditions of the 
colon, with increasing pH and decreasing nutrient availability from the proximal 
(vessel one, 280 mL, pH 5.5 ± 0.2), through the medial (vessel two, 300 mL, pH 
6.2 ± 0.2) to the distal colon (vessel three, 300 mL, pH 6.8 ± 0.2). All vessels 
were continuously agitated with a magnetic stirrer (VELP Scientifica, Italy) and 
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the pH maintained using pH controllers (Brighton Systems, Sussex, UK ) with 
Chemotrode P200 pH probes (Hamilton, Birmingham, UK) linked to 1 M 
solutions of HCL and NaOH (Fisher Scientific, Loughborough, UK). Vessel 
three had been previously modified to incorporate between 16 - 18 glass rods 
to facilitate multispecies biofilm formation and sampling at designated time 
points (Crowther et al., 2014b) without compromising the integrity of the system 
(Figure 2-2). Excessive foaming in the vessels was prevented by adding 0.5 mL 
of 10 % (w/v) polyethylene glycol (Sigma) when required. The gut models were 
set-up and maintained by the research technicians and research assistants 
within the Healthcare Associated Infection Research Group (HCAI), under the 
guidance of the principal investigator. Charmaine Normington assisted in the 
set-up and running of the models.   
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Figure 2-1 The Leeds in vitro gut model set-up. Vessels connected in a weir cascade, top fed by a complex growth medium 
and maintained to reflect physiological conditions of increased pH and decreased nutrient availability, from vessel one to three.  
The pH was controlled with pH probes in each vessel connected to a pH controller that automatically adjusted pH levels using 1 M 








Figure 2-2 Biofilm vessel from the in vitro gut model. The third vessel of the 
gut model had a modified lid to accommodate biofilm support structures 
that facilitated the formation and sampling of a multispecies biofilm.  
 
 
2.2.9 Preparation of Gut Model Growth Medium  
The gut model was top fed into vessel one with a complex growth medium. The 
growth medium was prepared in 2 L volumes, the list of constituents and 
quantities are listed in Table 2-1. Growth medium was prepared in 2 L Büchner 
flasks with a gas venting port (vent filter unit, Millex, USA) and plugged with a 
bung containing media delivery ports. The reduction-oxidation (redox) indicator 
resazurin (Sigma; 0.005 g/L) and glucose (Sigma; 0.4 g/L) were filter sterilised 
into the medium through 0.22 μm syringe filters (Millipore Corporation, Billerica, 
MA, USA) after autoclaving (and once it had cooled to 50°C). Resazurin was 
used as an indicator of anaerobicity, with a pink colour indicating an anaerobic 
environment and a yellow colour indicating an anaerobic environment. The 
growth media had a magnetic bead inserted into the flask prior to autoclaving 
and was kept on a magnetic stirrer to prevent sedimentation.  
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Table 2-1 Composition of the in vitro gut model culture media. 
 
Constituent Amount (g/ L) (unless 
otherwise stated) 
Supplier 
Magnesium sulphate 0.01 Sigma 
Calcium chloride 0.01 Sigma 




Potassium di-hydrogen phosphate 0.04 Fisher 
Sodium hydrogen carbonate 2.0 Sigma 
Tween-80 2.0 mL Anatrace 
Haemin 10.0 mL Sigma 
Cysteine HCL 0.5 Sigma 
Bile salts 0.5 Sigma 
Glucose (added after autoclaving) 0.4 Fisher 
Arabinogalactan 1.0 ChemCruz 
Pectin 2.0 Acros organics 
Starch 3.0 Oxoid 
Vitamin K 10 µL Sigma 
Peptone water 2.0 Oxoid 
Yeast extract 2.0 Oxoid 




2.2.10 Experimental design 
The basic model timeline consisted of periods of bacterial population 
equilibrium, microbiota disruption, CDI and rCDI, with each state induced with 
the appropriate intervention (Figure 2-3). After inoculation with the faecal slurry, 
bacterial populations were left to stabilise and reach a steady state. This period 
lasted between 27-33 days. Once the microbial population stabilised, assessed 
by sampling selected populations every alternate day and monitoring for 
fluctuations (as described in 2.2.11), vessel one of the models were inoculated 
with a C. difficile spore preparation of approximately 1 x 107 CFU/mL (see 
section 2.2.7). The populations were monitored for a further week to ensure 
colonisation resistance was established, characterised by the inability of C. 
difficile populations to proliferate. Another dose of C. difficile spores were 
introduced to the models as above, to re-establish C. difficile spore levels. To 
create an environment susceptible to CDI, the microbial populations had to be 
disrupted. This induced microbial dysbiosis was achieved with clindamycin 
instillation in vessel one for 7 days, four times daily (33.9 mg/L). Clindamycin 
was selected as it is an antimicrobial agent strongly associated with the 
development of CDI (Tedesco et al., 1974, Bartlett et al., 1977) and has been 
used previously to induce CDI in the gut models (Freeman et al., 2005, 
Freeman et al., 2007). Simulated CDI was deemed to be present when 
evidence of C. difficile germination (active C. difficile vegetative proliferation 
when compared to spore counts) was seen, accompanied by a C. difficile toxin 
titre of ≥ 2 relative units (RU, as described by Freeman et al. (2003)). 
During peak CDI, approximately two weeks after clindamycin treatment 
cessation, the system was dosed with vancomycin (125 mg/L 4 times daily, for 
7 days, vessel one), to treat the infection. After vancomycin treatment, the 
models were either left without intervention or treated with a microbiome-based 
intervention. Populations were monitored closely for evidence of rCDI for 
approximately four weeks after vancomycin cessation. Recurrent simulated CDI 
was defined as for CDI using C. difficile germination and associated toxin 




Figure 2-3 The general gut model timeline. A general timeline for gut model 
experiments showing approximate days for each stage. The steady state 
period allows time for the microbial populations to equilibrate and 
establish colonisation resistance. Colonisation resistance is confirmed 
with the failure of a C. difficile spore dose to germinate and cause 
infection within 7 days of inoculation. A second dose of C. difficile spores 
is added followed by clindamycin installation at 33.9 mg/L, four times 
daily, for 7 days. Clindamycin exposure disrupts the microbiota and 
creates an environment susceptible to CDI, resulting in induced CDI. CDI 
is then treated with vancomycin at 125 mg/ L, four times daily, for 7 days, 
and the model is then monitored for rCDI.   
 
2.2.11 Sampling planktonic populations 
Planktonic fluid was sampled from each vessel of the gut model via an outlet 
port secured by a glass stopper. Culturable populations were enumerated from 
the planktonic phase in vessels two and three every other day during steady 
state and everyday thereafter. With the exception of C. difficile counts, 
culturable populations from vessel one were not enumerated as this vessel 
reflected an area of the colon less physiologically relevant in CDI. Planktonic 
fluid was transferred immediately to an anaerobic cabinet where it was serially 
diluted in pre-reduced peptone water and plated out in triplicate on pre-reduced 
(anaerobic populations) selective and non-selective agars (Table 2-2, 
constituents appendix A3). As populations were sampled daily, dilution 
changes could be monitored to ensure the correct dilution range was chosen 
for sampling. For spore counts, equal volumes of planktonic fluid and 96 % 
(v/v) ethanol were thoroughly mixed and allowed to incubate at room 
temperature for one hour before serially diluting and enumerating. Bacterial 
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populations were identified to the genus level on the basis of colony 
morphology and colony characteristics on selective media, with selected 
colonies undergoing matrix-assisted laser desorption/ionisation (MALDI TOF) 
analysis (Bruker Daltonik Biotyper) (described in 2.2.13) for confirmation of the 
identification. Results were represented as the mean log10 CFU/mL planktonic 
fluid. Planktonic populations were sampled and enumerated by the research 
technicians and research assistants within the Healthcare Associated Infection 
Research Group (HCAI), under the guidance of the principal investigator.     
2.2.12 Sampling biofilm populations  
Biofilm populations were sampled and enumerated at designated time points 
(Figure 3-1 and Figure 4-1) due to the limited number of rods. Briefly, biofilm 
support structures with the multispecies biofilm attached (Figure 2-4), were 
removed from vessel 3 (Figure 2-2) and placed in 5ml pre-reduced PBS and 
thoroughly vortexed for 2 mins with 5mm sterile glass beads (Sigma), to enable 
homogenisation of the biofilm, prior to enumeration (Figure 2-5). Empty biofilm 
rod ports were sealed with sterile lid blanks. The biofilm pellet weight was 
determined by centrifugation (5 min, 16 000g) of the biofilm suspension in a 
pre-weighed Eppendorf, discarding the supernatant. The homogenised biofilm 
fluid was then serially diluted in pre-reduced peptone water and enumerated on 
pre-reduced selective and non-selective agars (Table 2-2). As biofilm 
populations were periodically sampled due to the limited number of rods 
available, dilutions were enumerated from neat to 10-7 in duplicate. Units were 
reported as the mean log10 CFU/g of biofilm biomass. Excess biofilm 
suspension was retained for DNA extraction. Charmaine Normington was 
solely responsible for the sampling, enumeration and analysis of the biofilm.  
                    
Figure 2-4 Biofilm support structure with multispecies biofilm attached. A 
biofilm support structure, with multispecies biofilm attached, was removed 
from the lid of vessel 3 of the gut model for analysis.  
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Figure 2-5 Biofilm sampling procedure. After the biofilm support structure 
was removed from the model, it was immediately transferred to 5 mL pre-
reduced PBS along with sterilised glass beads and vortexed to 
homogenise the biofilm. The biofilm suspension was then separated for 
DNA extraction, microbial enumeration and storage. For enumeration, the 
biofilm suspension was serially diluted and plated onto appropriate agar 
media in duplicate.  
 
2.2.13 Matrix-assisted laser desorption/ionisation (MALDI TOF) 
analysis  
MALDI TOF analysis was used on selected colonies to identify microorganisms 
from the gut models to a species level for use in biofilm batch culture 
experiments in Chapter 5. Colonies were transferred to a reusable, polished, 
stainless steel MALDI target plate (96 positions, one colony per position) using 
a cocktail stick. 1 µL of Matrix HCCA was added per target and air-dried. The 
target plate was run on a MALDI Biotyper (Bruker Daltonik Biotyper) by the 
Microbiology Department of Leeds General Infirmary and the mass spectrum 
was automatically compared against the MALDI Biotyper Reference Library 
(MBT Compass and MBT Explorer Software plus MBT Compass Library). The 
generated MALDI score is an indication of  the reliability of the identification. A 
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score of > 2.3 indicates the identification of the genus and species are reliable; 
a score of 2.0 – 2.29 indicates the genus is reliable and the species is 
probable; a score of 1.7 – 1.99 indicates the genus is probable and a score < 
1.7 indicates that the result is not reliable.    
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Table 2-2 Target microorganisms enumerated from the gut model 
experiments and appropriate culture media and growth conditions for 
their isolation. 
Target organisms Media  and Supplements  Growth at 37 °C 
C. difficile total viable 
counts  
Brazier’s CCEY agar  with 2 % lysed horse 
blood, 5 mg/L lysozyme, 250 mg/L D-
cycloserine, 8 mg/L cefoxitin, 2 mg/L 
moxifloxacin, 8 mg/L amphotericin B and 10 
mg/L colisin  
Anaerobic 
C. difficile spores  1:1 ethanol (96 %) shock for one hour 
followed by enumeration on Brazier’s CCEY 
agar with 2% lysed horse blood, 5 mg/L 
lysozyme, 250 mg/L D-cycloserine, 8 mg/L 
cefoxitin 
Anaerobic 
Total anaerobes and 
total Clostridia spp.   
Pre-poured FAA  with 5 % (v/v) horse blood  Anaerobic 
Lactobacillus spp.  52.5 mg/L MRS broth and 20 mg/L agar 
technical with 0.5 g/L L-cysteine and 20 
mg/L vancomycin 
Anaerobic 
Bifidobacterium spp. 42.5 mg/L Columbia agar and 5 mg/L agar 
technical with 5 mg/L glucose, 0.5 g/L L-
cysteine and 5 ml propionic acid, adjusted 
to pH 5.  
Anaerobic 
Bacteriodes spp.  Bacteroides bile aesculin agar with 2 % 
(v/v) haemin and 0.002 % vitamin K1.  
Anaerobic 
Enterococcus spp. Kanamycin aesculin azide agar with 10 
mg/L nalidixic acid, 10 mg/L aztreonam, 20 




Pre-poured nutrient agar Aerobic 
Lactose-fermenting 
Enterobacteriaceae 
Pre-poured MacConkey agar Aerobic 





2.2.14 DNA extraction and taxonomic sequencing of the biofilm 
DNA was extracted from the pellet remaining from centrifuging 2 mL of biofilm 
suspension (15 min, 16,000g) for 16S rRNA sequencing using a FastDNA Spin 
Kit for Soil (MP Biomedicals, Solon, USA) and following manufacturer’s 
instructions. All extractions were done within 24 hours of harvesting the 
sample, with the pellet remaining at –20°C until extracted. Final DNA 
preparations were eluted in 70 µL volumes and stored at –80°C until shipping 
for offsite analysis. Purity and concentration of the DNA was determined using 
Ultraviolet spectrophotometry at 260-280 nm (Infinite F 200 Pro, Tecan). DNA 
extracts were shipped to Seres Therapeutics (Cambridge, USA) and 16S rRNA 
sequencing performed through proprietary pipelines. Briefly, 16S rRNA V4 
sequences were PCR-amplified from 1 µL of DNA extract using the AccuPrime 
High Fidelity PCR kit (Invitrogen), with the primer pair 515F (5’ 
AGCMGCCGCGGTAA 3’) and 806R (5’ GGACTACHVGGGTWTCTAAT ‘3) 
containing Illumina MiSeq adaptors and single-end barcodes. Amplicons were 
pooled in equal quantities, cleaned with AMPure beads (Beckman Coulter) and 
paired-end sequenced on the MiSeq platform following Nextera XT library 
preparation (Illumina).  
Reads were demultiplexed with the split_libraries_fastq.py function in Qiime 
(version 1.9.1) (Caporaso et al., 2010) and identical sequences were binned 
into amplicon sequence variants (ASVs) using the program DADA2 (version 
1.4.0, parameters EE=2, TruncL=  c(200, 180) and q=10) (Callahan et al., 
2016). The assignTaxonomy function in DADA2 was used to assign a 
taxonomic name to each unique ASV using the RDP Classifier with the SILVA 
16S rRNA database (Silva nr v128) (Wang et al., 2007, Quast et al., 2013). 
Low abundance reads (≤ 10 reads) were removed from further analysis. Reads 
for each sample were assigned to the family taxonomic level and converted to 
percentage abundance. Results represent the mean abundance from at least 3 
biofilm support structures from each model. Bacterial families represent all 
families whose values were ≥1 % abundance at a single sampling point 
throughout the model timeline. The Shannon Diversity Index was used as a 
measure of the microbiota diversity at selected time points throughout the 




2.2.15 Bile acid analysis and quantification 
One mL samples of planktonic fluid were removed from vessel three of the gut 
models each day and centrifuged at 16 000g for 10 min. The supernatant was 
then removed and stored at –80°C until shipping for offsite analysis (Seres T 
Therapeutics, USA). Samples were analysed for bile acid composition and 
quantification using ultra-performance liquid chromatography through Seres 
Therapeutics proprietary pipelines. Briefly, 100 µL of the planktonic fluid 
supernatant was extracted 1:1 (v/v) with liquid chromatography-mass 
spectrometry (LC-MS) grade acetonitrile and filtered through a 96 well 0.2 µm 
hydrophilic polypropylene (GHP) membrane filter. The extracted samples were 
transferred to LC-MS sampling tubes for analysis. The bile acids cholic acid 
(CA), deoxycholic acid (DCA) and oxidation bile acids (Oxo-BAs; 3-iso-
deoxycholic acid, 3-oxo-chenodeoxycholic acid, 7-oxo-cholic acid, 12-oxo-
deoxycholic acid) were separated on a Microslov bidentate C18 column using 
an Agilent 1260 high-performance liquid chromatography (HPLC) series 
coupled to a Bruker Compact quadrupole time-of-flight mass spectrometer 
(qTOF-MS) equipped with electrospray ionisation.  
Liquid chromatography separation was achieved using a gradient of water and 
acetonitrile with 0.1 % (v/v) formic acid at 0.4 mL/min. The target bile acids fell 
between the mass range of 373.27 to 514.28 m/z. 5 µL of each of the samples 
and standards were injected into the system and target bile acids were 
identified using defined m/z and retention times compared with external 
standards. LC-MS grade pure bile acids were used to generate standard 
curves for quantification of the bile acids. Area under the curve was integrated 
using the Compass data analysis software (v4.4, Bruker). Data presented 
includes the concentration (nM/mg) of CA, DCA and the mean of the Oxo-BAs.  
2.2.16 Cytotoxin assay 
The Vero cell cytotoxin assay (Figure 2-6) was used to monitor levels of C. 
difficile toxin in the gut models and samples were taken during initial CDI and 
CDI recurrence. Samples of planktonic fluid were centrifuged at 16,000g for 10 
min before the removal and storage of supernatant at 4°C until required. Vero 
cells (African Green Monkey Kidney Cells, ECACC 84113001) were passaged 
throughout the experiment and cultured in flat bottom tissue culture flasks 
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(Nunc, Rochester, USA) containing 20 mL of Dulbecco’s Modified Eagles 
Medium (DMEM) (Sigma) supplemented with 10 % (v/v) newborn calf serum 
(Gibco, Paisley, UK), 1 % (v/v) L-glutamine (Sigma) and 1 % (v/v) 
antibiotic/antimycotic solution (Sigma) and incubated in 5 % CO2  at 37°C 
(Sanyo, Watford, UK) for 48 hours until Vero cell monolayers were at least 80 
% confluent upon examination under an inverted microscope (Olympus UK Ltd, 
Middlesex, UK). Vero cells were harvested by discarding the culture medium 
and gently washing with 1 mL of a 1:1 solution of trypsin-EDTA (sigma) and 
Hanks Balanced Salt Solution. A further 6 mL of this solution was added and 
incubated for 10 min at 37°C to detach the cells from the flask. The resulting 
suspension of cells was diluted 1 in 10 with fresh DMEM and used for either 
further passage or for setting up 96F microwell culture plates (Nunc, Rochester, 
USA).  
Trays were incubated in 5 % CO2 at 37°C for 48 hours and growth confluence 
examined microscopically before samples added. Samples were added to the 
tissue culture tray in triplicate at an initial 1 in 10 dilution, before being serially 
diluted to 10-6. C. sordellii antitoxin (Prolab Diagnostics, Bromborough, UK) was 
initially diluted 1 in 10 in PBS (inoculated into the tray 1:10 with a final 
concentration of 1 % v/v) and used to neutralise any cytotoxic effect caused by 
C. difficile toxins to ensure cell rounding was not caused by non-specific toxins 
found in the gut model fluid. A positive control using the supernatant of C. 
difficile 027 210 grown in BHI broth for 48 hours anaerobically at 37°C was 
used in each tray. Cell growth and appearance were assessed using inverted 
microscopy at 24 and 48 hours. Healthy, confluent Vero cells with < 50 % Vero 
cell rounding were deemed a negative result (Figure 2-7 a) whilst ≥ 50 % Vero 
cell rounding was deemed a positive result (Figure 2-7 b). Results were 
reported as relative units (RU), which are assigned based on the greatest 
dilution in which a positive result was seen. A positive result on the neat sample 
would return an RU of 1, on the 10-1 dilution would return an RU of 2 etc. The 
cytotoxin assays were conducted by the research technicians and research 
assistants within the Healthcare Associated Infection Research Group (HCAI), 




Figure 2-6 Graphical representation of the cytotoxin assay set up. Vero 
cells were cultured for 48 hours at 37°C and 5 % CO2 before harvesting 
and transferring to 96 well trays and incubated for a further 48 hours, until 
≥ 80 % cell confluence. Samples were added in triplicate to row A of the 
tray (1:10 v/v) and serially diluted (with the exception of row B). Row B, 
inoculated initially with 160 µL cell suspension, was inoculated with the 
sample (1:10 v/v) and C. sordellii anti-toxin (1:100 v/v) to act as a positive 
identifier for the action of C.difficile toxin. Vero cell growth and appearance 
were assessed with microscopy and ≥ 50 % cell rounding was deemed 
positive for C. difficile toxin. Positive controls of C. difficile supernatant and 





Figure 2-7 Image of Vero cell growth and appearance during the 
cytotoxicity assay. a) Toxin negative result demonstrating confluent 
growth of healthy Vero cells and b) C. difficile toxin positive result 
demonstrating ≥ 50 % cell rounding. Images at 400 x magnification.  
 
2.2.17 Antimicrobial bioassays  
An antimicrobial bioassay was used to monitor the antimicrobial concentrations 
achieved in the vessels during the experiment. Aliquots of gut model fluid (1 
mL) were removed daily from each vessel and centrifuged (15 min, 16,000g), 
filter sterilised through 0.22 μm syringe filters (Millipore Corporation, Billerica, 
MA, USA) and the supernatants frozen at – 20°C for retrospective analysis. 
Indicator organisms Kocuria rhizophila (ATCC 9341) and Staphylococcus 
aureus (ATCC 29213) were grown overnight in nutrient broth. 1 mL of a 0.5 
McFarland standard from each organism were inoculated into 100 mL bottles of 
sterile molten (50°C) Wilkins-Chalgren agar and Mueller-Hinton agar, 
respectively. K. rhizophila was used to determine clindamycin concentrations 
and S. aureus was used to determine vancomycin concentrations. Agars were 
gently mixed and poured into sterile bioassay plates (245 mm2, Nunc) and 
allowed to set at room temperature for one hour before drying at 37°C for 20 
mins. 25 wells (9 mm diameter) were cut from the agar using a sterile number 5 
cork borer and inoculated with a calibration series ranging from 4 to 256 mg/L 
for clindamycin and 8 to 512 mg/L for vancomycin. 20 µL of each sample were 
added to the wells, with each plate run in triplicate and incubated at 37°C for 24 
hours. Growth inhibition zone diameters were measured using callipers 
accurate to 0.1 mm. Calibration curves were determined from the squared zone 
diameters (red arrow, Figure 2-8) from the doubling dilution calibration series 
and used to determine the concentrations of the unknown samples (Figure 
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2-8). The antimicrobial bioassays were conducted by the research technicians 
and research assistants within the Healthcare Associated Infection Research 
Group (HCAI), under the guidance of the principal investigator.  
        
Figure 2-8 Antimicrobial bioassay plate. An antimicrobial bioassay was used 
to monitor antimicrobial concentrations achieved in each of the vessels of the 
gut model. Agar (either Wilkins-Chalgren agar or Mueller-Hinton agar) inoculated 
with the appropriate indicator organism (either K. rhizophila or S. aureus) were 
poured into a bioassay plate (245mm x 245mm) and 9 mm diameter holes were 
bored an equal intervals. On each plate, a calibration series of the target 
antimicrobial was added (top) and 20 µL of each sample was added to the 
remaining holes. Bioassay plates were incubated at 37°C for 24 hours and the 
zone of inhibition read and compared to the calibration curve generated with 




Chapter 3 Resolution of simulated recurrent CDI using FMT; 
delineating the sessile and planktonic populations  
3.1 Background  
The clinical success of FMT therapy against rCDI demonstrates the importance 
of restoring the gut microbiota to a pre-antibiotic state. FMT-based microbiota 
restorative therapy is based on introducing the healthy microbiota of a donor to 
a patient with intestinal dysbiosis. A recent systematic review and meta-
analysis of the efficacy of FMT therapy found an overall clinical cure rate of 
76.1 % (Tariq et al., 2018). This study revealed a significant difference in 
efficacy between randomised, controlled studies and open-label studies (WPR; 
67.7 % and 82.7 %, respectively). The efficacy of FMT therapy also has 
implications for other infectious intestinal disorders, including the reduction of 
antimicrobial resistance genes (Jouhten et al., 2016, Millan et al., 2016, Huttner 
et al., 2019). The indigenous microbiota of the intestinal tract is a diverse 
community displaying dynamic interactions with the host and other 
microorganisms. It is increasingly recognised as a regulator of the host immune 
and metabolic homeostasis (Bien et al., 2013).  
The microbiota of patients with rCDI is characterised by reduced community 
diversity and subsequent reduced community structure and function, 
characterised by a reduction in the phyla of Bacteroidetes and Firmicutes, with 
an increase in Proteobacteria (Chang et al., 2008, Khoruts et al., 2010). 
Antibiotic therapy has also been shown to cause metabolic changes in the gut, 
such as faecal bile acid metabolism. Broad spectrum antibiotics significantly 
diminish bacterial populations responsible for secondary bile acid metabolism, 
including the families Lachnospiraceae and Ruminococcaceae (Theriot et al., 
2014). Secondary bile acids are known to inhibit C. difficile spore germination 
(Weingarden et al., 2014). This leads to the accumulation of primary bile acids 
such as taurocholate and cholate, both being potent C. difficile germinants 
(Sorg and Sonenshein, 2008).  
The exact mechanisms underlying the success of FMT are not fully understood; 
however, bacterial diversity and richness of patient faeces was found to have 
increased after FMT instillation, with a community profile similar to that of the 
86 
 
donor (van Nood et al., 2013, Youngster et al., 2014, Kelly et al., 2016, Kumar 
et al., 2017). FMT therapy has been shown to normalise the metabolic profile 
demonstrating that FMT not only restores the structure and composition of the 
microbiota, but also influences its function (Mullish et al., 2019). Due to non-
standardised procedures for FMT preparation and installation, together with 
increased safety concerns, the identification of specific microbial taxa and 
mechanisms for FMT-mediated rCDI resolution is essential to enable a more 
targeted approach to microbiome restoration therapies.  
3.1.1 Rationale 
There is currently a lack of in vitro models that can predict the outcome of 
microbiome-based therapies. Additionally, most studies investigating microbial 
populations implicated in the efficacy of FMT therapy only consider luminal 
populations derived from faecal matter. Here we used our gut model to 
simulate rCDI which we adapted to mimic nasojejunal FMT therapy. Using this 
model we delineated the microbial planktonic and sessile dynamics during 
simulated CDI and FMT treatment to gain an understanding of the mechanisms 




3.2.1 Experimental design  
In this study, two in vitro gut models used to simulate rCDI were run in parallel, 
with one model adapted to facilitate a simulated FMT. The FMT model was 
later repeated for reproducibility and followed the same methodology, therefore 
will not be discussed here (results presented in appendix, A4). The initial set up 
of the gut models was as described in section 2.2.8. This experiment simulated 
a naso-jejunal FMT, and followed the experimental procedure used at Leeds 
General Infirmary (personal communication with Dr Jane Freeman, Clinical 
Scientist, LGI NHS Trust).  
The models followed the timeline detailed in Figure 3-1 and according to 
2.2.10, with deviations and exact time points detailed here. Briefly, both models 
were initially inoculated with a prepared faecal slurry (2.2.4) and populations 
left for 33 days in the steady state period. This period allowed the microbial 
populations time to stabilise and equilibrate. Models were sampled every other 
day to ensure populations recoveries were consistent. Both models were then 
challenged with a C. difficile spore dose (produced as described in section 
2.2.7) and from this point forward, planktonic populations were sampled daily 
according to section 2.2.11. As vessel three is more clinically reflective of CDI, 
results represented here are solely from this vessel. The models were left for a 
week to ensure the model had reached a point of colonisation resistance. This 
was demonstrated by the inability of the inoculated C. difficile spores to 
germinate during this phase. A second dose of C. difficile spores were added to 




Figure 3-1 The in vitro gut model timeline for the rCDI model (A) and the 
FMT model (B). The different stages of the model are indicated at the 
corresponding day in the timeline. Both models A and B followed the 
same progression (grey lines) up to the end of vancomycin treatment. 
After cessation of vancomycin, model A was left without further 
intervention (red line) and model B received a simulated FMT 3 days post 
vancomycin cessation (yellow line). Biofilm sampling time points are 
indicated by a blue circle.  
 
Clindamycin was used to disrupt the microbial populations and create an 
environment susceptible to CDI. Active CDI was deemed present when there 
was evidence of C. difficile spore germination accompanied with C. difficile 
outgrowth and toxin production. C. difficile toxin levels were monitored daily 
using the Vero cell cytotoxin assay described in section 2.2.16. Once peak 
toxin levels were detected, both models were dosed with vancomycin to treat 
the simulated CDI. Upon cessation of vancomycin, one model was left without 
further intervention for the duration of the experiment to model rCDI (model A), 
whilst model B received a simulated FMT 3 days post vancomycin cessation, 




3.2.2  Preparation of the FMT faecal slurry 
The FMT simulated in this study used a faecal slurry from fresh stool sourced 
from a healthy 30 year old donor. Donor recruitment and specimen collection 
protocol was as described in section 2.2.2 and 2.2.3 with the exception of the 
age of the participant. Additionally, the donor was a co-inhabiting relative of one 
of the donors that contributed to the original faecal slurry used to seed the 
models. The use of a relative’s or an intimate contact’s faecal matter is 
generally preferred clinically as the microbiota is believed to be similar to that of 
the recipient prior to dysbiosis as is the likelihood of sharing infectious risk 
factors (Bakken et al., 2011). The donor specimen was screened (described in 
section 2.2.3) and the FMT faecal slurry was prepared by homogenising the 
faecal matter with pre-reduced saline (10 % w/v) in a stomacher before being 
filtered to remove large particulate matter. The FMT slurry was prepared 
immediately prior to FMT instillation.  
3.2.3 Administration of the simulated FMT  
The 3 day period between vancomycin cessation and FMT instillation was to 
allow vancomycin levels to drop in vessel one to a level where it would not 
compromise the viability of the FMT. Preparation of the FMT slurry was 
described in section 3.2.2. 50 mL of the FMT slurry was top-fed into vessel one 
of model B to simulate a nasojejunal FMT through a sterile glass tube reaching 
the bottom of the vessel to prevent volume displacement (Figure 3-2). A 
peristaltic pump was used to deliver the slurry over a period of 1 hour (50 mL/ 
hr). 30 mL of pre-reduced saline was used to flush the line into the model after 
the FMT. After FMT instillation, the model was left for a further 30 days and 
monitored for evidence of rCDI. In addition to routine planktonic sampling, an 
aliquot of planktonic supernatant was stored each day for offsite bile acid 
analysis (2.2.15). Concentrations of clindamycin and vancomycin in the 
planktonic phase were retrospectively analysed using antimicrobial bioassays 
(2.2.17). To monitor sessile populations in the models, the biofilm was 
periodically sampled and enumerated as described in 2.2.12 (sampling 
schedule Table 3-1 and blue circles in Figure 3-1) with the addition of 
oxytetracycline-glucose-yeast extract agar (OGYEA) media for the isolation of 
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fungi. DNA was extracted from biofilm samples and sent for 3rd party taxonomic 
analysis (2.2.14). 
 
Figure 3-2 Simulated faecal microbiota transplantation (FMT) instillation 
into the triple stage gut model. 50 mL of the faecal microbiota slurry 
(blue arrow) was top fed into vessel one (enlarged) through a sterile glass 
tube using a peristaltic pump over a period of 1 hour (flow rate of 0.83 
mL/min), 3 days after vancomycin cessation. The line was flushed with 30 
mL of pre-reduced saline into the model after FMT instillation. The model 
was then left without further intervention for a further 30 days and 




Table 3-1 Biofilm sampling schedule. 
 







Pre-clindamycin 40 1 
Post-clindamycin 47 1 
Pre-vancomycin 63 2 
Post-vancomycin/ pre-FMT 73 3 
rCDI/ FMT instillation (+ 2 days) 78 3 
rCDI/ recovery 80 3 
rCDI/ recovery 85 1 




3.3 Results  
3.3.1 Viability of frozen faecal slurry  
To improve consistency between gut model runs, a faecal slurry was frozen 
and used to seed each gut model (procedure described in section 2.2.4). For 
each aliquot defrosted, selected bacterial populations were enumerated to 
determine if there was any loss of viability over time, using selective agars 
(Table 2-2). The slurry was frozen for a maximum of 81 weeks before use in 
the last model set (Chapter 4). Total viable counts (mean log10 CFU/mL) from 
three technical replicates from each aliquot and the log10 difference in range is 
listed in Table 3-2. The total facultative anaerobes, lactose fermenting (LF) 
Enterobacteriaceae, Enterococcus spp., Clostridium spp., Lactobacillus spp., 
and total spore populations remained fairly stable with a non-significant .(p ≥ 
0.05) ≤ 0.6 log10 CFU/mL difference in counts throughout the 81 week freezing 
period. There was a significant difference between total counts for Bacteroides 
fragilis gp., (difference of 0.8 log10 CFU/mL from 48 hours vs 81 weeks, p = 
0.026) and Bifidobacterium spp., (difference of 0.9 log10 CFU/mL from 41 
weeks vs 81 weeks, p = 0.017). The largest fluctuations in counts were found in 
the total anaerobes with a decrease of 1.3 log10 CFU/mL from 48 hours and 13 




Table 3-2 Comparison of the total viable counts of bacteria in the 
defrosted faecal emulsion used to seed the gut models 
 
Bacterial population 
Time concentrated faecal slurry frozen  
      48  
   hours 
   13  
weeks 
   29  
weeks 
    41  
 weeks 
    81       
weeks 
Range (log10  
difference)  
Facultative anaerobes 7.3 7.3 6.9 7.2 7.0 6.9 - 7.3 (0.4) 
LF Enterobacteriaceae
e 
7.3 7.2 6.9 6.9 6.8 6.8 – 7.3 (0.5) 
Enterococcus spp. 5.3 5.4 5.4 5.4 5.2 5.2 – 5.4 (0.2) 
Total anaerobes 9.3* 9.3* 9.0 9.0 8.0* 8.0 – 9.3 (1.3) 
Clostridium spp. 6.8 6.2 6.3 6.4 6.2 6.2 – 6.8 (0.6) 
Bacteroides fragilis gp. 5.6* 6.4 6.1 6.0 6.4* 5.6 – 6.4 (0.8) 
Bifidobacterium spp. 6.4 5.9 6.0 5.7* 6.6* 5.7 – 6.6 (0.9) 
Lactobacillus spp. 5.4 5.4 5.4 5.4 5.2 5.2 – 5.4 (0.2) 
Total spores 6.3 6.0 6.4 6.1 6.0 6.0 – 6.4 (0.4) 
 
a
 LF, Lactose fermenting. Values represent the mean log10 CFU/mL from 3 technical replicates. Statistical 
analysis done using a Kruskal-Wallis Pairwise comparison where p ≥ 0.05 was considered significant.  * 
significantly different (p ≤ 0.03). 
 
3.3.2 Planktonic population kinetics 
Each phase of the gut model and subsequent planktonic and biofilm population 
changes have been described in detail in this chapter as this is the first time the 
models are being outlined. In later chapters, trends will be discussed to avoid 
repetition.  
3.3.2.1 Planktonic population dynamics of commensal bacteria during 
steady state and spore reservoir phase.  
After inoculation with the faecal slurry, the models were left without intervention 
for 32 days during the steady state phase. This allowed the microbial 
populations to stabilize and establish colonisation resistance in the model. At 
the end of steady state, total anaerobes were approximately 9 log10 CFU/mL, 
Clostridia spp. were 6.5 – 7 log10 CFU/mL, Bacteroides fragilis gp. were 
approximately 8 log10 CFU/mL, Bifidobacterium spp. were approximately 8 log10 
CFU/mL and total spores were approximately 5 – 5.5 log10 CFU/mL (steady 
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state phase represented by the blue arrow Figure 3-3). In model A, the 
facultative anaerobic populations stabilized faster than model B, with model B 
experiencing an initial decrease in LF Enterobacteriaceae during the first week. 
By the end of steady state, the total facultative anaerobic populations were 
predominantly comprised of LF Enterobacteriaceae at approximately 8 – 9 log10 
CFU/mL and levels of Enterococcus spp. and Lactobacillus spp. reaching 6 – 7 
log10 CFU/mL and 7 log10 CFU/mL, respectively (steady state phase 
represented by the blue arrow, Figure 3-4).  
To ensure colonisation resistance was established in the models, a dose of           
C. difficile spores were added to vessel one of each model at the start of the    
C. difficile reservoir phase. Colonisation resistance was deemed to be 
established with the failure of C. difficile spores to germinate and produce 
toxins. This phase lasted one week in which population levels remained 
consistent (orange arrow, Figure 3-3 and Figure 3-4). After the initial inoculation 
with C. difficile spores, counts were approximately 5 log10 CFU/mL in each 
vessel, with C. difficile recoveries reducing over the week. As the C. difficile 
spores added to the model failed to colonise, the C. difficile spore reservoir was 





Figure 3-3 Enumeration of planktonic anaerobes in (a) the C. difficile 
recurrence model (model A) and (b) the simulated FMT model (model 
B). Bacterial enumeration of total anaerobes (black), B. fragilis gp. (red), 
Clostridium spp. (green), Bifidobacterium spp. (purple), and spores (yellow). 
Data demonstrates the disruption to the microflora during clindamycin and 
vancomycin therapy, and its rapid recovery after FMT in model B. Data 
shown are the mean log10 CFU/mL ± standard error from three technical 
replicates per day of the model timeline of a single biological replicate.  
Different model stages are separated by vertical broken lines (grey; FMT 
instillation red – model B only). Clind – clindamycin, Vanc – vancomycin, FMT – 





Figure 3-4 Enumeration of planktonic facultative anaerobes in (a) the C. 
difficile recurrence model (model A) and (b) the simulated FMT 
model (model B). Bacterial enumeration of total facultative anaerobes 
(black), lactose fermenting (LF) Enterobacteriaceae (red), Enterococcus 
spp. (green), and Lactobacillus spp. (purple). Data demonstrates an 
increase of facultative anaerobes during clindamycin and vancomycin 
therapy. Data shown are the mean log10 CFU/mL ± standard error from 
three technical replicates per day of the model timeline of a single 
biological replicate.  Different model stages are separated by vertical 
broken lines (grey; FMT instillation red – model B only). Clind – clindamycin, 






3.3.2.2 Clindamycin-induced dysbiosis resulted in simulated CDI.  
As CDI is associated with disruption of the microbiota, clindamycin was used to 
perturb the populations and create a microbial niche conducive to C. difficile 
colonisation and outgrowth. Both models were dosed with clindamycin in vessel 
one 4 times daily, for 7 days (purple arrow, Figure 3-3 and Figure 3-4). Gut 
model fluid was removed from each vessel on a daily basis throughout 
clindamycin exposure and for a further seven days post clindamycin cessation 
to monitor antimicrobial concentrations in each vessel. Peak clindamycin levels 
for model A were found in vessel one on day 5 of dosing at 105.5 mg/L and on 
day 6 for vessels two and three at 120.3 mg/L and 104.5 mg/L, respectively. In 
model B, peak clindamycin concentrations of 165.2 mg/L, 117.3 mg/L and 94.8 
mg/L were found on day 7 in vessel one, two and three, respectively (Table 
3-3). A number of factors could contribute to the discrepancy of clindamycin 
peak levels between dosing days, models and vessels. Flow rate between 
vessels most likely had the highest influence of antibiotic levels. Biofilm 
accumulation in the piping connecting vessels as well as the flow of nitrogen 
into the vessels could both affect flow through the model. Despite these 
differences, both models were able to induce CDI at the same time point, 
reaching the similar levels of C. difficile toxin titre. 
Clindamycin instillation resulted in dramatic changes to the microbial 
populations. The populations affected to the highest degree in both models 
were the Bacteroides fragilis gp., Clostridium spp., and Bifidobacterium spp.. 
Bacteroides fragilis gp. populations declined rapidly immediately after 
clindamycin instillation by approximately 3 – 3.5 log10 CFU/mL, and recovered 
to pre-dosing levels 4 days after clindamycin cessation. Clostridium spp. 
declined by approximately 3 – 4 log10 CFU/mL by mid-clindamycin dosing, with 
populations recovering from between 4 to 5 days post clindamycin cessation. 
The most dramatic effect was seen in Bifidobacterium spp. populations that 
reduced from approximately 8.2 log10 CFU/mL to below the limit of detection, 
and did not recover in this phase of the models. Total spore recoveries declined 
gradually during clindamycin exposure and continued to decline after 
clindamycin cessation from approximately 5 log10 CFU/mL to approximately 1.5 
log10 CFU/mL. Recovery of spore populations was gradual, with pre-dosing 
levels achieved 2 weeks after clindamycin cessation, with a spike in 
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populations to approximately 6 log10 CFU/mL at this point (purple and red 
arrows, Figure 3-3). The facultative anaerobic populations were not affected to 
the same degree, with only marginal disruption to populations that recovered 
rapidly (purple arrow, Figure 3-4).  
C. difficile populations began to show signs of germination approximately 9 - 10 
days post clindamycin cessation (Figure 3-5). Peak C. difficile was recovered 
approximately 2 week post-clindamycin in both models, with total counts of 5.5 
– 6 log10 CFU/mL and spore counts of approximately 2 – 3 log10 CFU/mL, 
indicating germination of C. difficile spores in both models. Germination was 
accompanied by the detection of C. difficile toxin, reaching peak levels of 3 RU 
and 2 RU approximately 2 weeks after clindamycin cessation for models A and 
B, respectively (black broken line, Figure 3-5). In both models, peak toxin titres 
were achieved in vessel 3 and persisted longer than in vessel two. No evidence 
of germination or toxin production was seen in vessel one (results not shown).   
 
Table 3-3 Peak clindamycin and vancomycin concentrations (mg/L) and 
corresponding treatment day in model A and model B. 
 Model A Model B 














Clindamycin One 5 105.5 7 165.2 
Two 6 120.3 7 117.3 
Three 6 104.5 7 94.8 
Vancomycin One 4 138.7 5 153.7 
Two 6 134.7 6 174.9 





Figure 3-5 Enumeration of planktonic C. difficile total and spore counts in 
(a) the C. difficile recurrence model (model A) and (b) the simulated 
FMT model (model B). Enumerations of C. difficile spores (red) and total 
viable counts (blue) are represented for both models in mean log10 
CFU/mL ± standard error (left axis). C. difficile toxin (black broken line) is 
represented as log reciprocal units (RU, right axis). Evidence of C. difficile 
recurrence is seen in model A but prevented after FMT in model B. Data 
shown are from three technical replicates per day of the model timeline of 
a single biological replicate. Different model stages are separated by 
vertical broken lines (grey; FMT instillation red – model B only). Clind – 
clindamycin, Vanc – vancomycin, FMT – faecal microbiota transplantation, CDI – C. 
difficile infection. 
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3.3.2.3 Planktonic microbial population dynamics during vancomycin 
treatment.  
Most of the populations enumerated recovered to pre-clindamycin levels with 
the exception of Bifidobacterium spp. which remained below the limit of 
detection in both models when entering the vancomycin treatment phase. 
Vancomycin was introduced to both models in vessel one, 4 times daily for 7 
days. Vancomycin was chosen as it is used clinically to treat CDI and has been 
used in our models previously to successfully model rCDI at the concentrations 
stated (Chilton et al., 2014b, Crowther et al., 2014a). Peak vancomycin levels 
in model A reached 138.7 mg/L (day 4 of treatment), 134.7 mg/L (day 6 of 
treatment) and 135.1 mg/L (day 7 of treatment) for vessel one, two and three, 
respectively. Peak vancomycin levels in model B reached 153.7 mg/L (day 5 of 
treatment), 174.9 mg/L (day 6 of treatment) and 154.9 mg/L (day 6 of 
treatment) for vessel one, two and three, respectively (Table 3-3). The 
population changes during vancomycin treatment were similar in both models, 
with the most dramatic changes occuring in Clostridium spp., and Bacteroides 
fragilis gp. with approximately 5 log10 CFU/mL and approximately 6 log10 
CFU/mL reductions in counts, respectively (green arrow, Figure 3-3 and Figure 
3-4). C. difficile TVC and spore counts rapidly declined, falling below the limit of 
detection in both models 3 days after vancomycin commencement (Figure 3-5). 
Most of the other populations enumerated remained unaffected or experienced 
minor, transient differences in population counts.  
3.3.2.4 Differences in planktonic populations between model A and 
model B after FMT instillation  
After vancomycin treatment, model A was left without further intervention 
whereas model B underwent a simulated FMT 3 days after vancomycin 
cessation. At the time of FMT intervention, vancomycin levels in model B were 
17.5 mg/L, 26.5 mg/L and 30.94 mg/L in vessel one, two and three, 
respectively. Vancomycin levels were below the limit of detection one day after 
FMT instillation. In model A, Clostridium spp. and Bacteroides fragilis gp. 
populations gradually recovered 7 and 10 days post-vancomycin, respectively. 
Bifidobacterium spp. remained undetectable for the duration of model A Figure 
3-3 a). C. difficile was detected 28 days after vancomycin cessation, with 
evidence of germination seen with an approximately 2 log10 CFU/mL 
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divergence in spore and total counts, with peak TVCs of 6.4 log10 CFU/mL. This 
was accompanied by the detection of C. difficile toxin, reaching peak titres of 3 
RU 33 days post-vancomycin (Figure 3-5 a), indicating the recurrence of CDI in 
this model.  
A considerable difference in recovery rate of commensal populations was 
evident immediately after FMT instillation in model B, with next day sampling 
revealing the complete recovery of Clostridium spp. and Bacteroides fragilis gp. 
to pre-vancomycin levels. Evidence of Bifidobacterium spp. recovery was seen 
immediately after FMT instillation (Figure 3-3 b). C. difficile was detected 
sporadically at very low levels, with no evidence of germination or toxin 
production (Figure 3-5 b), indicating that the FMT instillation successfully 
prevented rCDI in this model.  
3.3.3 Biofilm population kinetics 
3.3.3.1 Biofilm population dynamics during steady state and spore 
reservoir phase.  
Multispecies biofilms consistently formed on the walls of the vessels and the 
glass sampling rods (Figure 3-6). Vessel one appeared to have accumulated 
the most biofilm on the vessel walls, however sampling was not performed from 
this vessel due to the relevance of the third vessel in C. difficile infection. As the 
number of glass rods in each model was limited, earlier biofilm samples 
spanning steady state, spore reservoir and early CDI were extensively studied 
in earlier models (two models detailing early planktonic and biofilm sampling 
presented in appendix A5), with results comparable to models A and B Figure 
3-7 and Figure 3-8). These data suggested stable biofilm populations 
established in the steady state period that were not influenced by the addition 
of C. difficile spores. C. difficile spores rapidly became associated with the 
biofilm at level of approximately 4 – 5 log10 CFU/g (Figure 3-9). Total facultative 
anaerobes were the predominant populations recovered from the biofilm. In 
planktonic populations, the LF Enterobacteriaceae counts closely match the 
total facultative anaerobic populations; however, there was an approximately 2 
log10 CFU/g difference in these counts in biofilm populations, indicating a 
difference in composition of the total facultative anaerobic populations between 




Figure 3-6 Biofilm formation in the gut model. The presence of biofilm 
formation can be seen on the vessel walls of the gut model (blue arrow) 
and on the biofilm support structures inserted in the lid vessel three of the 
gut model (insert).  
 
3.3.3.2 Biofilm populations are more resilient to clindamycin treatment 
than planktonic populations.  
As in steady state and the spore reservoir phase, the biofilm populations were 
predominantly sampled during clindamycin instillation and CDI induction in 
previous model runs (appendix, A5) with results comparable to models A and B 
(Figure 3-7 and Figure 3-8). Biofilm populations were not affected to the same 
degree as the planktonic phase during clindamycin instillation, demonstrating 
the resilience of biofilms to antimicrobial stress. A approximately 1 – 2 log10 
CFU/g reduction in counts was seen in Bacteroides fragilis gp. after 
clindamycin instillation, with populations recovering during peak CDI. 
Bifidobacterium spp. population initially dropped by approximately 3 log10 
CFU/g after clindamycin dosing, with populations continuing to decline to below 
the limit of detection during CDI. Total facultative anaerobic populations 
increased during clindamycin dosing by approximately 2 log10 CFU/g before 
dropping back down to steady state levels during peak CDI. Different trends 
were seen in the total anaerobic populations and Clostridium spp., between the 
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two models. Total anaerobes in model A increased by approximately 1 log10 
CFU/g during clindamycin instillation followed by a fall in populations 
approximately 2 log10 CFU/g; whereas in model B an initial decrease of 
approximately 2 log10 CFU/g was seen after clindamycin dosing, followed by an 
increase in populations of approximately 1.5 log10 CFU/g during CDI. 
Clostridium spp. populations in model A gradually increased from the spore 
reservoir phase, through clindamycin treatment and into CDI; whereas in model 
B there was a transient decrease in the populations during clindamycin 
instillation that recovered rapidly during CDI. C. difficile was isolated from the 
multispecies biofilm at approximately 4 – 5 log10 CFU/g throughout clindamycin 




Figure 3-7 Enumeration of biofilm anaerobes in (a) the C. difficile 
recurrence model (model A) and (b) the simulated FMT model (model 
B).  Bacterial enumeration of total anaerobes (black), B. fragilis gp. (red), 
Clostridium spp. (green), Bifidobacterium spp. (purple), and spores 
(yellow) from the biofilm recovered from biofilm support structures of the 
gut models. Data demonstrates the disruption to the biofilm populations  
during clindamycin and vancomycin therapy. Data shown are the mean 
log10 CFU/g biofilm mass ± standard error from three technical replicates 
of a single biological replicate. Clind – clindamycin, Vanc – vancomycin, FMT – 




Figure 3-8 Enumeration of biofilm facultative anaerobes in (a) the C. 
difficile recurrence model (model A) and (b) the simulated FMT 
model (model B). Bacterial enumeration of total facultative anaerobes 
(black), lactose fermenting (LF) Enterobacteriaceae (red), Enterococcus 
spp. (green), Lactobacillus spp. (purple), and fungi (yellow) from the 
biofilm recovered from biofilm support structures of the gut models. The 
facultative anaerobic populations of the biofilm remained stable through 
antimicrobial therapy. Data shown are the mean log10 CFU/g biofilm mass 
± standard error from three technical replicates of a single biological 
replicate. Clind – clindamycin, Vanc – vancomycin, FMT – faecal microbiota 
transplantation, CDI – C. difficile infection, d – days, wk – weeks. 
 
Clind – clindamycin  




3.3.3.3 Vancomycin treatment induced pleiotropic changes in biofilm 
populations in Model A.  
Total obligate anaerobic populations remained stable throughout vancomycin 
treatment, with levels between 9 – 10.5 log10 CFU/g. Clostridia spp. populations 
reduced by approximately 3 log10 CFU/g during vancomycin treatment, 
recovering approximately 7 days post-vancomycin cessation to steady state 
levels. B. fragilis populations gradually dropped during vancomycin treatment, 
reducing by approximately 4 log10 CFU/g, 5 days post treatment cessation. 
Recovery of this population began 7 days after the end of treatment with counts 
between 7 - 8 log10 CFU/g for the remainder of the experiment. Bifidobacterium 
spp. levels dropped below the limit of detection after clindamycin treatment and 
remained so until the last biofilm sample 33 days after the last vancomycin 
dose with levels similar to that seen in steady state. Total spore counts dropped 
by 2 log10 CFU/g by the end of vancomycin treatment, recovering 5 days later 
and maintaining populations between 6 – 7.5 log10 CFU/g (Figure 3-7a).   
Total facultative anaerobic populations and LF Enterobacteriaceae experienced 
an increase in counts during vancomycin treatment of 1 and 2.5 log10 CFU/g, 
respectively. Lactobacillus spp. populations increased by approximately 1 log10 
CFU/g and Enterococcus spp. decreased by approximately 1 log10 CFU/g 
during vancomycin treatment, with both populations recovering to pre-
vancomycin levels 12 days after treatment ended. Fungal populations in the 
biofilm during steady state reached levels of approximately 5.5 log10 CFU/g. 
Levels dropped to 4.5 log10 CFU/g during clindamycin treatment and continued 
to decline to below the limit of detection after vancomycin treatment, recovering 
2 weeks after vancomycin cessation (Figure 3-8 a). C. difficile levels remained 
between 3.5 – 4.3 log10 CFU/g for the duration of the experiment, with C. 
difficile predominantly in spore form (Figure 3-9).  
3.3.3.4 FMT fails to eradicate C. difficile from the biofilm.  
Clostridia spp. populations reduced from approximately  8 to 4 log10 CFU/g 
during vancomycin treatment with levels increasing to approximately 7 log10 
CFU/g 4 days after FMT instillation. B. fragilis gp. counts decreased throughout 
vancomycin dosing reaching 4 log10 CFU/g before levels increased to 8 log10 
CFU/g 4 days after FMT instillation. Bifidobacterium spp. failed to recover after 
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clindamycin treatment and therefore levels were undetectable during 
vancomycin treatment. Bifidobacterium spp. was detected 7 days after FMT 
instillation and levels remained stable for the duration of the experiment. Total 
spores decreased by approximately 2 log10 CFU/g during vancomycin 
treatment and reached steady state levels 2 days post FMT instillation (Figure 
3-7b).  
Total facultative anaerobic populations and LF Enterobacteriaceae spp. 
increased by approximately 1 log10 CFU/g during vancomycin before stabilising 
at approximately 10 log10 CFU/g for the duration of the experiment.  
Enterococcus spp. dropped by 1 log10 CFU/g after vancomycin treatment 
followed by a gradual increase in populations to steady state levels 4 days after 
FMT, further increasing by 1.5 log10 CFU/g at the end of the experiment. Total 
fungal populations increased slightly after clindamycin treatment from 
approximately 4.5 – 5.5 log10 CFU/g before counts dropped during vancomycin 
treatment to 4 log10 CFU/g. After FMT instillation, fungal populations stabilised 
at approximately 5 log10 CFU/g. Lactobacillus spp. were stable throughout 
vancomycin treatment and FMT instillation (Figure 3-8 b). C. difficile counts 
decreased marginally after FMT instillation; however, C. difficile was not 
eliminated from the biofilm and remained associated with sessile communities 
for the remainder of the experiment at levels of approximately 3.5 - 4 log10 





Figure 3-9 Enumeration of C. difficile total and spore counts recovered 
from the biofilm in models A and B. Bacterial enumeration of the total 
viable counts (TVC - solid line) and spore counts (broken line) of C. 
difficile for the recurrence model (model A - red) and the faecal microbiota 
transplant model (model B – blue) from biofilm recovered from biofilm 
support structures in the respective models. Data demonstrates the 
persistence of C. difficile cells in the biofilm through antimicrobial and 
faecal microbiota transplant therapy. Data shown are the mean log10 
CFU/g biofilm mass ± standard error from three technical replicates of a 
single biological replicate, at various stages throughout the model 
timeline. Clind – clindamycin, Vanc – vancomycin, FMT – faecal microbiota 






3.3.3.5 Taxonomic analysis of biofilm populations 
DNA was extracted from biofilm pellets after centrifugation and the A260/A280 
ratio was used as an indication of DNA purity. All DNA extracts had ratios of 
between 1.8 – 2.0, indicating acceptable DNA purity, and extracts were then 
shipped for offsite taxonomic analysis using16 SV4 rRNA Illumina sequencing 
and analysis (section 2.2.14). Reads were aligned to a curated database 
consisting of the full-length 16S region. Operational taxonomic units (OTU) with 
fewer than 10 reads in a given sample were discarded. The OTU data was 
organised at the family level, with the 14 most prevalent families considered.   
In both models, treatment with clindamycin and vancomycin were associated 
with an increase in Enterobacteriaceae populations and a decrease in 
Eubacteriaceae and Bifidobacteriaceae. Vancomycin treatment had a larger 
effect on microbial communities, with additional decreases in Bacteroidaceae, 
Lachnospiraceae, Ruminococcaceae and Comamondaceae; and increases in 
Synergistaceae, Lactobacillaceae and Desulfovibrionaceae. In model A, 
Enterobacteriaceae and Synergistaceae populations continued to increase to 
38.9 % and 19.5 % abundance, respectively. Eubacteriaceae, Lachnospiraceae 
and Bifidobacteriaceae remained low, recovering 4 weeks post-vancomycin 
treatment. Bacteroidaceae, Ruminococcaceae and Comamondaceae failed to 
recover to pre-antibiotic levels by the end of sampling (Figure 3-10 a). These 
population changes were associated with rCDI in the planktonic phase. 
In contrast, model B post-FMT analysis revealed a decrease in 
Enterobacteriaceae, Synergistaceae and Desulfovibrionaceae populations to 
1.16 %, 8.2 % and 1.2 % respectively. This was accompanied with the rapid 
recovery of Bacteroidaceae, Eubacteriaceae, Lachnospiraceae, 
Bifidobacteriaceae and Ruminococcaceae (Figure 3-10 b). Analysis of the 
microbiota diversity, using the Shannon diversity index, showed an increase in 
diversity of samples post-FMT in model B, increasing from 1.72 ± 0.51 to 2.03 ± 
0.52 at one week post-FMT and continued to increase, ending the experiment 
on 2.33 ± 0.21. Model A by comparison, had a diversity index of 1.79 ± 0.52 
one week post vancomycin cessation, dropping to 1.76 ± 0.28 the following 





Figure 3-10 Changes in bacterial taxonomic abundance of the biofilm 
microbial community at selected time points in the recurrence model 
(A) and the simulated FMT model (B). Taxonomic abundance 
(percentage) of the top 14 bacterial families recovered from biofilm 
support structures in the triple stage gut models. Graphs constructed 
using the mean (of least 3 support structures) percent abundance of 
bacterial OTUs assigned to a family taxonomic level, for one biological 
replicate for the recurrence model and two biological replicates for the 
FMT model. Clind – clindamycin, Vanc – vancomycin, FMT – faecal microbiota 
















Figure 3-11 Shannon Diversity Index of biofilm samples from model A and 
model B. The Shannon (alpha) diversity of the biofilm populations was 
measured after vancomycin treatment for model A (red) and model B 
(blue). There was an increase in bacterial diversity in model B from 7 days 
post vancomycin cessation when compared to model A, which lasted to 
the end of the experiment. The Shannon Diversity Index was calculated 
using bacterial OTUs assigned to a family taxonomic level using mean 
data from at least 3 support structures for each time point, for one 
biological replicate for the recurrence model and two biological replicates 
for the FMT model. Error bars indicate standard deviation. FMT – faecal 




3.3.3.6 Changes in bile acid levels during rCDI and FMT  
Bile acid metabolism has been demonstrated to play an important role in CDI 
and therefore we wanted to monitor the changes to the bile acid profile during 
rCDI and FMT treatment. The levels of the primary bile acid, cholic acid (CA), 
and the secondary bile acids deoxycholic acid (DCA) and oxo-bile acids (oxo-
BAs) were analysed at different time points throughout the models. CA and 
DCA were components of our gut model growth media and were continuously 
fed to the model. Bile acid levels stabilised during steady state, with similar 
levels seen in both models. Antimicrobial therapy resulted in an increase in CA 
levels, accompanied by a decrease in DCA levels, indicating a decrease in 
microbiome mediated 7α - dehydroxylation bile acid metabolism using CA with 
antimicrobial treatment. CA levels decrease while DCA and OXO-Bas increase 
as the microbiota diversity increased. In model A, high levels of CA were seen 
for an extended period of time after vancomycin treatment. This was 
accompanied by relatively high levels of DCA and low levels of oxo-BAs. As 
DCA was continuously added to the model in the growth media, increased 
levels could indicate the accumulation of DCA from the input rather than CA 
metabolism. The potential accumulation of DCA and low oxo-BA levels could 
indicate a decrease in downstream bile acid metabolism by the microbiome 
(Figure 3-12 a). In model B, there was a rapid decrease in CA levels post-FMT. 
This was accompanied by an increase in DCA and oxo-BA levels, indicating 
downstream secondary bile acid metabolism as the microbiome diversity was 





























Figure 3-12 Bile acid analysis of the C. difficile recurrence model (A) and 
the faecal microbiota transplant model (B). The concentration of cholic 
acid (CA; blue, diamond), deoxycholic acid (DCA; red, square) and oxo-
bile acids (oxo-BAs; green, triangle) were measured in nM/mg at selected 
time points during the model timeline. Total bile acids (black, circle) 
represent the sum of CA, DCA and Oxo-Bas. Data demonstrates 
increased CA levels during clindamycin and vancomycin instillation, with 
prolonged elevated CA levels in model A coinciding with CDI recurrence. 
Data are single samples from one biological replicate. CD – C. difficile, Clind – 




With the clinical success of FMTs in preventing rCDI, microbiota restoration has 
become a key area of interest. Currently, there is no standard protocol for 
either FMT preparation or FMT administration, and with increasing safety 
concerns regarding the unknown long term effects of FMT therapy (DeFilipp et 
al., 2019), there has been increased interest in determining the mechanisms of 
FMT efficacy and the drive to develop more defined, regulated microbiome 
based therapeutics. To date, there are insufficient in vitro models to test 
microbiome based therapeutics. Here we sought to modify our current in vitro 
gut model to simulate FMT treatment of rCDI to determine whether the model 
could be used to accurately predict the outcome of microbiome based therapies 
used to prevent rCDI. The University of Leeds in vitro gut models have been 
used previously to determine the propensity of antimicrobials to induce 
simulated CDI, as well as the efficacy of antimicrobials against primary and 
rCDI (Freeman et al., 2003, Freeman et al., 2007, Chilton et al., 2014b). The 
gut models have been demonstrated to be clinically reflective in both microbial 
contents and study outcome (Freeman et al., 2003, Baines et al., 2005). This 
model also has the advantage of facilitating the development and longitudinal 
sampling of biofilm populations (Crowther et al., 2014a, Crowther et al., 2014b), 
which is an area severely lacking in CDI research. Two gut models were run in 
parallel, one simulating rCDI and the other simulating an FMT, allowing a direct 
comparison between the two using culture of the planktonic and sessile 
populations, bile acid profiling and taxonomic analysis of sessile communities.   
During the initial stages of the models, the indigenous intestinal microbiota 
were left to equilibrate, modelling the environment of a healthy gut. This was 
confirmed when C. difficile spores were added and populations monitored for 
one week. There was no evidence of C. difficile germination or outgrowth 
during this period, indicating colonisation resistance was established in the 
models. This is critical in the validation of the model as it ensures that the 
model is reflective of a healthy microbiota by inhibiting pathogen invasion and 
that the resulting CDI was as a result of antibiotic-induced dysbiosis of the gut 
microflora, a step which has not been demonstrated in previous simulated FMT 
models (McDonald et al., 2018a). Biofilm composition during this period 
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revealed an abundance of populations, dominated by the phyla Firmicutes, 
Bacteroidetes and Proteobacteria, consistent with in vivo findings (Hold et al., 
2002, Lyra et al., 2012). As CDI is dysbiosis-mediated, clindamycin was used 
to perturb the microbiota, generating an environment susceptible to C. difficile 
outgrowth. This disruption was characterised by a reduction in B. fragilis, 
Bifidobacterium spp. and Clostridia spp. with an increase in facultative 
anaerobic populations. Biofilm response to antibiotic instillation was delayed 
and not as dramatic as those seen in planktonic populations, demonstrating the 
resilience of biofilms in hostile environments. Taxonomy of biofilm populations 
reflected findings of increased recoveries of Enterobacteriaceae following 
antibiotic treatment, confirming dysbiosis in the sessile communities, in line with 
in vivo observations (Morgan et al., 2012, Shin et al., 2015). Planktonic levels 
of the primary bile acid CA increased during clindamycin instillation, 
accompanied by a decrease in DCA levels, indicating the potential loss of 
microbiome mediated 7 α – dehydroxylation secondary bile acid synthesis. 
Active CDI was confirmed with evidence of C. difficile spore germination and 
vegetative outgrowth, accompanied by toxin production, approximately 9 days 
post-clindamycin cessation. Recovery of the microbiota to pre-clindamycin 
levels coincided with a decrease in CA and increase of DCA levels.  
Vancomycin treatment of CDI in our models successfully reduced planktonic C. 
difficile populations to below the limit of detection, accompanied with the loss of 
toxin detection. Vancomycin instillation had a dramatic effect on microbial 
populations, with reductions in B. fragilis gp., Clostridium spp., and the 
continued suppression of Bifidobacterium spp., together with increased 
abundance of Enterobacteriaceae. Once again, sessile communities displayed 
a similar trend to those seen in planktonic populations; however, these were 
not as susceptible to antimicrobial therapy and populations changes more 
gradual. Consistent with clindamycin instillation, vancomycin dosing resulted in 
an increase in CA levels, with decreased DCA and oxo-BAs. Planktonic 
enumeration of Clostridium spp., and B. fragilis gp., from Model A, indicated 
population recovery 7 and 10 days after vancomycin cessation, respectively. 
Bifidobacterium spp., failed to recover in planktonic populations, with sessile 
recovery seen in the last sample of the model. The ability of Bifidobacterium 
longum and Bifidobacterium breve to reduce the growth of C. difficile in vitro 
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has led to the potential use of these organisms as pro and prebiotics (Valdes-
Varela et al., 2016) and therefore the reduction and/or absence of these 
populations during initial and rCDI could be significant. 
Evidence of rCDI was seen 28 post-vancomycin treatment in Model A, 
consistent with findings from previous models (Chilton et al., 2014b, Crowther 
et al., 2014a). Bile acid profiling demonstrated a prolonged exposure to high 
levels of CA. Primary bile acids, such as CA, are associated with C. difficile 
spore germination (Sorg and Sonenshein, 2008) and therefore this increased 
exposure to the biofilm-associated C. difficile spores could potentially contribute 
to the development of rCDI in this model. High levels of DCA during this period 
indicates an accumulation of DCA in the model from the media input, most 
likely due to a reduction in the downstream metabolism of bile acids. Reduced 
levels of oxo-BAs seem to confirm this theory. Biofilm 16S rRNA sequencing 
demonstrated increased Enterobacteriaceae after vancomycin treatment, 
accompanied by reduced levels bacterial families predominantly responsible for 
bile-acid metabolism, namely Bacteroidaceae, Bifidobacteriaceae and 
Ruminococcaceae (Song et al., 2019, Vital et al., 2019).  
In model B, 3 days after vancomycin cessation, a simulated FMT was 
performed. Almost immediately following simulated FMT instillation, planktonic 
Clostridia spp. and B. fragilis gp recovered to pre-treatment levels, 
accompanied by the more gradual recovery of Bifidobacterium spp.. It took on 
average 10 days for populations to fully stabilise after the FMT dose, indicating 
a potential time frame for microbial engraftment, raising the possibility of rCDI 
risk within early phases after FMT, which could explain the need for multiple 
FMT instillations in the clinical setting (Lee et al., 2016). FMT instillation had a 
notable effect on biofilm communities, with the reduction in Enterobacteriaceae 
and the rapid recovery of Bacteroidaceae and Bifidobacteriaceae. Bile acid 
analysis indicated a rapid reduction in CA levels following FMT treatment. Oxo-
BA levels also increased, indicating increased microbial secondary bile acid 
metabolism which coincided with the restoration of these bile-acid metabolising 
families. This rapid restoration of the microbiota successfully prevented rCDI in 
this model, for the duration of the experiment. These results are consistent with 
findings from McDonald et al. (2018a) that demonstrate that FMT restores 
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microbial populations responsible for performing key metabolic functions that 
prevent CDI.  
The dynamics of the sessile communities during antibiotic treatment, CDI, rCDI 
and FMT instillation have not been well studied due to the inaccessibility of the 
mucosal populations. In our models, modifications to the vessel reflecting the 
distal colon with glass rods enabled the longitudinal sampling of mature, 
multispecies biofilms without compromising the integrity of the system 
(Crowther et al., 2014b). Results from the sessile communities confirmed the 
tolerance of biofilms to antibiotic treatment (Stewart, 2002) as the populations 
showed high resilience to both clindamycin and vancomycin treatment. Our 
results show that C. difficile spores became intimately associated with the 
healthy biofilm early on. This could have major implications for clinical 
prescribing practises, as well as raising questions on under reported 
asymptomatic carriage rates of C. difficile. The levels of C. difficile spores 
remained steady between 3 to 5 log10 CFU/g throughout the experiment and 
were not affected by vancomycin treatment or eliminated by the FMT 
instillation. This was in contrast to the planktonic phase where C. difficile viable 
and spore counts dropped below the limit of detection, with only transient C. 
difficile detection. We hypothesise that the biofilm acts as a reservoir for C. 
difficile spores, with spores detaching from the biofilm to periodically seed the 
planktonic phase. When the spores encounter an environment susceptible to C. 
difficile outgrowth, as seen in model A, the spores are able seed the planktonic 
phase and lead to vegetative cell proliferation. If the environment is not 
favourable, as seen in model B after FMT- mediated microbiota restoration, the 
spores fail to germinate; however, the spores are still detectable in the biofilm. 
This suggests that patients who have undergone FMT therapy potentially 
remain at risk of CDI with future antibiotic exposure. It also highlights the need 
to develop therapies with greater activity against sessile communities to reduce 
the risk of future CDI and/or eradicate C. difficile from the biofilm. Lower 
recurrence rates of CDI are seen with fidaxomicin treatment when compared to 
vancomycin (Cornely et al., 2012a), in which the higher activity against biofilms 
as well as the persistence of fidaxomicin on spores could be a factor (James et 
al., 2017).   
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The success of FMT infusions has previously been rationalised as the re-
establishment of colonisation resistance by introducing commensal micro-
organisms to restore the function and structure of the community (Khoruts and 
Sadowsky, 2016). A number of specific metabolic pathways have been shown 
to influence CDI and therefore determining the shifts in populations that are 
responsible for these pathways could expand our understanding of the 
functional profile of the microbiome. It is believed that the reduction in members 
of the indigenous bacterial community that are responsible for converting 
primary bile acids into secondary bile acids reduces the resistance to C. difficile 
colonisation and increases the risk for CDI (Winston and Theriot, 2016). The 
presence of secondary bile acids are essentially absent in patients with multiply 
recurrent CDI (Weingarden et al., 2014). Treatment with Clostridium scindens, 
a bile acid 7α-dehydroxylating bacterium, enhanced resistance to CDI in a 
mouse model in a secondary bile acid mediated manner (Buffie et al., 2015). A 
correlation analysis looking at the burden of C. difficile relative to other species 
revealed a negative association with C. scindens (Daquigan et al., 2017). 
Indeed, the restoration of the bile acid profile through the modulation of the 
microbiota has been demonstrated to play a key role in the effectiveness of 
FMT therapy (Mullish et al., 2019).  
Bacteroides thetaiotaomicron has been shown to act symbiotically with C. 
difficile and aids in its expansion by producing fermentation end-products 
succinate and sialic acid which C. difficile is able to exploit and metabolise to 
butyrate (Ng et al., 2013, Ferreyra et al., 2014). Levels of succinate are 
transiently elevated after antibiotic therapy, which C. difficile is able to utilize in 
order to proliferate (Ferreyra et al., 2014). Genes relating to the succinate-
butyrate pathway are present in the C. difficile spore proteome, indicating that 
these pathways are utilised soon after germination (Lawley et al., 2009b). An 
understanding of the spatial organisation in the indigenous communities would 
also prove valuable in understanding functional aspects of the microbiota, as 
indicated by an increased prevalence of Clostridium spp. closely associated 
with the intestinal mucosa, with a role in colonocyte maintenance in mice 
(Lopetuso et al., 2013). A study by Ott et al. (2017) examined the efficacy of 
sterile faecal filtrate transfers (FFT) to treat rCDI. Although only a small study 
involving five patients with multiply recurrent CDI, clinical cure was achieved in 
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100 % of cases. This raises the question of whether the underlying 
mechanisms of FMT involve microbial components, metabolites and 
bacteriophages rather than the live micro-organisms themselves. This 
highlights the need to study the structural and functional profile of the microbial 
community.  
In this study, we successfully simulated a FMT using a clinically reflective gut 
model that facilitates the longitudinal analysis of planktonic and sessile 
populations, as well as the metabolic profiling of the communities. The ability of 
this model to clinically predict the outcome of a FMT could prove an invaluable 
tool in developing more targeted microbiome therapies. We also found that 
despite vancomycin reducing planktonic C. difficile populations below the limit 
of detection, C. difficile remained associated with the biofilm, potentially 
providing a reservoir for future infections. FMT treatment successfully 
prevented rCDI; however, the combined vancomycin and FMT treatment failed 
to eradicate C. difficile spores from the biofilm, demonstrating the potential of 




Chapter 4 Increased dosing of targeted microbiome 
therapeutic SER-109 prevents rCDI in an in vitro model of 
the human gut.  
4.1 Background 
The success of FMT therapy has demonstrated the effectiveness of 
microbiome restoration in preventing rCDI (Kassam et al., 2013, Cammarota et 
al., 2014, Tariq et al., 2018); however, safety concerns regarding long term 
implications, transmissible infections, non-standardised procedures, and patient 
reluctance has led to the development of more targeted microbiome therapies 
(DeFilipp et al., 2019). The concept of microbiome restoration with a defined 
microbial consortium was initially proposed by Tvede and Rask-Madsen in 
1989, when they used a mix of ten bacterial strains to successfully treat rCDI in 
six patients (Tvede and Rask-Madsen, 1989). Lawley et al. (2012) used a 
mouse model of CDI to successfully model the restoration of the mouse 
microbiota using a combination of six phylogenetically diverse intestinal 
bacteria. They were able to demonstrate that this targeted therapy could trigger 
major shifts in the microbial community structure and function, effectively 
displacing C. difficile and resolving disease. The Human Microbiome Project 
and the Metagenomics Project of the Human Intestinal Tract have provided 
new insights into the human microbiome and increased the understanding of 
the microbiota in health and disease. These projects have demonstrated that 
there is great diversity in the microbiome of healthy individuals (Lloyd-Price et 
al., 2017) and as such dysbiosis is linked with functional changes in the 
microbiome.  
Seres Therapeutics, a clinical biopharmaceutical company, specialises in the 
development of microbiome therapies. Using computational models to identify 
and characterise functional differences between healthy and dysbiotic 
microbiomes, Seres has developed investigational Ecobiotic ® drugs targeted 
to restore the underlying ecology and function of a healthy microbiome. One of 
these products, SER-109, is a collection of bacterial spores purified from 
healthy human faeces, and is an investigational oral microbiome therapeutic for 
the prevention of rCDI. SER-109 is believed to prevent rCDI by replenishing 
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helpful bacteria in the gut. Initial Phase 1 clinical results were promising, with 
86.7 % of patients meeting the primary efficacy end point, and 96.7 % of 
patients achieving clinical cure (Khanna et al., 2016). In contrast, in the Phase 
2 clinical trial, the relative risk of CDI recurrence for placebo compared with 
SER-109 recipients was not statistically significant. An in depth post-trial 
analysis indicated that suboptimal dosing and patient selection/CDI diagnosis 
issues could have impacted the measured clinical efficacy of this drug. It was 
found that Phase 1 subjects receiving a higher dose of SER-109 had 
significantly higher species richness in spore-forming bacteria when compared 
with subjects receiving a low dose, indicating the dose used in Phase 2 trials 
was insufficient. Here, we aim to determine whether increased doses of SER-
109 are more efficacious in rCDI.  
4.1.1 Rationale  
After demonstrating the efficacy of an undefined microbial therapy (FMT) in our 
gut model, we evaluated the efficacy of different doses of SER-109 in our 
system. We used taxonomic analysis, bile acid analysis and identified 
microbial-microbial signalling mechanisms to understand the mechanism of 
action behind both SER-109 therapy failure and success to inform further 
clinical trials.  
122 
 
4.2 Methodology  
4.2.1 Experimental design 
In this study, two gut models used to simulate rCDI were run in parallel. One 
model was used to determine the efficacy of a single SER-109 dose and the 
other to determine the efficacy of a single SER-109 dose given over 3 
consecutive days. The experiment was repeated to ensure reproducibility. 
Results are an average of the two models for each dose combined. The model 
timelines are depicted in Figure 4-1. As timescales ran slightly differently for 
each model run, days are approximate. The initial set up of the gut models was 
as described in section 2.2.8 and followed the experimental design in section 
2.2.10. Briefly, during steady state, model planktonic populations were sampled 
every other day until challenge with C. difficile spores (spore preparation 
detailed in section 2.2.7) where populations were sampled daily thereafter 
(section 2.2.11). Results presented were from vessel 3 only. Once colonisation 
resistance was confirmed by the lack of C. difficile spore germination, another 
C. difficile spore dose was added before dosing the model with clindamycin. 
Active CDI was deemed present with evidence of C. difficile spore germination, 
vegetative cell proliferation and peak toxin levels detected; models were then 
dosed with vancomycin. Three days after vancomycin cessation, the models 
were dosed with SER-109, a single dose in one model, and 3 doses in the 
other (1 dose per day for 3 days). Preparation of the SER-109 spores is 
detailed in 4.2.2. Models were then left without further intervention for 30 days 
and monitored for evidence of rCDI. Planktonic samples were taken daily, 
centrifuged at 16 000g and the supernatant kept for third party bile acid 
analysis, cytotoxin testing and antimicrobial bioassays (sections 2.2.15, 2.2.16 
and 2.2.17, respectively). Biofilms were sampled at designated time points 
(blue dots, Figure 4-1and Table 4-1) according to section 2.2.12. Most of the 
biofilm rods were kept for sampling in the later stages of the model to study the 
effects of SER-109 dosing in sessile communities. DNA was extracted from 
biofilm samples and sent for third party 16S rRNA analysis (section 2.2.14). 
Biofilm sample supernatants were retained at - 20°C for investigations into AI-2 




Figure 4-1 The in vitro gut model timeline for SER-109 dosing regimes. 
The different stages of the model are indicated at the corresponding day 
in the timeline. Both models followed the same preogression (grey lines) 
up to the end of vancomycin treatment. SER-109 was added to the 
models 3 days after vancomycin cessation (red broken line). One model 
received 1 SER-109 dose (red arrow) and the other model received 1 
dose of SER-109 daily, for 3 days (green arrow). Biofilm sampling time 




Table 4-1 Biofilm sampling schedule of the SER-109 single and triple dose 
models. 
 
Model stage Day (approximate) Number of rods per model 
1 dose 3 doses  
    
Pre-clindamycin 35 35 1 
Post-clindamycin 42 42 1 
Pre-vancomycin 57 57 1 
Post-vancomycin 64 64 2 
SER-109 67 67 2 
End SER-109 + 7 days 74 77 2 
End SER-109 + 14 days 81 84 3 
End SER-109 + 21 days 88 91 3 
End of experiment 95 98 3 
 
4.2.2 Preparation of SER-109 spores.  
SER-109 spores were prepared as instructed by Seres Therapeutics. Briefly, 
two aliquots of SER-109 (30 mL each) were received from Seres Therapeutics 
and stored at -80°C until ready to use. SER-109 aliquots were defrosted at 
room temperature, centrifuged to pellet the bacterial spores and the 
supernatant discarded. The spore pellet was washed with sterile PBS 
supplemented with 12 % glycerol before being aliquoted into 10 mL volumes 
and frozen at -80°C. When a dose was required, an aliquot was defrosted at 
room temperature and 10 mL added to the base of vessel one of each model.  
4.2.3 Detection of quorum sensing Autoinducer-2 in biofilms 
The presence of the quorum sensing molecule, autoinducer-2 (AI-2), was 
measured in biofilm supernatants from one set of models. Once the biofilm rod 
had been processed (2.2.12) and samples taken for DNA extraction (2.2.13), 
the biofilm supernatant was removed from the biofilm pellet and filter sterilised 
before being frozen at – 20°C until required for AI-2 detection. Aliquots were 
defrosted at room temperature prior to use.  
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4.2.3.1 Bacterial strains and growth conditions 
The AI-2 bioassay was used to detect and quantify the presence of 
autoinducer-2 signalling molecules in biofilm samples. Vibrio campbellii strains 
BB-170 (ATCC BAA-1117) and BB-152 (ATCC BAA-1119), previously 
designated Vibrio harveyi (Bassler et al., 1993, Thompson et al., 2007) were 
grown on nutrient agar plates at 30°C aerobically. V. campbellii BB-152 was 
grown in Luria-Bertani (LB) broth (Lennox) overnight with agitation, followed by 
centrifugation at 16 000g for 15 min and filter sterilisation. The supernatant was 
maintained at -20°C for use as a positive control. Autoinducer bioassay (AB) 
medium was used for analysis during the AI-2 assay and was prepared 
according to Bassler et al. (1994). Briefly, medium was prepared in 1L volumes 
and contained 0.3M sodium chloride, 0.05 M magnesium sulphate and 0.2 % 
vitamin-free casamino acids, adjusted to pH 7.5 before sterilisation. After 
cooling, 10 mL of 1M potassium phosphate, 10 mL of 0.1M L-arginine, 20 mL 
glycerol, 1 mL of 10 µg/mL riboflavin and 1 mL of 1 mg/mL thiamine were 
added.  
4.2.3.2 AI-2 assay 
V. campbellii strain BB-170 luxN::Tn5kan AI-1 sensor negative AI-2 sensor 
positive reporter strain (Bassler et al., 1993) was grown aerobically at 30°C on 
nutrient agar for 24 hours. The AI-2 assay was performed according to 
Lombardia et al. (2006) with the following variations. The overnight culture was 
scraped off the plate and resuspended in fresh AB medium and adjusted to an 
OD600 of 0.5 and then further diluted 1:100 in AB medium. Filter sterilised 
sample cell-free supernatants, previously obtained and stored at -20°C from 
the gut models, were defrosted and added in triplicate to a white 96 microwell 
plate (93F Nunclon Delta), along with the reporter strain suspension to a final 
volume of 10 % (v/v).  V. campbellii BB-152 was used as a positive control, with 
results recorded at the point of maximum bioluminescence from this positive 
control. PBS was used as a negative control and to determine the baseline 
bioluminescence. The cultures were shaken at 30°C in a thermoshaker (Grant-
bio) and bioluminescence (Infinite Pro, Tecan) measured every hour, for 8 
hours. Results were reported as relative light units (RLU) per gram of biofilm 
mass normalised using the value of bioluminescence from the negative control.  
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4.3 Results  
4.3.1 Multiple changes to planktonic populations after antibiotic 
treatment. 
Antibiotic treatment with both clindamycin and vancomycin resulted in 
considerable changes to the planktonic populations (Figure 4-2 and Figure 
4-3). Peak levels of clindamycin and vancomycin were 68.8 mg/L and 234.9 
mg/L in vessel one, respectively. Clindamycin instillation resulted in the 
successful induction of CDI, with a divergence of 2.2 – 3.5 log10 CFU/mL 
between TVCs and spore counts, accompanied with peak C. difficile cytotoxin 
levels reaching between 2 – 3 RU. Reductions B. fragilis gp., Clostridium spp., 
Bifidobacterium spp., and total spores were seen with both antibiotics, 
consistent with findings from models in Chapter 3, with vancomycin causing the 
most dramatic effect (Figure 4-2). Additionally, Enterococcus spp. counts 
reduced after vancomycin treatment (Figure 4-3). In contrast to our previous 
models, Bifidobacterium spp., began to recover immediately before vancomycin 
dosing; however, these populations dropped to below the limit of detection 
soon after vancomycin commencement. Lactobacillus populations increased 
during vancomycin treatment and remained high for the duration of the 
experiment, most likely due to the innate resistance of this species to 
vancomycin. C. difficile levels and consequently toxin levels decreased to 
below the limit of detection during vancomycin instillation.   
4.3.2 Only three doses of SER-109 successfully prevented rCDI.  
All models followed the same timeline up to the end of vancomycin treatment. 
Three days after vancomycin cessation, the models were dosed with either a 
single dose of a SER-109 spore preparation or with a single dose for three 
consecutive days (vancomycin levels in vessel one of 4.97 to 5.86 mg/L at the 
time of dosing, respectively). In models with a single SER-109 dose, total 
spores and Clostridium spp., populations increased modestly, with populations 
fluctuating between 3.5 - 5 log10 CFU/mL and 3 - 4.5 log10 CFU/mL, 
respectively, and B. fragilis gp., populations increasing to approximately 7 log10 
CFU/mL 10 days post-SER-109 dosing. Bifidobacterium spp., failed to recover 
for the duration of the experiment (Figure 4-2 a). 10 days after vancomycin 
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cessation, evidence of C. difficile spore germination was seen, with a difference 
in TVC and spore populations of 3 log10 CFU/mL, accompanied with the 
detection of C. difficile cytotoxin at 3 RU, confirming a relapse in CDI with a 
single dose of SER-109 (Figure 4-4 a). In models with SER-109 dosed on three 
consecutive days, B. fragilis gp., populations increased to pre-antibiotic levels 
of between 7 – 8 log10 CFU/mL 4 days after the last SER-109 dose. Clostridium 
spp. and total spore populations increased 2 days after the last dose, with 
levels of Clostridium spp.  exceeding those seen in the single SER-109 dose 
model by 1 log10 CFU/mL. Spore populations in this model decreased by 
approximately 2 log10 CFU/mL 3 days after the last SER-109 dose, recovering 
soon after. This was in line with increased Clostridium spp. recoveries and 
could potentially indicate increased germination in this model. Bifidobacterium 
spp., populations did not recover for the duration of these models (Figure 4-2 
b). C. difficile levels dropped below the limit of detection during vancomycin 
treatment, and although sporadic detection, C. difficile failed to colonise the 
planktonic phase and rCDI was prevented (Figure 4-4 b).  
4.3.3 Increased exposure to cholic acid corresponds with rCDI 
As in our previous rCDI and FMT models, levels of bile acids CA, DCA and 
oxo-BA were analysed at different time points in the planktonic phase. During 
steady state, low levels of CA were seen, accompanied by increased DCA 
levels. Exposure to clindamycin resulted in an increase in the pro-germinant CA 
and the decrease in DCA levels, indicating a decrease in microbiome mediated 
7α - dehydroxylation bile acid metabolism. In line with microbiome recovery, the 
CA levels reduced and the DCA levels increased accordingly until vancomycin 
dosing where a similar trend was seen. In the single dose model (Figure 4-5 a), 
higher levels of CA were seen for a prolonged period of time when compared 
with levels in the triple dosed model (Figure 4-5 b), and this correlated with 
rCDI. In the triple dosed model, CA levels reduced rapidly with an increase in 





Figure 4-2 Enumeration of planktonic anaerobes in (a) the single SER-109 
dose model and (b) the triple SER-109 dose model. Bacterial 
enumeration of total anaerobes (black), B. fragilis gp. (red), Clostridium spp. 
(green), Bifidobacterium spp. (purple), and spores (yellow). Data 
demonstrates the disruption to the microflora during clindamycin and 
vancomycin therapy and a  more rapid recovery in the triple SER-109 dosed 
model. Data shown are the mean log10 CFU/mL ± standard error from three 
technical replicates per day of the model timeline of two biological replicates. 
Different model stages are separated by vertical broken lines (grey; SER-
109 instillation - red). Clind – clindamycin, Vanc – vancomycin, FMT – faecal microbiota 




Figure 4-3 Enumeration of planktonic facultative anaerobes in (a) the single 
SER-109 dose model and (b) the triple SER-109 dose model. Bacterial 
enumeration of total facultative anaerobes (black), lactose fermenting (LF) 
Enterobacteriaceae (red), Enterococcus spp. (green), and Lactobacillus spp. 
(purple). Data demonstrates an increase in facultative anaerobes following 
clindamycin and vancomycin therapy. Data shown are the mean log10 
CFU/mL ± standard error from three technical replicates per day of the model 
timeline of two biological replicates. Different model stages are separated by 
vertical broken lines (grey; SER-109 instillation - red). Clind – clindamycin, Vanc – 




Figure 4-4 Enumeration of planktonic C. difficile total and spore counts in (a) 
the single SER-109 dose model and (b) the triple SER-109 dose model. 
Enumerations of C. difficile spores (red) and total viable counts (blue) are 
represented for both models in mean log10 CFU/mL ± standard error (left axis). 
C. difficile toxin (black broken line) is represented as log reciprocal units (RU, 
right axis). Evidence of C. difficile recurrence was seen in the single SER-109 
dose model but absent in the triple SER-109 dosed model. Data shown are 
from three technical replicates per day of the model timeline from two 
biological replicates. Different model stages are separated by vertical broken 
lines (grey; SER-109 instillation - red). Clind – clindamycin, Vanc – vancomycin, FMT 













Figure 4-5 Bile acid analysis of the (a) 1 SER-109 dose model and (b) 3 
SER-109 doses model. The concentration of cholic acid (CA; blue, 
diamond), deoxycholic acid (DCA; red, square) and oxo-bile acids (oxo-
BAs; green, triangle) were measured in nM/mg at selected time points 
during the model timeline. Total bile acids (black, circle) represent the sum 
of CA, DCA and Oxo-Bas. Prolonged elevated levels of CA were seen 
after a single sER-109 dose; whereas, increased oxo-BAs were seen after 
a triple SER-109 dose. Data are single samples from one biological 




4.3.4 Biofilm population diversity increased after multiple SER-109 
doses 
Clindamycin dosing resulted in decreases of 2 – 3 log10 CFU/g in Clostrdium 
spp. and a decrease of approximately 8 log10 CFU/g in Bifidobacterium spp., 
dropping below the limit of detection (Figure 4-6). This was accompained with 
approximately 1 log10 CFU/g increases in total facultative anaerobes, LF 
Enterobacteriaceae and Lactobacillus spp. (Figure 4-7). In contrast to previous 
models, there was an increase of approximately 1 log10 CFU/g in the B. fragilis 
gp. C. difficile was recovered from the biofilm at 5 – 6 log10 CFU/g and was 
unaffected by clindamycin dosing (Figure 4-8). During CDI, total facultative 
anaerobes dropped back to pre-clindamycin levels and spores, Clostridium 
spp. and Bifidobacterium spp. numbers increased by approximately 0.5 – 1 
log10 CFU/g, 1 – 2 log10 CFU/g and 2 – 4 log10 CFU/g, respectively. 
Vancomycin instillation had a more dramatic effect on the sessile populations, 
with Clostridium spp. reducing by 1 – 2 log10 CFU/g and B. fragilis gp. and 
Bifidobacterium spp. dropping below the limit of detection (Figure 4-6).  
A week after SER-109 dosing in the single dose model, B. fragilis gp. was 
isolated at 4.1 log10 CFU/g and enterococci increased from 6.4 – 8.1 log10 
CFU/g. Bifidobacterium spp. began recovering 14 days after the SER-109 dose 
and maintained levels of beween 3.8 – 4 log10 CFU/g for the duration of the 
experiment. B. fragilis gp. increased 8.3 log10 CFU/g and maintained similar 
levels for the duration of the model run (Figure 4-6 a and Figure 4-7 b). In the 
triple SER-109 dosed model, B. fragilis gp. was isolated at 7 log10 CFU/g 7 
days after the last dose, which was approximately 3 log10 CFU/g higher than 
the single dose model. Enterococcus spp. increased from 6 – 7.6 log10 CFU/g 
and this level remained stable for the duration of the experiment. 
Bifidobacterium spp. failed to recover in this model and remained below the 
limit of detection for the duration of experiment (Figure 4-6 b and Figure 4-7 b). 
Throughout both models, C.difficile was consistently isolated at approximately 4 




Figure 4-6 Enumeration of biofilm anaerobes in (a) the single dose SER-
109 model and (b) the triple dosed SER-109 model. Bacterial 
enumeration of total anaerobes (black), B. fragilis gp. (red), Clostridium 
spp. (green), Bifidobacterium spp. (purple), and spores (yellow) from the 
biofilm recovered from the biofilm support structures of the gut models. 
Data demonstrates the disruption to the biofilm populations during 
clindamycin and vancomycin therapy. Data shown are the mean log10 
CFU/g biofilm mass ± standard error from three technical replicates of two 
biological replicates. Clind – clindamycin, Vanc – vancomycin, FMT – 




Figure 4-7 Enumeration of biofilm facultative anaerobes in (a) the single 
dose SER-109 model (b) the triple dosed SER-109 model. Bacterial 
enumeration of total facultative anaerobes (black), lactose fermenting (LF) 
Enterobacteriaceae (red), Enterococcus spp. (green), Lactobacillus spp. 
(purple), and fungi (yellow) from the biofilm recovered from biofilm support 
structures of the gut models. The facultative anaerobic populations of the 
biofilm remained stable through antimicrobial therapy. Data shown are the 
mean log10 CFU/g biofilm mass ± standard error from three technical 
replicates of two biological replicates. Clind – clindamycin, Vanc – vancomycin, 





Figure 4-8 Enumeration of C. difficile total and spore counts recovered 
from the biofilm in the SER-109 gut models. Bacterial enumeration of 
the total viable counts (TVC - solid line) and spore counts (broken line) of 
C. difficile for the single SER-109 dosed model (red) and the triple dosed 
SER-109 model (blue) from biofilm recovered from biofilm support 
structures. Data demonstrates the persistence of C. difficile cells in the 
biofilm through antimicrobial and SER-109 therapy. Data shown are the 
mean log10 CFU/g biofilm mass ± standard error from three technical 
replicates of two biological replicates, at various stages throughout the 
model timeline. Clind – clindamycin, Vanc – vancomycin, TVC – total viable counts, 




Taxonomic analysis of the biofilm populations revealed an abundance of 
Enterobacteriaceae of 26.8 % before SER-109 dosing which reduced 7 days 
after dosing to 21.1 % and 7.1 % in the single dose model and the triple dose 
model, respectively. After 28 days however, Enterobacteriaceae comprised 
20.6 % abundance in the single dose model and 8.7 % in the triple dose model. 
Bacteroidaceae increased from 0.5 % to 1.5 % in the single dose model and 10 
% in the triple dose model after 28 days. Lactobacillaceae decreased from pre-
dose levels of 16.4 % to 6.3 % and 2.5 % in the single and triple dosed model, 
respectively. Bifidobacteriaceae at pre-dose levels of 3.3 % increased to 6.7 % 
after 7 days and 25.9 % after 28 days in the single dose model. This population 
did not increase in abundance in the triple dose model. Methanobacteriaceae 
abundance remained steady in the single dose model, but increased from 3.4 
% to 13.4 % in the triple dosed model. The family Porphyromonadaceae 
increased from 0.02 % pre-dose to 6.1 % at 28 days in the triple dose model. 
This population remained at 0.1 % in the single dose model (Figure 4-9). 
Overall at 28 day post-dosing, the triple dosed model displayed a greater 
variation in different bacterial families, indicating increased diversity in 
population abundance. The predominant phyla abundance of the single dose 
model was 28.8 % Proteobacteria, 30.8 % Firmicutes and 25.9 % 
Actinobacteria whereas the triple dose model was comprised of 11.7 % 
Proteobacteria, 33.6 % Firmicutes and 16.1 % Bacteroidales.  Analysis of the 
microbiota diversity, using the Shannon diversity index, showed the greatest 
increase in diversity from the triple dosed SER-109 model. Pre-SER-109, the 
diversity index was 1.72 ± 0.51 which increased to 2.31 ± 0.26 and 2.49 ± 0.42, 
for weeks three and four, respectively. In the single dose SER-109 model, an 
initial increase in diversity from 1.55 ± 0.10 to 1.84 ±0.14 was seen at two 
weeks post-SER-109, increasing to 1.89 ± 0.36 at the end of the experiment. 
The reduced diversity in the single dose model, when compared to the triple 
dose model, was associated with the recurrence of CDI (Figure 4-10). 
4.3.5 Evidence of AI-2 mediated quorum sensing in biofilms 
The presence of the quorum sensing AI-2 was determined using the reporter 
organism V. campbellii in the AI-2 bioluminescence assay. The increase in 
bioluminescence of V. campbellii was proportional to the amount of AI-2 
present and therefore could be quantified in biofilm samples at selected times. 
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Biofilms from both models were positive for AI-2 production. Clindamycin 
exposure resulted in a dramatic decrease of approximately 2 log10 RLU in AI-2 
detection during disruption to the biofilm. In line with post-antibiotic recovery of 
the biofilm, increased AI-2 was seen with levels similar to pre-antibiotic 
exposure. A similar trend was seen after vancomycin dosing; however, the AI-2 
detection did not reduce to the same degree as seen in clindamycin. AI-2 levels 
increased at SER-109 dosing in both models and remained stable for the 
duration of the experiment with the exception of a transient 1.5 and 1 log10 RLU 
drop in AI-2 levels (single SER-109 dose and triple SER-109 dose, 
























Figure 4-9 Changes in bacterial taxonomic abundance of the biofilm 
microbial community at selected time points in the (a) single dose 
SER-109 model and (b) the triple dosed SER-109 model. Taxonomic 
abundance (percentage) of the top 14 bacterial families recovered from 
biofilm support structures in the triple stage gut models. Graphs 
constructed using the mean (of least 3 support structures) percent 
abundance of bacterial OTUs assigned to a family taxonomic level for two 
biological replicates. Clind – clindamycin, Vanc – vancomycin, CDI – C. difficile 








Figure 4-10 Shannon Diversity Index of biofilm samples from the SER-109 
triple stage gut models. The Shannon (alpha) diversity of the biofilm 
populations was measured immediately before SER-109 dosing (x1 dose, 
red; x3 doses, blue) and weekly thereafter, for four weeks. The model that 
received three consecutive SER-109 demonstrated increased microbial 
diversity in the last two weeks of the experiment. The Shannon Diversity 
Index was calculated using bacterial OTUs assigned to a family taxonomic 
level using mean data from at least 3 support structures for each time 
point, for two biological replicates. Error bars indicate standard deviation., 







Figure 4-11 Vibrio campbellii bioluminescence in response to the 
presence of Autoinducer-2 molecules in biofilms isolated from gut 
models dosed with SER-109. V. campbellii bioluminescence was 
measured using the Autoinducer-2 assay in response to the presence of 
AI-2 quorum sensing molecules (represented as log10 relative light units – 
RLU ± standard error) in the biofilms from gut models receiving a single 
dose of SER-109 (red) and a triple dose of SER-109 (blue). A drop in 
bioluminescence was detected after clindamycin instillation which 
coincided with disruption to the biofilm, and again two weeks after SER-
109 instillation. Data represents three technical replicates from one 






The models used in this experiment were designed to determine the efficacy of 
different SER-109 dosing regimens to prevent simulated rCDI. Pleiotropic 
changes to the microbiota during clindamycin treatment induced CDI and 
vancomycin treatment caused further disruption to the microbiota, similar to 
findings in the previous models. Clindamycin instillation was characterised by 
reductions in Clostridium spp., Bifidobacterium spp., and B. fragilis gp., which 
created a niche for C. difficile colonisation leading to active CDI with vegetative 
cell outgrowth and subsequent toxin production. It should be noted that the 
extent of clindamycin-induced CDI differed between the two treatment models, 
with total C. difficile counts reaching approximately 6 log10 CFU/mL the single 
SER-109 dose model; whereas in the triple dose model, these levels peaked at 
4.5 log10 CFU/mL. This was reflected in a higher toxin titre of 3.5 RU in the 
single dose model and 2 RU in the triple dose model. It is unknown whether 
this had any impact on the outcome of the study.  
Although vancomycin instillation resulted in the reduction of planktonic C. 
difficile levels, further and more exaggerated dysbiosis to the microbiota was 
seen, including increases in facultative anaerobic populations and LF 
Enterobacteriaceae. Bile acid analysis indicated an increase in the primary bile 
acid CA during antibiotic treatment, accompanied by a reduction in the 
secondary bile acid DCA, indicating a reduction of secondary bile acid 
metabolism using CA as a substrate during antibiotic instillation, consistent with 
antibiotic-induced metabolic shifts in mouse models (Theriot et al., 2014). CA 
has been shown to be a pro-germinant to C. difficile spores whilst the presence 
of DCA was inhibitory to C. difficile vegetative growth (Sorg and Sonenshein, 
2008). The CA/DCA balance was restored in line with recovery of the 
microbiome. Sessile populations were not affected by antibiotic instillation to 
the same degree and any antibiotic-mediated effect was delayed in comparison 
with planktonic populations. The presence of biofilm-associated C. difficile cells 
were unaffected by antibiotic instillation, potentially providing a reservoir for 
disease recurrence should they encounter a susceptible environment.  
During Phase 1 clinical trials, the use of the microbiome therapeutic SER-109 
has previously been shown to be effective at preventing rCDI (Khanna et al., 
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2016), with 86.7 % of patients meeting the primary efficacy end point and 96.7 
% achieving clinical resolution. This clinical success was not repeated in Phase 
2 trials, with the study not achieving the end point of reducing the relative risk of 
recurrence for up to 8 weeks when compared with placebo (Ratner, 2016). 
During an in-depth Phase 2 trial analysis, it was determined that misdiagnosis 
of CDI, caused by using stand-alone PCR testing, and suboptimal dosing of 
SER-109 when compared to Phase 1 trials could explain these findings (Press 
release, Seres Therapeutics, 2017). 
In this experiment, we tested the efficacy of two different dosing regimens of 
SER-109 to prevent rCDI. In our models, treatment with the two different doses 
of SER-109 was associated with distinct changes to the microbial population 
recoveries. A single dose of SER-109 was associated with unstable, fluctuating 
Clostridium spp. recoveries and the recovery of B. fragilis gp. approximately 10 
days after dosing. In the triple dose models, Clostridium spp. recovered rapidly, 
with populations stabilising approximately 1 log10 CFU/ml higher than the single 
dose models. B. fragilis gp. also recovered roughly 4 days earlier in the triple 
dose models. A drop in spore populations in the triple dose model, 
accompanied by the subsequent increase in Clostridium spp. could potentially 
indicate enhanced germination with increased dosing of SER-109.  
Bile acid analysis indicated an increased and prolonged exposure to the 
primary bile acid CA in the single dose models, accompanied with a decrease 
in the secondary bile acid DCA and oxo-BA. This suggests a drop in 
microbiome mediated bile acid metabolism in these models. These results 
reflected findings in our previous model of rCDI and correlated with the relapse 
of CDI. In the triple SER-109 dosed models, CA levels rapidly declined after 
SER-109 dosing, with increases in DCA and oxo-BA levels. These results 
reflect findings in our FMT model, with both sets of models successfully 
preventing rCDI. As CA is a pro-germinant for C. difficile spores (Sorg and 
Sonenshein, 2008), it was not surprising that increased levels were associated 
with rCDI. Indeed, it was found that after FMT therapy, bile acid profiles closely 
resembled that of donors, indicating the efficacy of FMT was closely related to 
bile acid metabolism (Weingarden et al., 2014). Our results demonstrate a 
similar trend in bile acid profiles comparing the triple dose SER-109 and the 
FMT models, indicating a similar restoration of bile acid metabolism. These 
143 
 
results are consistent with findings of targeted reconstruction of the microbiome 
leading to increased resistance to rCDI in mouse models in a secondary bile 
acid dependent manner (Buffie et al., 2015). These results contributed to the 
progression to Phase 3 clinical trials despite the setback from the Phase 2 trial 
results (ClinicalTrails.gov Identifier: NCT03183128). 
Enumeration of the sessile communities demonstrated only minor changes 
after SER-109 dosing. One of the main differences between the two model sets 
was the recovery of B. fragilis gp. which recovered more rapidly, and to a 
higher dregree in the triple verses single dose model. 16S rRNA sequencing of 
these populations revealed an increased abundance of Enterobacteriaceae 
after antibiotic treatment. A single dose of SER-109 transiently reduced levels 
of Enterobacteriaceae; however, at the end of the experiment, these levels 
increased again to levels seen with antibiotic treatment, and reflected those 
seen in a dysbiotic microbiome (Shin et al., 2015). With a triple dose of SER-
109, levels of Enterobacteriaceae abundance decreased from post-antibiotic 
abundance of 26.8 % to 8.7 %. This was accompanied by the general increase 
in relative abundances of the top 13 bacterial familes, indicating a greater 
diversity in sessile populations at the end of the experiment with multiple doses 
of SER-109. The difference in the sessile bacterial abundances 28 days after 
SER-109 treatment in the triple dosed models indicates increased 
diversification of the commensal bacteria. Increases in family abundance was 
not limited to sporulating bacteria that potentially originated in the SER-109 
spore preparation, indicating both engraftment and possible augmentation of 
commensals present, mediated by the incresed SER-109 dose, consistent with 
Khanna et al. (2016). Despite the triple dose of SER-109 successfully 
preventing rCDI, both SER-109 dosing regimens failed to displace C. difficile 
cells from the biofilm. This was consistent with findings with the vancomycin-
only treatment arm and the FMT models. This population of C. difficile cells that 
remain associated with the biofilm, despite vancomycin treatment and 
microbiome restoration therapies, raises the posibility of risk of rCDI with future 
antibiotic therapy. Transient C. difficle detection in the planktonic phase leads 
to speculation that they arise from the biofilm and that the biofilm acts as a C. 
difficile reservoir, seeding the planktonic phase with C. difficile cells. Potentially, 
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if the enviroment is susceptible as in the case of the vancomycin-only treatment 
arm and the single dose SER-109, relapse may occur.  
I have previously demonstrated the potential role of biofilms in rCDI using in 
vitro models. Given the potential of biofilms in rCDI, I set out to further examine 
interactions of C. difficile with other commensal in the biofilm by determining if 
AI-2 quorum sensing could be demonstrated in the multispecies biofilms within 
the gut models. AI-2 mediated quorum sensing represents a key mechanism 
that regulates social activities in mixed microbal populations (Li and Tian, 
2012). Detected in a diverse range of both Gram positive and Gram negative 
species, it represents a means to allow inter-species communication and social 
interactions (Bassler et al., 1993, Bassler et al., 1994, Bassler et al., 1997). 
Using the V. campbellii reporter bioluminescence assay, I was able to 
demonstrate the presence of the AI-2 signalling molecules within the biofilm at 
various time points of the models. I was also able to show that the levels of AI-2 
detected altered during antibiotic treatment, with levels decresing in line with 
reductions in bacterial numbers in the bioflm due to antibiotic therapy. During 
microbiome restoration, detection of AI-2 molecules increased with the 
reconstruction of the multispecies biofilm, demonstrating social interaction and 
community dynamics in biofilms in this in vitro model. The AI-2 signalling 
system has been found in C. difficile (Carter et al., 2005) and mutation 
experiments of the luxS gene in C. difficile revealed a disruption to biofilm 
formation in C. difficile and altered interactions with other commensals (Ðapa et 
al., 2013, Slater et al., 2019), suggesting this could be an important signalling 
system in C. difficile biofilm dynamics.  
One of the greatest defense mechanisms against pathogen establishment is 
through colonisation resistance mediated by a healthy microbiome. This 
colonisation resistance is established by multiple members of the microbiota 
interacting to produce a healthy functional and structural profile. Antibiotic-
induced alterations of the microbiome creates an enviroment susceptible to 
CDI. FMT therapy has successfully been used to prevent multiply reccurent 
CDI and has paved the path to understanding colonisation resistance and 
developing more targerted microbiome restoration therapies (Lawley et al., 
2012, Schubert et al., 2015). C. difficile has also been shown to exacerbate 
intestinal dysbiosis and maintain this environment during CDI (Horvat et al., 
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2017). Here, we were able to successfully prevent rCDI in an in vitro model 
using an increased dosing strategy of the targeted SER-109 faecal spore 
preparation. SER-109 administered on 3 consecutive days was able to 
effectively disrupt the microbiota dysbiosis and facilitated the restoration of the 
microbiota through both engraftment and augmentation of the commensal flora. 
146 
 
Chapter 5 Influence of intestinal microorganisms on C. difficile 
biofilm formation 
 
5.1 Background  
It is commonly accepted that biofilms may constitute the predominant mode of 
bacterial growth in the environment and in the human body (Costerton et al., 
1995). Biofilms are rarely composed of mono-culture species, being typically 
composed of numerous species of microorganisms that form complex and 
diverse communities. The composition and structure of a biofilm varies 
depending on the microorganisms present and the environment in which the 
biofilm formed. Different bacterial species interact extensively with each other 
and the attachment surface, and these interactions influence the structure and 
functional dynamics of the subsequent multispecies biofilms. To understand the 
complex interactions seen in a multispecies biofilm, it is critical to identify the 
different species present and the influence they have on the biofilm community.  
Competition is one of the most common interactions seen in a biofilm due to 
limited space and nutrient availability. Many microorganisms have developed 
ways to inhibit the growth of competing microorganisms as was demonstrated 
by the suppression of Streptococcus mutans growth by Streptococcus 
oligofermentans through the production of hydrogen peroxide via lactate 
oxidase activity (Tong et al., 2008). The production of p-cresol by C. difficile 
was found to inhibit hypha formation in C. albicans affecting both biofilm 
formation and virulence of the yeast (van Leeuwen et al., 2016) and also gave 
C. difficile a competitive advantage over Gram negative bacteria in a mouse 
model (Passmore et al., 2018). Interactions can also be co-operative, with 
different microorganisms benefiting from excreted metabolic by-products or 
facilitating the expression of genes beneficial to growth in that environment, 
such as Actinomyces naeslundii stabilising Streptococcus gordonii expression 
of genes involved in arginine biosynthesis in co-aggregates (Jakubovics et al., 
2008). This has also been seen in the gut with Bacteroides ovatus and 
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Bacteroides vulgatus. B. ovatus is capable of expressing extracellular inulin 
glycoside hydrolases, which are not required for its own growth on inulin. The 
metabolic products but were required to promote B. vulgatus growth, which 
lacks these enzymes and hence the ability to utilize inulin. Growth of B. ovatus 
in proximity to B. vulgatus is enhanced, and therefore benefits reciprocally 
through an unknown mechanism (Rakoff-Nahoum et al., 2016). These 
interactions also have the ability to influence the function of the community 
such as the increased resistance to vancomycin displayed in polymicrobial 
biofilms with Staphylococcus aureus and Candida albicans in serum (Harriott 
and Noverr, 2010).   
5.1.1 Rationale 
Biofilms have been associated with the persistence and recurrence of 
infections, and due to the chronic nature of biofilm-associated infections, they 
have been implicated in relapsing C. difficile infection. The ability of C. difficile 
to become incorporated into intestinal sessile communities was demonstrated 
using the in vitro gut model adapted to facilitate biofilm formation (Crowther et 
al., 2014a, Crowther et al., 2014b). Little is known about the relationship 
between sessile species of the intestinal tract and  C. difficile colonisation and 
persistence. Here, I sought to better understand the role of the individual 
species within biofilms in CDI. A range of microorganisms present in the biofilm 
during simulated CDI in the in vitro gut model were isolated and identified to the 
species level and combined with C. difficile in biofilm co-culture batch 





5.2 Methods  
5.2.1 Bacterial Strains and growth conditions  
All strains used in this study are listed in Table 5-2. The C. difficile PCR 
ribotype 027 strain R20291 was isolated during a CDI outbreak at the Stoke 
Mandeville Hospital (Aylesbury, UK) in 2006 and was supplied courtesy of Dr 
Anthony Buckley (University of Leeds) and was used in all co-culture 
experiments. The C. difficile PCR ribotype 027 strain 210 (BI/NAP1/toxinotype 
III) was isolated during an outbreak of CDI at the Maine Medical Centre 
(Portland, ME, USA) and supplied courtesy of Dr Robert Owens (formally at 
Maine Medical Centre) and was used to compare biofilm growth against strain 
R20291. Other microorganisms used in co-culture experiments were isolated 
from a series of in vitro CDI and rCDI gut model experiments conducted in this 
study, detailed in chapters 3 and 4, with the exception of Finegoldia magna and 
Fusobacterium polymorphum that were sourced from the National Collection of 
Type Cultures (NCTC). Overnight liquid cultures were grown in pre-reduced 
BHIS (Brain heart infusion medium supplemented with 5 mg/mL yeast extract) 
at 37°C with agitation in T25 constant airflow tissue culture flasks (Nunc 
EasYFlask, T25).  
5.2.2 Microbial isolation from the in vitro gut models  
A series of in vitro gut models simulating CDI and rCDI were run in separate 
experiments (Chapters 3 and 4). Outcomes from these models have been 
demonstrated to reflect clinical outcomes and have been used extensively to 
assess therapeutic interventions in CDI (Macfarlane et al., 1998, Freeman et 
al., 2003, Baines et al., 2005). These models were seeded with human 
microbiota and the isolated microbial species are routinely found in the human 
intestine. The isolates from the gut models were recovered from sessile 
populations adherent to biofilm support structures located in the final vessel of 
the models. Colonies were selected from enumeration plates (chapters 3 and 
4) at various time points during the model timeline (Table 2-2). Additional agar 
types were trialled in order to isolate a wider range or microorganisms from 
sessile communities (Table 5-1). Different colony morphologies were selected 
for isolation and identification from selective and non-selective agars used in 
the microbial enumeration in the gut model experiments to generate an isolate 
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culture bank of biofilm-associated microorganisms for use in co-culture 
experiments. After sub-culturing colonies on CBA to ensure purity, 
microorganisms were identified by MALDI-TOF mass spectrometry analysis 
(section 2.2.13) to a species level and stored at -80°C in 12 % (v/v) glycerol. 
Isolates were sub-cultured from frozen stocks onto CBA and incubated either 
aerobically or anaerobically at 37°C (see Table 5-2 for culture conditions).  
Table 5-1 Additional agars used to expand recoveries of sessile 
populations in the gut models. 
Target genus Agar  Source 
Vibrio spp.  Thiosulphate Citrate Bile Salts Sucrose Agar E & O 




Columbia Agar Base with 5% horse blood 
supplemented with colistin sulphate(10 mg/L) and 
nalidixic acid (15 mg/L) 
E & O 
Neisseria spp.  Gonococci selective agar supplemented with 
vancomycin (3 mg/L), colistin sulphate (7.25 mg/L), 
nystatin (12.5 IU/L), trimethoprim (5 mg/L).  
E & O 
Actinomyces spp.  Actinomyces Agar E & O 
Fungi and yeasts  Sabouraud Dextrose agar E & O 




Table 5-2 Microbial strains used in co- and poly culture experiments, 
including source, culture conditions and MALDI-TOF analysis score. 













C. difficile 027 210 Maine Medical 
Centre (Portland) 
Anaerobic  Brazier’s 
CCEY 
NA 
Candida albicans in vitro gut model Aerobic OGYE 2.152 
Candida parapsilosis in vitro gut model Aerobic OGYE 2.002 
Enterococcus gallinarum in vitro gut model Aerobic KAA 2.216 
Staphylococcus aureus in vitro gut model Aerobic CBA 2.132 
Staphylococcus warneri in vitro gut model Aerobic CBA 2.243 
Klebsiella pneumoniae in vitro gut model Aerobic CBA 2.364 
Morganella morganii in vitro gut model Aerobic CBA 2.342 
Lactobacillus rhamnosus in vitro gut model Anaerobic  MRS 2.298 
Bifidobacterium longum in vitro gut model Anaerobic BM 2.12 
Bacteroides 
thetaiotaomicron 
in vitro gut model Anaerobic BBE 2.224 
Clostridium butyricum in vitro gut model Anaerobic FAA 2.181 
Clostridium celecrescens In vitro gut model Anaerobic FAA 2.063 
Clostridium 
clostridioforme 
in vitro gut model Anaerobic FAA 2.328 
Clostridium symbiosum in vitro gut model Anaerobic FAA 2.09 
Clostridium 
paraputrificum 
in vitro gut model Anaerobic FAA 2.335 
Finegoldia magna NCTC 11804 Anaerobic FAA NA 
Fusobacterium 
polymorphum 
NCTC 10562 Anaerobic FAA NA 
CCEY – cycloserine/cefoxitin egg yolk, MXF – moxifloxacin, OGYE – oxytetracycline glucose yeast extract, KAA - 
Kanamycin aesculin azide agar, CBA- Columbia blood agar, MRS – De Man, Rogosa, Sharpe agar, BM – 
Bifidobacterium medium, BBE - Bacteroides bile aesculin agar, FAA – fastidious anaerobe agar 
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5.2.3 Biofilm assay 
The biofilm assay, modified from Dawson et al. (2012)  was used to evaluate 
the ability of different microorganisms to form a biofilm in vitro, and to assess 
the influence of these species on C. difficile biofilm formation. Biofilms were 
quantified using the Crystal Violet (CV) assay and selected co-cultures were 
additionally evaluated using total viable counts (TVCs). Briefly, isolates were 
inoculated in pre-reduced BHI and grown with agitation for 18-24 hours at 37°C 
either anaerobically or aerobically, depending on the species (Table 5-2). 
Sterilised circular glass coverslips (Appleton Woods, UK) were placed in each 
well of a sterile 24 well plate (Nunc, UK) together with fresh BHISC media 
(BHIS media supplemented with 0.05 % (w/v) L-cysteine) and pre-reduced 
overnight. The amount of BHISC added to the wells depended on how many 
microorganisms were to be inoculated into the wells. 1.8 mL was added for 
mono-cultures, 1.6 mL for co-cultures and co-inoculation biofilms of C. difficile 
with cell-free supernatants (CFS), and 1.4 mL for polycultures (three 
microorganisms cultured together). The overnight broth culture for each 
microorganism was adjusted to an OD600 of 0.5 ± 0.03 (Genesys 20 
spectrophotometer, Thermo Scientific) in an attempt to normalise the culture. It 
is acknowledged that individual growth rate and cell size may impact the 
outcome of this intervention; however, results from this assay were only used 
as a preliminary screen to identify potential microorganisms of interest and 
therefore was sufficient for the scope of this study. 200 µL of the overnight, 
adjusted broth were inoculated into their respective wells. A glass coverslip with 
uninoculated culture medium was used as a negative control in all experiments. 
Trays were placed in a humidified container to prevent evaporation and 
incubated for 3 days anaerobically at 37°C where the biofilms were either 
analysed for biofilm biomass in the CV assay or TVCs (Figure 5-1). Results 
shown are the median values and interquartile range from at least three 



























Figure 5-1 The biofilm batch culture assay set up and analysis. After 
inoculation with an overnight culture, biofilms are grown for three days 
before being analysed with either the crystal violet assay or enumerated 
for total and/or spore counts. AU – absorbance units, PBS – phosphate buffered 
saline, CV – crystal violet, TVC – total viable counts.  
Enumeration -  Total 
viable counts/spores  
Overnight culture adjusted to 
OD600 0.5 ± 0.3 AU.  
Dilute 1 in 10 to a final 
volume of 2 mL in BHISC 
in wells containing sterile 
glass coverslips.  
After 3 days anaerobic 
incubation at 37°C, glass 
coverslips with attached biofilms 
are carefully removed.  
 
2 x PBS wash 
Crystal violet (CV) assay 
Biofilms stained with 
CV for 30 minutes, 
washed twice in PBS 
and the dye extracted 
with methanol.  
Methanol extraction 
serially diluted in PBS 
and the absorbance 
measured.  
Serial dilution 
and culture  
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5.2.4 Semi-quantitative Crystal Violet (CV) assay for total biofilm 
biomass  
Each biofilm assay was incubated for 3 days anaerobically and the biomass of 
each biofilm was semi-quantitatively analysed using the CV assay. The CV 
assay has been used extensively as a means to semi-quantitatively measure 
total biofilm biomass as the dye is capable of staining both live and dead cells, 
as well as certain components of the biofilm EPS (Merritt et al., 2005, Skogman 
et al., 2012, Stiefel et al., 2016, Azeredo et al., 2017). The microorganisms 
used in this assay can be found in Table 5-2. The glass coverslips containing 
the biofilms were carefully removed from wells using sterilised forceps, washed 
by dipping twice in PBS, and placed in a well containing 1 mL of a 1 % (w/v) CV 
solution, followed by incubation at room temperature for 30 minutes. Coverslips 
were again carefully removed, washed twice by dipping in PBS and incubated 
at room temperature for 30 minutes in 500 µL of 100 % methanol (BDH 
Laboratory Supplies, Poole, UK) to extract the CV. The extracted CV/methanol 
solution was transferred to a 96 well plate in duplicate and serially diluted in 
PBS. The presence of cells and biofilm matrix in the extract may impact the 
colorimetric measurement and therefore this assay was only used as a screen 
to identify potentially antagonistic and co-operative interactions. The optical 
density was then measured at 595 nm (Infinite P 200 Pro, Tecan). A negative 
control well containing an uninoculated glass coverslip was used to normalise 
the results against the methanol, PBS and CV carryover.  
5.2.5 Total viable and spore counts   
Total viable counts were used to evaluate the total number of viable cells 
present in selected mono-, co- and poly culture biofilms. Coverslips with 
biofilms attached were carefully removed from the wells, washed twice in PBS 
and placed in wells with 500 µL of pre-reduced PBS. Biofilms were then 
disrupted by vigorous pipetting. To determine the proportion of spores making 
up the TVCs in C. difficile mono-culture biofilms, 250 µL of this suspension was 
then incubated for one hour at room temperature in a 1:1 ratio with 100 % (v/v) 
ethanol. The biofilm suspension was serially diluted in pre-reduced PBS and 
plated onto appropriate agars in triplicate (Table 2-2 and Table 5-2) and 
enumerated after 48 hours incubation. In co-cultures with L. rhamnosus, C. 
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difficile was cultured on CCEYL MXF medium (medium formulation found in 
Table 2-2) to reduce the Lactobacilli overgrowth on the CCEYL plates. Results 
were reported as median log10 CFU/mL.  
5.2.6 Effect of culture media pH on C. difficile biofilm formation    
To find the optimum pH for C. difficile R20291 biofilm formation, the ability of C. 
difficile to form a biofilm in a pH range typically found as you traverse the colon 
was assessed. As such, pH 5 was selected to roughly reflect conditions seen in 
the proximal colon and pH 7 to reflect conditions encountered in the distal 
colon. Due to the presence of pH gradients within a biofilm, the effect of a 
highly alkaline environment of pH 9 was also tested. Biofilms were grown in 
BHISC medium with the pH adjusted to pH 5, pH 7 and pH 9 using 1M NaOH 
and 1M HCl, according to section 5.2.3 and analysed using the CV assay 
(section 5.2.4) and enumeration of total and spore counts 5.2.5). 
5.2.7 Co- and poly culture biofilm assay 
The ability of different microorganisms’ isolated form the gut model to form an 
in vitro co-culture biofilms with C. difficile was investigated (Table 5-2). Each 
microbial strain, including C. difficile, was individually grown overnight as 
described in section 5.2.15.2.3. Overnight cultures were adjusted to an OD600  
of 0.5 ± 0.3 with BHISC before being diluted 1 in 10 with pre-reduced BHISC to 
a final total volume of 2 mL in a 24 well plate, as stated in section 5.2.3. Each 
assay consisted of a mono-culture biofilm for each microorganism investigated 
in addition to being cultured with C. difficile in a co-culture. Selected 
microorganisms were then cultured in a polyculture that consisted of two test 
microorganisms cultured together with C. difficile (Figure 5-2). Combinations of 
microorganisms used in poly-culture experiments can be found in Table 5-3. L. 
rhamnosus, B. longum, B. thetaiotaomicron and C. butyricum were selected as 
each of these microorganisms have been suggested as potential probiotics 
(Takahashi et al., 2004, Lebeer et al., 2008, Chang et al., 2019, Martín et al., 
2019, Wang et al., 2020). M. morganii was chosen to co-culture alongside C. 
butyricum as they were observed to grow in close proximity on enumeration 
plates from the gut models and M. morganii was often found growing over C. 
butyricum colonies. S. aureus and C. albicans were selected to investigate 
poly-culture growth with C. difficile as C. albicans has been demonstrated to 
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enhance S. aureus adhesion and biofilm formation (Kean et al., 2017). Results 
from the C. difficile monoculture biofilm were compared with the results in the 





Table 5-3 Microbial combinations for poly-culture biofilms.  
Co-culture Co-culture Poly-culture 
C. difficile and L. rhamnosus C. difficile and C.albicans 
 
C. difficile, L. rhamnosus and 
C.albicans  
C. difficile and B. longum 
 
C. difficile and                             
B. thetaiotaomicron 
 
C. difficile, B. longum 
and B. thetaiotaomicron 
C. difficile and S. aureus C. difficile and C. albicans C. difficile, S. aureus and 
C.albicans  
C. difficile and C. butyricum 
 
C. difficile and M. morganii  C. difficile, C. butyricum and M. 
morganii  
 
5.2.8 Co-culture biofilms with cell free supernatants  
Microbial metabolites or secreted factors have been implicated in the ability of 
certain species to reduce the toxicity of C. difficile cell-free supernatants (CFS) 
(Valdés-Varela et al., 2016). However, some effects require viable cells to be 
present (Woo et al., 2011). To determine whether these interactions extend to 
biofilm formation and whether the effect seen in co-culture biofilms was due to 
interaction with viable cells or metabolic products, the ability of C. difficile to 
form a biofilm in the presence of CFS from selected microorganisms was 
investigated. Bacterial strains L. rhamnosus and B. longum were selected for 
this experiment due to the observe decrease or increase in biofilm formation in 
co-culture with C. difficile. In these experiments, C. difficile was co-inoculated 
(1:1) with the CFS from overnight cultures of the above microorganisms and 
results compared to those obtained in co-cultures with viable cells and C. 
difficile mono-culture biofilms (Figure 5-2). The CFS was obtained by 
centrifuging overnight cultures of target microorganisms (after normalisation to 
OD600 of 0.5 ± 0.03) at 16 000g for 10 mins followed by filter sterilising. The 
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production of organic acids from Lactobacilli and Bifidobacterium have been 
implicated as a potential inhibitory mechanism to C. difficile growth, therefore 
for our experiments with L. rhamnosus and B. longum, an additional CFS 
experiment was conducted whereby the CFS was neutralised to pH 6.8 to 
equal that of the culture medium BHIS with 1M NaOH. 200 µL of C. difficile 
overnight culture and 200 µL of the CFS from the selected microorganism was 
then co-inoculated into 1.6 mL of BHISC in the wells, as in section 5.2.7.   
 
 
Figure 5-2 Inoculation of the biofilm batch culture experiments for co- and 
poly-culture assays. To investigate the nature of the interactions of C. 
difficile in co- and poly-culture with selected microorganisms (1 and 2), 
biofilm batch culture assays were used. For each microorganism, a mono 
culture biofilm was grown comprising of 1.8 mL culture medium and 200 
µL of overnight broth culture. Co-culture experiments consisted of 1.6 mL 
culture media and 200 µL of C. difficile and  200 µL of the microorganism 
or cell free supernatant (CFS). Poly-culture experiments consisted of 1.4 
mL culture medium and 200 µL of C. difficile and 200 µL of each of the 
two target microorganisms or CFS. The biofilms were then left to grow for 






5.2.9 C. difficile cytotoxin testing 
In selected biofilms, the amount of C. difficile cytotoxin was quantified using the 
Vero cell cytotoxin assay as described in section 2.2.16. Briefly, the biofilm was 
resuspended by vigorous pipetting in 500 µL PBS, as for TVC counts. This 
biofilm suspension was then centrifuged at 16 000g for 10 minutes and filter 
sterilised. The biofilm suspension was serially diluted in pre-prepared Vero cell 
culture trays and left for 48 hours incubation. All biofilms were assayed in 
duplicate and results reported as relative units (RU).  
5.2.10 Scanning Electron Microscopy – sample preparation and 
biofilm imaging  
Biofilms were grown on glass coverslips as per section 5.2.3, harvested after 3 
days and rinsed twice in PBS. Biofilms were fixed in 2.5 % (v/v) glutaraldehyde 
in 0.1 M phosphate buffer overnight and washed twice in 0.1 M phosphate 
buffer for 30 min each. Biofilms were post fixed in 1 % osmium tetroxide (w/v) 
in phosphate buffer for 2 hours and washed twice for 20 mins in phosphate 
buffer. Biofilms were dehydrated using an ascending acetone series (20 %, 40 
%, 60 %, 80 %, 100 %, (v/v)) for 30 mins each change, washing twice with 
phosphate buffer after each change. Biofilms were then critical point dried in a 
critical point drying apparatus (Polaron E3000, Quorum Technologies) using 
liquid CO2 as the transition fluid. The biofilm samples were mounted on 13mm 
diameter pin stubs with double sided adhesive tape and coated with platinum to 
a thickness of 5 nm using a high resolution sputter coating unit (Cressington 
208HR). Biofilms were observed and imaged using an Hitachi SU8230 ultra 
high resolution field emission scanning electron microscope (FE-SEM) at 5000, 
10 000, 20 000  and 25 000 x magnification. Assistance with sample 
processing and SEM imaging were provided by Mr Martin Fuller, Astbury 
Centre for Structural Molecular Biology and Mr Stuart Micklethwaite, Leeds 
Electron Microscopy and Spectroscopy Centre, The University of Leeds. 
Selected images were false-coloured using Adobe Photoshop CC version. 
5.2.11 Statistical analysis and graphical software   
Statistical analysis was performed using IBM SPSS Statistics 22 for Windows. 
Co-culture data were analysed using a Mann-Whitney U test. Poly cultures, the 
effect of pH on C. difficile biofilm formation and all co-cultures involving 
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supernatants were analysed with the Kruskall Wallis one-way analysis of 
variance with a pairwise comparison. P values of ≤ 0.05 were considered 
statistically significant. GraphPad Prism 5 for Windows, version 5.03 and 




5.3 Results  
5.3.1 Characterisation of the C. difficile biofilm  
The ability of hyper-virulent C. difficile ribotype 027 strains R20291 and 210 to 
form a biofilm in vitro were compared. TVC and spore counts were performed 
to gain an insight into the composition of these biofilms. R20291 was used as it 
is known produce a robust biofilm (Dawson et al., 2012), these results were 
compared with 210 strain as the latter strain was used in the in vitro gut model 
experiments, thus assessing its ability to form biofilms was necessary. The 
semi-quantitative crystal violet assay was used to measure the total biofilm 
biomass. Crystal violet is able to non-specifically bind to negatively charged 
molecules and therefore is capable of binding to live and dead cells, and to 
certain negatively charged components of the biofilm EPS matrix (Pitts et al., 
2003, Petrachi et al., 2017). Results from the CV assay demonstrated that 
R20291 formed a biofilm with significantly increased biofilm biomass compared 
with strain 210 (median absorbance of 10.0 and 8.5 AU, respectively, p = 
0.012) (Figure 5-3 a). Enumeration of cells within the biofilms revealed no 
significant difference in TVC between the two strains (median log10 CFU/mL of 
7.6 and 7.7, respectively, p = 0.924); however, R20291 formed considerably 
more spores than 210 (median log10 CFU/mL of 6.7 and 5.7, respectively, p < 
0.001) (Figure 5-3 b). As the difference in biofilm biomass seen in the CV assay 
could not be attributed to an increase C. difficile growth, it is possible that a 
larger degree of cell death or an increase in EPS production in R20291, when 
compared to 210, could be responsible. Mono culture biofilms of C. difficile 
strain R20291 attached to glass coverslips were visualised by SEM after 3 days 
incubation. The image at x 5000 magnification revealed a mat of aggregated C. 
difficile vegetative cells and cell debris adherent to the abiotic surface and the 
presence of EPS matrix-like substance (Figure 5-4 a). Enlargement of images 
at x10 000 and x20 000 magnification revealed what appears to be an EPS 
matrix with a filamentous and web–like appearance, linking cells together 





































































Figure 5-3 Crystal Violet staining and enumeration of C. difficile ribotype 
027 strains R20291 and 210 biofilms. The biofilm produced by two C. 
difficile strains was analysed using (A) the semi-quantitative crystal violet 
assay (absorbance - AU) (R20291 – striped, 210 - clear) measured at 595 
nm and (B) enumeration of total (striped) and spore (clear) counts in log10 
CFU/mL. R20291 produced significantly (**p = 0.012) more biofilm 
biomass when compared to 210 in the crystal violet assay. Similar levels 
of total counts were recovered between the two strains; however, R20291 
produced significantly (***p < 0.001) more spores than 210. Results 
represent the median with interquartile range from at least three technical 




Figure 5-4 Scanning electron microscopy of C. difficile R20291 biofilms 
grown for 3 days. A) Robust C. difficile biofilm with a web-like 
extracellular polymeric substances and cell debris at x 5 000 
magnification. B) Enlargement of image A at x 20 000 magnification 
clearly demonstrating the biofilm matrix linking the C. difficile cells and cell 
debris together. C) Mat of C. difficile R20291 vegetative cells and cell 
debris adherent to an abiotic surface, x 5 000 magnification. D) 
Enlargement of image C at x 10 000 magnification showing fibrous strings 
of matrix linking cells together. Black boxes indicate the enlarged sections, 





5.3.2 Impact of pH on biofilm formation 
The ability of C. difficile R20291 to form a biofilm at pH 5, pH 7 and pH 9 was 
assessed using the crystal violet assay and enumeration of TVC and spores. 
The proximal colon has an acidic pH and therefore medium at pH 5 was used 
to mimic this environment. As the pH of the environment increased, this 
corresponded to an increase in biofilm formation from pH 5 to pH 9 (median 
absorbance of 1.1, 8.8 and 19.7 AU for pH 5, 7 and 9, respectively, p ≤ 0.001)       
(Figure 5-5 a). This was accompanied with an increase TVCs of 7.0, 7.5 and 
7.8 log10 CFU/mL (Figure 5-5 b) and spores of 4.0, 5.4 and 6.3 log10 CFU/mL 
for pH5, 7 and 9 (Figure 5-5 c), respectively (p ≤ 0.001). As C. difficile infection 
is usually associated with the distal colon that has a pH closer to neutral, the 
results comparing biofilm formation at pH5 and pH 7 was expected.  
The largest amount of biofilm biomass and growth was observed when the 
media was adjusted to pH 9 (p < 0.001). The clinical significance of this finding 
is not clear as the pH in the planktonic phase of the colon typically does not 
exceed pH 7; however, little is known regarding the pH levels within biofilms 
and pH gradients have been demonstrated previously in a mixed biofilm 
comprised of 10 oral bacteria ranging from pH 3 – pH 7.2 (Vroom et al., 1999). 
However, members of the ‘core’ gut microbiome are generally associated with 
metabolic by-products that are acidic in nature (Oliphant and Allen-Vercoe, 
2019) and therefore it is unlikely that the pH would rise to the level tested here 





Figure 5-5 Crystal violet quantification and enumeration of C. difficile from 
biofilms formed in medium with different levels of pH. C. difficile biofilms 
were grown at pH 5, pH 7 and pH 9 were quantified using (a) the crystal 
violet assay (absorbance at 595nm) (b) enumeration of total viable counts 
(log10 CFU/mL) and (c) enumeration of spores (log10 CFU/mL). C. difficile 
biofilm biomass, total viable cells and spore recoveries increased with 
increasing pH. Results represented are the median with interquartile range 
for at least three technical replicates from each of three biological replicates. 



















































































5.3.3 The effect of microorganisms isolated from the GI tract on C. 
difficile biofilm formation.  
5.3.3.1 Initial screen of co-culture biofilms with C. difficile using the 
crystal violet assay.  
To further understand the influence of biofilms on CDI, the impact of individual 
microorganisms on C. difficile biofilm formation was investigated. This was 
done by screening multiple microorganisms, isolated from the in vitro gut 
models (Chapter 3 and 4) and identified to a species level (section 2.2.13), for 
biofilm formation with C. difficile in co-culture. During initial co-culture biofilms, 
a mixture of obligate anaerobes and facultative anaerobes. For each 
experiment, a mono culture biofilm was grown for each microorganism as well 
as the co-culture biofilm with C. difficile. The crystal violet assay was used in 
this initial screen to identify microorganisms that would be used in further 
experiments. The tested microorganisms can be found listed in Table 5-2. This 
was done my comparing the co-culture biofilm result with the C. difficile mono 
culture biofilm. Co-culture biofilms of C. difficile together with Klebsiella 
pneumoniae, Morganella morganii, Clostridium symbiosum, Bifidobacterium 
longum (p ≤ 0.001), Bacteroides thetaiotaomicron, Clostridium butyricum (p ≤ 
0.02), Lactobacillus rhamnosus, and Clostridium celerecrescens (p ≤ 0.05), 
resulted in significantly less biofilm formed when compared with C. difficile 
mono-culture (Figure 5-6). The individual mono-culture data for each of these 
microorganisms suggests that these particular strains, in the conditions 
examined, are relatively poor biofilm formers. Co-culture biofilms of C. difficile 
together with Staphylococcus warneri (p ≤ 0.02), Clostridium paraputrificum 
and Fusobacterium polymorphum (p ≤ 0.001) resulted in significantly more 
biofilm formed when compared with C. difficile mono-culture. M. morganii, B. 
longum, B. thetaiotaomicron, C. butyricum, L. rhamnosus, C. albicans, S. 
aureus and S. warneri were selected to further investigate interactions with C. 
difficile. Although the co-culture of C. difficile with C. paraputrificum and F. 
polymorphum were significantly larger than C. difficile mono-culture, these 
microorganisms were not selected for further study. F. polymorphum is more 
relevant to the oral microbiota and therefore was not considered further. C. 
paraputrificum was not selected for follow up experiments due to 
inconsistencies in bacterial growth of overnight cultures. Even with agitation, C. 
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paraputrificum would form large aggregates in the overnight culture that would 
not readily disperse, resulting in difficulty adjusting the overnight growth 
concentration to 0.5 AU. The mono-culture results of C. paraputrificum, with a 
mean of 53 AU, far exceeded the mean 16 AU of C. difficile. It is therefore likely 
that the increase seen in biofilm co-cultures was as a result of C. difficile 
incorporation into the C. paraputrificum biofilm and not an example of 
interaction between the two species. Results from all mono and co-culture 
biofilm experiments are from at least three technical replicates of each of at 
least three biological replicates. 
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Figure 5-6 Quantification of mono and co-culture biofilms using the crystal violet assay. Biofilms were cultured in mono-culture 
(C. difficile – red, test microorganisms – blue) and in co-culture with C. difficile (grey) for three days before being analysed using 
the crystal violet assay (absorbance, AU with standard error). The absorbance of the co-culture was compared to the absorbance 
of the C. difficile mono-culture, and the interactions were assessed for significance using a Kruskal-Wallis test with pairwise 
comparisons (* p ≤ 0.05, ** p ≤ 0.02, *** p ≤ 0.001). The majority of the microorganisms tested were poor biofilm formers and 
resulted in decreased amounts of biofilm produced in co-culture with C. difficile when compared with C. difficile mono-culture.     
CD - C. difficile, KP – K. pneumoniae, MM – M. morganii, CS – C. symbiosum, BL – B. longum, BT – B. thetaiotaomicron, CB – Clostridium butyricum, LR – L. rhamnosus, 
CC – Clostridium celerecrescens, FM – F. magna,  Candida albicans, CP – Candida parapsilosis, SA - S. aureus, EG – Enterococcus galinarum, SW -  S. warneri , Cl.P - 
Clostridium paraputrificum and FP - Fusobacterium polymorphum.
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5.3.3.2 Investigating the effect of cell-free supernatants (CFS) on C. 
difficile biofilm formation.  
To further investigate the interactions of  C. difficile with L. rhamnosus, B. 
longum, S. warneri and S. aureus, the co-culture biofilm assay was repeated 
using the cell free supernatant from the test microorganisms overnight culture 
to determine whether the effect seen in co-culture with C. difficile was as a 
result of cell viability or mediated by secreted factors and by-products. 
Additionally, as organic acid metabolic products of L. rhamnosus and B. 
longum are both known to reduce pH levels of the culture medium, this was 
measured to be pH 5.8 and pH 5.6 in overnight culture supernatants, 
respectively, a portion of the CFS was adjusted to pH 6.8 using 1M NaOH. A 
further co-culture biofilm experiment was done to include co-culture of C. 
difficile with the neutralised CFS (nCFS). In the CV assay, co-culture of C. 
difficile with L. rhamnosus, L. rhamnosus CFS and L. rhamnosus nCFS 
resulted in a significant decrease in biofilm formation in all conditions tested (p 
< 0.001), with largest decrease seen in co-culture with the CFS, resulting in a 
mean decrease of 8.4 AU vs the 3.6 RU decrease seen in nCFS, indicating that 
pH was partly responsible for the decrease seen in the co-culture (Figure 5-7 
a). The TVC data shows a significant difference between C. difficile counts in 
the co-culture biofilm with L. rhamnosus when compared to mono-culture, with 
an approximate 3 log10 CFU/mL decrease in C. difficile TVCs in co-culture (p < 
0.001) (Figure 5-7 b). The TVC from L. rhamnosus indicates an increase in 
counts in co-culture vs mono-culture, despite the reduced biomass of the 
biofilm. TVC of C. difficile in co-culture with L. rhamnosus CFS and nCFS were 
not significantly different from the C. difficile mono culture TVC, suggesting that 
viable L. rhamnosus cells are required to inhibit C. difficile growth. C. difficile 
cytotoxin testing was performed on these biofilms and results were consistent 
with TVC values, with toxin levels in co-culture with L. rhamnosus decreasing 
from 3.5 RU in mono-cultures to 1.75 RU in co-culture (p = 0.01), whereas in 
co-cultures with the CFS and nCFS, there was no significant difference when 
compared to the mono-culture (3.6 and 3.5 RU, respectively) (Figure 5-9). The 
data suggests that the decrease in C. difficile toxin levels in co-culture were 
most likely a result of decreased cell numbers in the presence of L. rhamnosus 
viable cells.  
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Co-cultures of C. difficile with B. longum resulted in a significant decrease in 
biofilm formation (absorbance reduced by 9.2 AU, p < 0.001), when compared 
to the C. difficile monoculture (Figure 5-8 a). There was no significant 
difference in biofilm biomass in co-cultures of C. difficile with either the CFS or 
the nCFS. TVC revealed a significant decrease in C. difficile counts in co-
culture with B. longum viable cells (decrease of 1.2 Log10 CFU/mL, p = 0.01) 
(Figure 5-8 b). In line with the results in the crystal violet assay, there was no 
significant difference in TVC in the co-cultures of C. difficile with either B. 
longum CFS or nCFS. Cytotoxin testing demonstrated a reduction in toxin 
levels in co-culture with B. longum effect on C. difficile toxin levels. Co-culture 
of C. difficile from 3.5 RU in mono-culture to 2 RU in co-culture with B. longum, 
whereas co-culture with either the CFS or nCFS had no effect on toxin levels 
(Figure 5-9). From this data, it appears that B. longum viable cells are required 




Figure 5-7 Co-culture biofilm experiments between C. difficile and L. 
rhamnosus. C. difficile and L. rhamnosus biofilms were cultured alone 
(blue) and in co-culture (grey), alongside C. difficile biofilm co-cultures 
with L. rhamnosus cell free supernatant (CFS – grey, diagonal pattern) 
and neutralised cell free supernatant (nCFS – grey, vertical pattern). 
Results were analysed using (a) the crystal violet assay (absorbance, AU) 
and (b) total viable counts (log10 CFU/mL). There was a significant 
decrease in biofilm biomass in each co-culture when compared with the 
C. difficile mono culture in the crystal violet assay (p ≤ 0.001) and in the 
total counts when L. rhamnosus viable cells were present (p ≤ 0.001). 
Results represent median and interquartile range from at least three 
technical replicates of each of three biological replicates. CD- C. difficile, LR – 
L. rhamnosus, CFS – cell free supernatant, nCFS – neutralised cell free supernatant, TVC – total 
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Figure 5-8 Co-culture biofilm experiments between C. difficile and B. 
longum. C. difficile and B. longum biofilms were cultured alone (blue) and 
in co-culture (grey), alongside C. difficile biofilm co-cultures with B. 
longum cell free supernatant (CFS – grey, diagonal pattern) and 
neutralised cell free supernatant (nCFS – grey, vertical pattern). Results 
were analysed using (a) the crystal violet assay (absorbance, AU) and (b) 
total viable counts (log10 CFU/mL). There was a significant decrease in 
biofilm biomass and total counts when C. difficile was co-cultured with B. 
longum viable cells (p ≤ 0.001 and p ≤ 0.01, respectively). Results 
represent median and interquartile range from at least three technical 
replicates of each of three biological replicates. CD- C. difficile, BL – B. longum, 






Figure 5-9 C. difficile toxin production in co-culture biofilms. Levels of C. 
difficile toxin were measured using the Vero cell cytotoxicity assay 
(measured in relative units – RU) in co-culture biofilms with L. rhamnosus 
and B. longum, as well as co-cultures with the cell free supernatant (CFS) 
and the neutralised cell free supernatant (nCFS) from each. There was a 
significant decrease in toxin production in co-cultures of C. difficile with L. 
rhamnosus and B. longum viable cells (p ≤ 0.01). Data represents three 
technical replicates of three biological replicates. CD – C. difficile, LR – L. 







5.3.4 Effect of poly-culture biofilms on C. difficile biofilm formation  
 
In nature, biofilms are comprised of communities of microorganisms and the 
presence of additional species to the biofilm can potentially change its structure 
and function. To evaluate the effect of more than one micro-organism on C. 
difficile biofilm formation, poly-microbial biofilm cultures were conducted 
comprising of C. difficile cultured together in equal quantities with two other 
microorganisms isolated from the in vitro gut models. Briefly, each of the three 
microorganisms were cultured in mono-culture biofilms. C. difficile was then co-
cultured with each of the two microorganisms selected and finally all three 
microorganisms were cultures together. Two of the poly-culture experiments 
were comprised of two sets of microorganisms that demonstrated reduced 
biofilm formation when in co-culture with C. difficile, namely B. longum and B. 
thetaiotaomicron; and C. butyricum and M. morganii. The latter poly-culture 
was chosen as an observation from culture plates from the in vitro gut models 
that revealed C. butyricum growing intimately associated with M. morganii, 
often one colony on top of the other, therefore this relationship warranted 
further investigation. As interactions between C. difficile and yeasts are not well 
documented, poly-cultures of C. difficile and C. albicans with S. aureus or L. 
rhamnosus were investigated.  
The poly-culture of C. difficile, B. longum and B. thetaiotaomicron had a median 
absorbance of 3.1 AU in the CV assay. This value was not significantly different 
from the median values from co-cultures of C. difficile with B. longum (2.5 AU) 
and B. thetaiotaomicron (5.4 AU); however. it was significantly different from 
the C. difficile mono-culture of 17.3 AU (p < 0.001) (Figure 5-10 a). TVCs from 
the co-cultures experiments revealed a decrease of 1.1 – 1.3 log10 CFU/mL 
which was significantly less than that of the C. difficile mono-culture (p < 
0.001), for B. longum and B. thetaiotaomicron, respectively. TVCs from the 
poly-culture demonstrated a reduction in C. difficile numbers of 2.3 log10 
CFU/mL (p < 0.001) when compared to C. difficile mono-culture (Figure 5-10 
b). These results suggest that there is a larger reduction in C. difficile biofilm 
biomass and growth within a biofilm when cultured with B. longum and B. 









































Dual cultureMono culture  Poly culture























Figure 5-10 Poly-microbial biofilm culture of C. difficile with B. longum 
and B. thetaiotaomicron. Mono-culture (blue), co-culture (grey) and 
poly-culture (red) biofilms are shown for C. difficile, B. longum and B. 
thetaiotaomicron for (a) the crystal violet assay (absorbance – AU) and (b) 
total viable counts (log10 CFU/mL). In both the co- and poly-culture 
biofilms, there was a significant reduction in C. difficile biofilm biomass 
and cell growth when compared to the mono-culture biofilm. Results 
represent the median and interquartile range of three technical replicates 
of each of three biological replicates. *** p ≤ 0.001.  CD- C. difficile, BL – B. 




The combined effect of co-culture of C. butyricum and M. morganii with C. 
difficile maintained a reductive effect, but the median value of the poly-culture 
was between that of the co-cultures with absorbance values of 7.4, 2.4 and 5.8 
AU for co-culture with C. butyricum, co-culture, with M. morganii, and the poly-
culture, respectively. All were significantly less than that of the measured 
absorbance for C. difficile mono-culture (11.8 AU, p ≤ 0.002) (Figure 5-11 a). C. 
difficile TVCs from co-cultures were approximately 1 log10 CFU/mL lower (p < 
0.01) when compared to the C. difficile mono-culture; however, the C. difficile 
TVCs from the poly-culture were not significantly different from the mono-
culture (Figure 5-11 b). C. butyricum TVCs increased in both co-and poly-
cultures whereas M. morganii TVC was unaffected in co culture with C. difficile 
but decreased in the poly-culture.  
The biofilm biomass of the poly-culture between S. aureus, C. albicans and C. 
difficile was not significantly different from the C. difficile mono-culture biofilms 
(p ≤ 0.3) (Figure 5-12 a). There was a significant decrease in C. difficile TVC in 
co-culture with S. aureus (p ≤ 0.01), but this effect was lost in poly-culture 
(Figure 5-12 b). Although the quantity of biofilm recovered was not significantly 
different, observations from SEM imaging revealed a change in the nature of 
the observed EPS matrix. SEM imaging of C. difficile mono-culture biofilms 
revealed an EPS matrix that is filamentous and web-like in nature, whereas 
Candida spp. mono-culture biofilm has an EPS matrix that has a dense, 
granular appearance (Figure 5-13 a and b). The poly-microbial biofilm formed 
between C. difficile, Staphylococcus spp. and Candida spp., shows all three 
closely interacting with each other, where both types of EPS matrix are present, 
indicated by the white arrows, and contribute to the biofilm (Figure 5-13 c and 
d). This indicates that although the amount of biofilm biomass or micro-
organism growth may not have changed, the nature of the interactions, spatial 
organisation and the appearance EPS matrix have altered. It is acknowledged 
that the nature of the processing of biofilms samples for SEM imaging affects 
the EPS matrix; however, differences in the appearance of the matrix between 
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Figure 5-11 Poly-microbial biofilm culture of C. difficile with C. butyricum 
and M. morganii. Mono-culture (blue), co-culture (grey) and poly-culture 
(red) biofilms are shown for C. difficile, B. butyricum and M. morganii for 
(a) the crystal violet assay (absorbance – AU) and (b) total viable counts 
(log10 CFU/mL). The crystal violet assay revealed a significant decrease in 
biofilm biomass in all cultures examined when compared to the C. difficile 
mono-culture (***P ≤ 0.002), whereas the total counts revealed a 
significant decrease in C. difficile growth in both co-cultures but not in 
poly-culture (**P ≤ 0.01). Results represent the median and interquartile 
range of three technical replicates of each of three biological replicates. 
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Figure 5-12 Poly-microbial biofilm culture of Clostridium difficile with S. 
aureus and Candida albicans. Mono-culture (blue), co-culture (grey) and 
poly-culture (red) biofilms are shown for C. difficile, S. aureus and C. 
albicans for (a) the crystal violet assay (absorbance – AU) and (b) total 
viable counts (log10 CFU/mL). There was a significant difference in C. 
difficile total counts in co-culture with S. aureus when compared to C. 
difficile mono-cultures (**P ≤ 0.01). This reduction in C. difficile growth 
was not seen in the poly-culture. Results represent the median and 
interquartile range of three technical replicates of each of three biological 
replicates. CD- C. difficile, SA – S. aureus, CA – C. albicans, P – poly-culture, TVC – 





Figure 5-13 False-coloured scanning electron microscopy image of 3 day 
old mono- and poly-microbial biofilms. (a) C. difficile mono culture 
biofilm, scale bar 2µm) (b) Candida sp., mono culture biofilm, scale bar 
5µm and (c) poly-microbial biofilm comprised of C. difficile (red cells), 
Staphylococcus spp., (blue cells) and Candida spp., (green cells, (scale 
bar 20µm)). (d) insert of the extracellular matrix at a higher magnification, 
scale bar 2µm. Arrows show the different appearance of the extracellular 
matrix from C. difficile and C. albicans. 
 
As the presence of C. albicans appeared to inhibit the ability of S. aureus to 
reduce C. difficile growth in the poly-culture biofilm, another poly-microbial 
culture was conducted that included L. rhamnosus, C. albicans and C. difficile. 
This was done to determine whether C. albicans could negate the effect seen 
in L. rhamnosus co-cultures as it did with S. aureus. In this poly-culture, there 
was a significant reduction of 8.7 AU in biofilm biomass when compared with C. 
difficile mono-culture biofilms (p < 0.001) (Figure 5-14 a). Co-culture TVCs with 
L. rhamnosus resulted in a 3.5 log10 CFU/mL decrease in C. difficile counts (p 
<0.001) whereas in the poly culture only a reduction of 0.3 log10 CFU/mL was 
seen (p > 0.05) (Figure 5-14 b). These results indicate that although the biofilm 
biomass decreased, the presence of C. albicans in the biofilm prevented the 
reduction of C. difficile growth in the biofilm by L. rhamnosus, as seen in the 
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Figure 5-14 Poly-microbial biofilm culture of Clostridium difficile with L. 
rhamnosus and Candida albicans. Mono-culture (blue), co-culture (grey) 
and poly-culture (red) biofilms are shown for C. difficile, L. rhamnosus and 
C. albicans for (a) the crystal violet assay (absorbance – AU) and (b) total 
viable counts (log10 CFU/mL). There was a significant difference in 
absorbance (AU) between the C. difficile mono-culture when compared to 
the co-culture with L. rhamnosus and the poly-culture (*** p ≤ 0.009). C. 
difficile total counts were reduced in co-culture with L. rhamnosus but not 
in poly-culture (*** p ≤ 0.009). Results represent the median and 
interquartile range of three technical replicates of each of three biological 
replicates. CD- C. difficile, LR – L. rhamnosus, CA – C. albicans, P – poly-culture, TVC 




5.4 Discussion  
In this chapter, the effect of different microbial species on biofilm formation of 
C. difficile was investigated. The ability of C. difficile to form biofilms in vitro has 
been previously demonstrated (Dawson et al., 2012, Ðapa et al., 2013, 
Semenyuk et al., 2014), showing significant strain variation in the amount of 
biofilm formed, such as the increased biofilm formation of the 027 ribotype 
when compared with strain 630 (Ðapa et al., 2013). Using the CV assay to 
quantify biofilm biomass, it was demonstrated that strains 027 R20291 and 027 
210 form robust biofilms on glass coverslips, with reduced turbidity of the 
culture medium and no fluid surface biofilm formation, in agreement with 
Dawson et al. (2012) and Ðapa et al. (2013). The hypervirulent R20291 strain 
formed significantly more biofilm than the 210 strain. Biofilms from both strains 
were comprised of vegetative cells and spores, with R20291 forming 
significantly more spores than the 210 strain. Strain dependent variations in 
biofilm forming ability and composition have previously been demonstrated, 
with the hypervirulent strains generally forming larger biofilms than other clinical 
isolates (Dapa and Unnikrishnan, 2013, Hammond et al., 2014, Pantaléon et 
al., 2014), which highlights the potential of biofilms in virulence. Indeed, 
R20291 was found to display unique behaviour in a mouse model by forming 
numerous aggregates associated with the mucus layer (Lawley et al., 2009a, 
Buckley et al., 2011, Soavelomandroso et al., 2017).  
Donelli et al. (2012) was the first to show that C. difficile was capable of forming 
dual culture biofilms with another species, and that the interaction between C. 
difficile and F. magna changed the overall size and structure of the biofilm, 
indicating a co-operative relationship. C. difficile was also found as a minority 
member in the mucosal communities in a mouse model (Semenyuk et al., 
2015). During in vitro gut model experiments seeded with human faeces, the 
presence of C. difficile spores and vegetative cells within the multispecies 
biofilm was demonstrated, in agreement with Crowther et al. (2014b). Biofilms 
in nature exist as complex multispecies communities and the composition of 
these biofilms is integral to the function of the biofilm. Little is known about the 
relationship of different sessile species and C. difficile, including its recruitment 
into the biofilm and how variation in the microbial composition of mucosal 
181 
 
biofilm may alter virulence. In addition to identifying species present in the 
biofilm during CDI, it is also important to characterise the interactions of these 
organisms with C. difficile in a biofilm. To further understand the interaction of 
C. difficile with other commensal microorganisms in biofilms, a number of 
different microorganisms that co-existed with C. difficile as part of a 
multispecies biofilm from our gut models were isolated and identified. A 
selection of these microorganisms were then co-cultured alongside C. difficile 
to determine their impact on C. difficile biofilm formation.  
As previous gut model results have shown a decrease in sessile 
Bifidobacterium spp., Bacteroides spp, and Clostridium spp. after antimicrobial 
therapy and leading to CDI, representative strains from each of these species 
were used in co-culture experiments with C. difficile to determine if they had an 
inhibitory effect on C. difficile biofilm formation. B. longum was consistently 
isolated during the gut models and has also been extensively studied as a 
potential probiotic strain to prevent and treat antibiotic-associated diarrhoea 
(AAD) (Valdes-Varela et al., 2016) and therefore we used this bacterium in a 
number of co-culture and poly-culture experiments. Overall, C. difficile co-
culture with B. longum resulted in a decrease in both biofilm production and C. 
difficile cell and toxin production in the biofilm. Similar results were seen with L. 
rhamnosus. Both B. longum and L. rhamnosus have been suggested as 
potential probiotic strains due to their ability to reduce the expression of C. 
difficile toxin; however, in contrast to the results presented here, there was no 
reduction in C. difficile growth in co-culture (Trejo et al., 2010). It was believed 
that the production of organic acids (and so reduced media pH) may account 
for the inhibitory effect of these two bacteria. In line with this theory, 
experiments here examining C. difficile biofilm formation in culture media with 
various pH levels revealed diminished C. difficile biofilm production and 
vegetative cell proliferation in an acidic environment. By neutralising the CFS 
from overnight cultures of B. longum and L. rhamnosus, this pH effect was 
negated. Co-culture of C. difficile with L. rhamnosus CFS and neutralised CFS 
had similar effects, with a reduction in biofilm formation but no change in the 
number of C. difficile cells. As no significant reductions were seen in the 
number of sessile cells observed in the absence of L. rhamnous, the decrease 
in CV absorbance could be due to a decrease in biofilm biomass, specifically 
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EPS production. This indicated that secreted factors may affect the C. difficile 
biofilm biomass; however, viable L. rhamnosus cells are required to reduce the 
growth of C. difficile in the biofilm. CFS and nCFS of B. longum had no effect 
on C. difficile biofilm formation or cell recovery and therefore the reduction of C. 
difficile biofilm formation and growth by B. longum is most likely mediated by 
the presence of viable cells and not metabolic by-products. This confirms 
results by Valdes-Varela et al. (2016) who showed that viability of B. longum is 
required to exert protective effects against clostridial toxins.  
Another probiotic strain that we used in co-culture experiments was C. 
butyricum. C. butyricum has been previously shown to reduce the toxicity of C. 
difficile CFS (Woo et al., 2011) and was found to be antagonistic to CDI in mice 
(Kamiya et al., 1997). Clinical trials using concomitant C. butyricum with 
antibiotics resulted in reduced disturbance in commensal flora and 
subsequently reduced AAD in patients (Seki et al., 2003). This protective effect 
to the commensal flora was also seen when C. butyricum was used after 
Helicobacter pylori eradication therapy and in the treatment and prevention of 
on Enterohemorrhagic Escherichia coli (EHEC) 0157:H7, resulting in less 
disruption to obligate anaerobic populations and subsequent reduced levels of 
AAD (Takahashi et al., 2004, Imase et al., 2008). C. butyricum has also been 
shown to support the growth of endemic Lactobacillus populations (Ichikawa et 
al., 1999). The results presented here suggest that C. butyricum is able to 
reduce C. difficile biofilm formation and its growth in a biofilm, providing another 
potential mechanism of C. butyricum antagonism to CDI.  
As Bacteroides was highlighted as a potential key genus in CDI during the in 
vitro gut models, B. thetaiotaomicron was selected as a representative species 
from this genus. B. thetaiotaomicron was one of the predominant strains 
isolated in the sessile populations, which is consistent with Macfarlane et al. 
(2005) who found that Bacteroides was a major genus in mucosal biofilms. Co-
culture of B. thetaiotaomicron with C. difficile resulted in both a decrease in 
biofilm production and C. difficile growth in the biofilm. Similar results were 
reported by Slater et al. (2019), who found that the presence of Bacteroides 
fragilis resulted in a decrease in biofilm biomass and C. difficile cell numbers in 
co-culture biofilms, further supporting the theory that the Bacteroides genus 
plays a potential role in th4e prevention of CDI. In contrast to results from 
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biofilm formation and growth within a biofilm, B. thetaiotaomicron has been 
found to be beneficial for planktonic C. difficile germination and growth after 
antimicrobial therapy in mice (Ferreyra et al., 2014). This relationship is based 
on B. thetaiotaomicron producing high levels of the metabolite succinate (Curtis 
et al., 2014). Succinate is not normally seen in a healthy gut due to cross-
feeding of the commensal flora; however, perturbations of the gut facilitates 
succinate accumulation which has been implicated in C. difficile spore 
germination (Lawley et al., 2009b). The complexity of this system was not 
replicated here, which highlights an important danger of drawing conclusions 
from simple batch culture experiments, as they are unable to account for the 
dynamics seen in a complex systems such as antimicrobial-induced dysbiosis 
and its subsequent metabolic shifts.  
One of the main limitations of the study presented here was the use of the 
same culture conditions for each of the microorganisms. For optimum biofilm 
formation, appropriate growth conditions should be established for each 
microorganism studied, including the choice of growth medium, substratum, 
time of incubation and environment (O'Toole, 2011). Here, conditions optimised 
for C. difficile growth were used such as anaerobic incubation, a glass 
substratum and BHISC medium, which could have had an impact on the ability 
of the other microorganisms selected to form a biofilm. This was reflected in the 
relatively poor biofilm formation of K. pneumoniae and M. morganii 
demonstrated here, in contrast to other studies with aerobic growth on a plastic 
substratum (Seifi et al., 2016, Zheng et al., 2018). In an attempt to provide a 
culture medium more reflective of the gut model that the strains were isolated 
from, the complex growth medium from the gut model experiments was 
attempted in batch culture biofilms; however, the mono culture control biofilm 
did not form well and increased sedimentation from the medium interfered with 
CV staining (data not shown). Additionally, the strains selected were isolated 
from the in vitro gut models and therefore it is possible that they are more 
adapted to living as a community and not alone in a biofilm. Conversely, the 
particular strains used may not have been proficient biofilm producers.  
Although limited, data from these simple batch culture experiments can offer 
important insight into the interactions in biofilms. Co-culture experiments of C. 
difficile with L. rhamnosus resulted in decrease in biofilm biomass and a 
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significant reduction in C. difficile growth in the biofilm; however, in poly-
cultures with the addition C. albicans, the reduction of biofilm biomass was still 
seen but the suppression of C. difficile growth was completely lost. This was 
also seen with S. aureus cultures with C. difficile, where the effect was lost in 
poly-culture with C. albicans. Biofilm co-culture with C. albicans has previously 
been shown to confer an advantage to C. difficile survival in aerobic conditions 
(van Leeuwen et al., 2016). C. difficile metabolism was also shown to influence 
C. albicans virulence and mode of growth. This illustrates the importance of 
studying the community dynamics and interspecies interactions within biofilms 
and how the different composition of microorganisms can influence the 
characteristics of the biofilm. Thus, data from experiments examining the 
effects of single bacterial species, labelled as probiotics, on C. difficile can be 
misleading once the interactions in complex community scenarios are 
considered. 
In conclusion, the interactions of selected commensal microorganisms and their 
effect on C. difficile biofilm formation in batch co-culture experiments was 
examined. Using mixed microbial biofilms from in vitro gut models simulating 
CDI, target commensal microorganisms originating in these sessile 
communities were isolated and identified. In co- and poly-microbial biofilms, 
selected microorganisms were able to either increase or decrease C. difficile 
biofilm biomass, as well as reduce C. difficile growth within the biofilm. B. 
longum and L. rhamnosus were shown to reduce C. difficile biofilm formation, 
and reduce growth and toxin production within the biofilm. Poly-culture 
experiments with B. longum and B. thetaiotaomicron displayed a greater 
reduction in biofilm formation than seen in individual co-culture biofilms. 
Interactions of C. difficile with L. rhamnosus and B. longum were further 
characterised by neutralising the possible antagonistic effect of metabolic 
organic acids, demonstrating that cell viability was required to mediate the 
reduction of C. difficile biofilm formation and growth by both B. longum and L. 
rhamnosus. The microorganisms S. warneri, F. polymorphum and C. 
paraputrificum were also demonstrated to increase C. difficile biofilm formation. 
SEM imaging confirmed close interactions between the different species in poly 
culture biofilms, with the sharing of EPS matrix to anchor the different species 
together in a dense and heterogeneous layer. These results demonstrate that 
185 
 
C. difficile interacts with different members of the sessile community, which 




Chapter 6 Sessile C. difficile cells can contribute towards 
recurrent disease  
6.1 Background 
The incidence of disease recurrence following antimicrobial therapy occurs in 
up to 20 – 30% of CDI cases (Kelly and LaMont, 2008, Cornely et al., 2012b) 
with the risk of further recurrence increasing with each subsequent episode 
(McFarland et al., 1994, McFarland et al., 2002). In the majority of rCDI cases, 
it was found that disease was caused by the strain responsible for the initial 
episode, indicating disease relapse as opposed to reinfection with a different 
strain (Durovic et al., 2017). This suggests that C. difficile can occupy a 
protective niche whereby antimicrobial therapy is ineffective. Biofilms represent 
such a niche and C. difficile has been demonstrated to form a biofilm in vitro 
(Dawson et al., 2012, Donelli et al., 2012, Ðapa et al., 2013, Hammond et al., 
2014, Semenyuk et al., 2014) and in vivo (Buckley et al., 2011, Semenyuk et 
al., 2015, Soavelomandroso et al., 2017), displaying an altered gene 
expression profile from planktonic cells (Poquet et al., 2018). C. difficile can 
also interact with commensal microorganisms as part of a multispecies biofilm 
(Donelli et al., 2012, Crowther et al., 2014a, Slater et al., 2019) which has also 
been demonstrated here in continuous (Chapter 3 and 4) and batch biofilm 
cultures (Chapter 5).  
A biofilm offers the residing microorganisms protection from external stress 
conditions such as the hosts immune response and antimicrobial treatment, 
making biofilm-associated infections particularly resilient. Increasing evidence 
suggests an important role for biofilms in chronic infections, especially in 
disease persistence and relapse. It is believed that roughly 65% of all bacterial 
infections and 80% of chronic infections are associated with biofilm formation 
(Percival et al., 2015, Jamal et al., 2018). Often these infections are 
characterised by their slow, progressive nature and are inherently difficult to 
treat, requiring aggressive and sustained antimicrobial therapy. This contrasts 
with the relatively rapid onset of acute infections resulting from infection with 
planktonic bacteria that are, in general, more responsive to antimicrobials 
(Bjarnsholt, 2013).  Indeed, biofilms were found to be significantly tolerant to 
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antimicrobials when compared with their planktonic counterparts, and this 
reduced susceptibility contributes to the persistence of biofilm-associated 
infections (Nickel et al., 1985, Stewart, 2002, Ahmed et al., 2018). Ðapa et al. 
(2013) demonstrated that three day old hyper-virulent C. difficile R20291 strain 
biofilms were able to tolerate exposure to vancomycin at 100 times the MIC 
usually effective against the planktonic cells. It was also found that exposure to 
sub-inhibitory levels of antimicrobial agent may promote increased biofilm 
formation in C. difficile (Vuotto et al., 2015).    
Biofilms have been associated with dental infections (Larsen and Fiehn, 2017), 
chronic wounds (Davis et al., 2008), cystic fibrosis infections (Hoiby, 2011), 
chronic otitis media (Post, 2001), urinary tract infections (Hatt and Rather, 
2008), infections involving indwelling devices (Donlan, 2001b) and they have 
also been implicated in chronic Helicobacter pylori infection (Hathroubi et al., 
2018). The life-cycle of biofilms include a number of highly regulated stages, 
including attachment, aggregation with EPS production, maturation and finally 
dispersal. Dispersal is characterised by an active phenotypic switch to a 
planktonic-like state and the subsequent release of free-floating bacteria or 
bacterial aggregates and cell clusters from either mono or mixed species 
biofilms (Stoodley et al., 2001, Sauer et al., 2004). This facilitates the 
dissemination of bacteria to colonise a new habitat leading to the persistence of 
infection (Kaplan, 2010).  
6.1.1 Rationale  
The mucosal populations in the GI tract have gathered much interest in health 
and disease (Macfarlane and Dillon, 2007), particularly the disruption and 
subsequent dispersal of biofilm-associated cells leading to disease 
development (Buret et al., 2019). The chronic nature of rCDI and its 
recalcitrance to antimicrobial therapy leads to the speculation of biofilm 
involvement; however, biofilms have not yet been proven as a cause of rCDI. In 
our gut models, we found that vancomycin and microbiome-based therapies 
reduced planktonic C. difficile; however, these therapies failed to eradicate C. 
difficile cells from the biofilm. This was consistent with findings from Crowther 
et al. (2014a). Here, we set out to determine whether a biofilm harbouring C. 
difficile cells has the potential to disperse from the biofilm and repopulate the 
planktonic phase, which could lead to the relapse of CDI.  
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6.2 Materials and Methodology 
Three gut models were used in this experiment to determine whether C. difficile 
spores originating in the biofilm can lead to repopulation of the planktonic 
phase and subsequent induction of CDI. Briefly, multispecies biofilms 
containing C. difficile cells were transplanted from a donor model, model D, into 
a susceptible recipient model, model R. A control model, model C, was run 
parallel with model R and dosed with C. difficile spores as a positive control 
model and to compare CDI from biofilm and planktonic origins. 
6.2.1 Donor screening and slurry preparation  
In this experiment, two separate faecal slurries were prepared; one for the 
donor model and another for the control and recipient models. Donors were 
recruited and screened as in section 2.2.2 and 2.2.3. Each slurry was freshly 
prepared at the start of each gut model using either 5 or 4 faecal donors for the 
donor model and the control/recipient models, respectively. The slurries were 
prepared by diluting the faeces to 10% (W/V) solution using pre-reduced PBS. 
The suspension was emulsified and filtered as per section 2.2.4, and 
approximately 160 mL was added to each vessel.  
6.2.2 The in vitro gut model set up 
All three models were set up according to section 2.2.8 with the exception of 
models R and C in which vessel two was comprised of biofilm vessels (Figure 
6-1). This was done to accommodate the transplantation of biofilm rods from 
model D. C. difficile spores are normally added to vessel one, allowing time for 
colonisation throughout the model; however, in this case it was not possible to 
perform the biofilm transplantation in vessel one due to different volumes of the 
vessels. Additionally, transplanting the biofilm into vessel two and enumerating 
the lack of C. difficile populations in vessel one ensured there was no cross-




Figure 6-1 The Recipient and Control in vitro gut  model set up. The 
recipient (model R) and control model (model C) were set up using a 
biofilm vessel for vessel two to facilitate the biofilm transplantation into 
model R. 
 
6.2.3 Experimental design 
The models followed the timeline in Figure 6-2 and in line with section 2.2.10. 
The donor model was set up first and had a two week steady state period 
followed by dosing with C. difficile spores (section 2.2.7) into vessel one. This 
was left for 7 days to ensure colonisation resistance in the model. A further 
spore dose was added to replenish the C. difficile spore reservoir before 
clindamycin dosing commenced for 7 days. The model was then monitored for 
the development of CDI using C. difficile total viable and spore counts, as well 
as cytotoxin testing (section 2.2.11 and 2.2.16). Once the model reached peak 
CDI, a sample from the biofilm was taken to enumerate the sessile C. difficile 
populations (one biofilm rod, processed according to section 2.2.12), before 




Figure 6-2 Model timeline of the biofilm transplant experiment. The biofilm 
support structures with associated multispecies biofilm were transplanted 
from Model D (top) into the C. difficile naïve (green line) model R, which 
had been exposed to clindamycin (blue arrow) to create an environment 
susceptible to C. difficile growth. Model C was run in parallel with Model R 
and infected with C. difficile spores as a positive control.  
 
Models C and R were set up with a fresh faecal slurry when model D started 
clindamycin dosing. As per section 2.2.10, both models had a two week steady 
state period followed by two doses of C. difficile spores being added to vessel 
one of model C only, one week apart. Model R did not receive a C. difficile 
spore dose (indicated by the green arrow, Figure 6-2). Both models were then 
dosed with clindamycin for 7 days as per 2.2.10 to create an environment 
susceptible to CDI. To investigate the ability of sessile C. difficile to repopulate 
the planktonic phase and induce CDI, the biofilm from model D, harbouring C. 
difficile cells after vancomycin dosing, was transferred to the recipient model 
(Figure 6-3). Planktonic C. difficile levels in Model D dropped to below the limit 
of detection with vancomycin treatment, ensuring that the C. difficile transferred 
originated from the biofilm. The biofilm vessel lid (vessel three) from model D, 
and associated biofilm support structures, was carefully removed and 
transferred to the biofilm vessel (vessel two) of Model R (Figure 6-2 and Figure 
6-3). At the time of biofilm rod transplantation, a sample of the biofilm was 
removed from the pH probe in vessel three of Model D to enumerate total C. 
191 
 
difficile biofilm populations post vancomycin treatment. This sample was 
processed according to section 2.2.12. Previously, biofilm samples from the pH 
probes and vessels walls were enumerated at found to be comparable to those 
from the biofilm support structures (results not shown). All planktonic 
populations were sampled as per section  2.2.11, on every alternate day from 
model commencement until the C. difficile reservoir stage and daily thereafter 
until biofilm transplantation. After biofilm transplantation, only C. difficile TVCs 
and spores were enumerated on every alternate day until model completion. 
Results from Model R were compared with Model C to determine the difference 
in CDI induction with C. difficile originating from the biofilm and from the 
planktonic phase (exogenous C. difficile). The C. difficile cytotoxin assay and 
antimicrobial bioassays were performed on all models as described in sections 





Figure 6-3 Diagram of the gut model set-up for the donor model, the 
recipient model and the control model, illustrating the 
transplantation of biofilm support structures. The biofilm support 
structures, located in vessel three of the donor model (top left), were 
transplanted into the second vessel of the recipient vessel (bottom left) 
after vancomycin treatment. The control model (right) was dosed with C. 





6.3 Results  
To investigate the ability of C. difficile originating solely from a biofilm to re-
populate the planktonic phase and induce CD, a series of three gut models 
consisting of a biofilm donor model, a biofilm recipient model and a control 
model were used. The donor model was run to model CDI, mediated by 
clindamycin induced dysbiosis of the microbial communities, followed by the 
subsequent treatment with vancomycin to generate an environment susceptible 
to rCDI. This model was equipped with a vessel that enabled the formation and 
removal of the multispecies biofilm containing C. difficile cells for 
transplantation into the susceptible recipient model. 
6.3.1 Donor model 
Commensal planktonic populations were monitored throughout the Model D 
timeline. Following a two week steady state period in which populations were 
allowed to equilibrate, two doses of C. difficile spores were added to the model, 
7 days apart, to ensure colonisation resistance in the model. The antimicrobial 
effect of clindamycin was consistent with previous models (Chapters 3 and 4), 
namely, B. fragilis gp., Clostridium spp., Bifidobacterium spp., and Lactobacillus 
spp., populations were reduced and an increase in total facultative anaerobes, 
LF Enterobacteriaceae and Enterococcus spp.. All populations recovered to 
pre-antibiotic levels soon after clindamycin cessation, with the exception of 
Bifidobacterium spp. that recovered more gradually and remained 
approximately 1 - 1.5 log10 CFU/mL lower than steady state levels throughout 
CDI (Figure 6-4).  
C. difficile total viable counts, spores and cytotoxin were closely monitored for 
evidence of CDI. Divergence of C. difficile total and spore counts were seen 7 
days post-clindamycin, reaching peak levels of 5.5 log10 CFU/mL with spore 
and TVC divergence of 1.5 log10 CFU/mL, with the subsequent detection of C. 
difficile toxin reaching peak levels of 3 RU 3 weeks post-clindamycin (Figure 
6-5 a).   
At peak CDI, one biofilm rod was removed to enumerate the C. difficile 
populations in the multispecies biofilm. Based on the counts from this sample, 
C. difficile was found to be associated with the biofilm with levels of 5.32 log10 
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CFU/g biofilm biomass (Figure 6-5 b), consistent with data from previous 
biofilm models (Chapter 3 and 4).  
After peak CDI was assumed, the model was dosed with vancomycin for 7 
days, causing a profound effect on the planktonic microbiota, with B. fragilis gp. 
recoveries reducing by approximately 8 log10 CFU/mL with Bifidobacterium spp. 
and Clostridia spp. dropping below the limit of detection (Figure 6-4 a). 
Planktonic C. difficile total and spore counts also dropped below the limit of 
detection after vancomycin treatment with undetectable levels of cytotoxin 
activity (Figure 6-5 a). These results were consistent with previous models 
(Chapter 3 and 4). Three days after vancomycin cessation, the biofilm rods 
from vessel 3 were transplanted into the recipient model. At the time of 
transplantation, a sample of biofilm was removed from the pH probe in vessel 3 
of model D and C. difficile populations enumerated (Figure 6-5 c). Vancomycin 
treatment had caused an approximate 2 log log10 CFU/g decrease in biofilm C. 
difficile counts, with the level of C. difficile in the biofilm being transplanted 
approximately 3.6 log10 CFU/g biofilm weight. There were 15 biofilm rods 
remaining at the time of transplantation and based on average biofilm weight 
per rod across previous models, it was determined that approximately 1.6 g of 
biofilm was transferred from Model D to model R, with an estimated total 




Figure 6-4 Enumeration of planktonic populations in the in vitro Donor 
gut model. (a) Bacterial enumeration of total anaerobes (black), B. 
fragilis gp. (red), Clostridium spp. (green), Bifidobacterium spp. (purple), 
and spores (yellow). (b) Bacterial enumeration of total facultative 
anaerobes (black), lactose fermenting (LF) Enterobacteriaceae (red), 
Enterococcus spp. (green), and Lactobacillus spp. (purple). Data 
demonstrates the disruption to the microbial populations when treated 
with clindamycin (purple arrow) and vancomycin (green arrow). Data 
shown are the mean log10 CFU/mL ± standard error from three technical 
replicates per day of the model timeline of one biological replicate. 
Different model stages are separated by vertical broken lines.               























Figure 6-5 Enumeration of planktonic and sessile C. difficile total and 
spore counts in the in vitro Donor gut model. Enumerations of C. 
difficile spores (red) and total viable counts (blue) are represented the 
Donor model in mean log10 CFU/mL and log10 CFU/g ± standard error (left 
axis). C. difficile toxin (black broken line) is represented as log reciprocal 
units (RU, right axis). (a) Enumeration of planktonic C. difficile 
populations. Total and spore counts drop below the limit of detection after 
vancomycin instillation. (b) Enumeration of sessile C. difficile populations 
during peak CDI. (c) Enumeration of sessile C. difficile prior to biofilm 
transfer, showing predominantly spore populations remaining. Data shown 
are from three technical replicates per day of the model timeline from one 
biological replicate CD – C. difficile, Clind – clindamycin, Vanc – vancomycin, CDI – 





6.3.2 Recipient Model (R) and Control Model (C) 
The recipient model had an extended steady state period compared with the 
other two models as there was no C. difficile spore reservoir phase. 
Populations stabilised around 6 days after model set up and remained so for 
the duration of steady state. Model C was given two doses of C. difficile spores, 
one week apart, before both models began clindamycin dosing. Despite a drop 
in Clostridium spp. and Bifidobacterium spp. leading up to clindamycin 
treatment, C. difficile spores showed no sign of germinating during the reservoir 
phase in Model C, suggesting colonisation resistance was established. 
Bacterial recoveries from both models were comparable through this period, 
entering clindamycin treatment at similar levels. In both models, there was a 
decrease in Clostridia and Bifidobacterium recoveries; however, this did not 
compromise the colonisation resistance established. Furthermore, this 
demonstrated that the introduction of C. difficile spores to model C did not 
affect the microbiota. This was consistent with results from previous gut model 
experiments (Chapters 3 and 4). Clindamycin was introduced to both models, 
resulting in disruption to the commensal microflora. This was characterised by 
an approximately 3 - 3.5 log10 CFU/mL reduction in Clostridium spp. and the 
Bifidobacterium spp. dropping to below the limit of detection in both models 
(Figure 6-6). Increases in bacterial recoveries for total facultative anaerobes, 
LF Enterobacteriaceae and Enterococcus spp. of approximately 1 log10 
CFU/mL were seen in both models (Figure 6-7). Similar levels of clindamycin 
were seen in both models, with peak levels of 128.3 mg/L and 120.0 mg/L 
detected in vessel one on day 6 of dosing for Model R and Model C, 
respectively. Four days after clindamycin cessation, the biofilm rods containing 
C. difficile cells associated with the multispecies biofilm were transplanted from 
Model D into Model R. From this point in both models, only C. difficile 
planktonic populations were monitored (Figure 6-8 and Figure 6-9).  
In Model C, acting as a positive control in this experiment, C. difficile total and 
spore populations were recovered at equal measures of approximately 4 log10 
CFU/mL in each vessel during the C. difficile reservoir phase. Evidence of C. 
difficile spore germination was seen 10 days after clindamycin cessation in 
vessel three, with C. difficile TVCs reaching peak levels of 6.6 log10 CFU/mL. 
C. difficile cytotoxin was detected 18 days post-clindamycin, with peak levels of 
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2 RU detected 21 days post-clindamycin, indicating active CDI (Figure 6-9). 
Germination and toxin production with similar levels were also seen in vessel 2 
and although C. difficile was recovered from vessel one, no evidence of CDI in 
this vessel was found (data not shown). In Model R, vessel one remained C. 
difficile free for the entire experiment (data not shown). Transient C. difficile 
was recovered from vessel two approximately 5 days after the biofilm 
transplant, with evidence of stable planktonic population recoveries 15 days 
after transplantation from 1.5 – 3.4 log10 CFU/mL (Figure 6-8 a). C. difficile was 
recovered from vessel three approximately 10 days after transplantation, with 
evidence of germination seen 15 days post-transplant with a 1 log10 CFU/mL 
divergence in TVC and spore recoveries. This was accompanied with the 
detection of C. difficile cytotoxin at 0.25 RU corresponding with peak TVC 
recoveries of approximately 4 log10 CFU/mL (Figure 6-8 b). Peak C. difficile 
recovery in Model R was approximately 3 log10 CFU/mL lower than those 






Figure 6-6 Enumeration of planktonic anaerobes in (a) the recipient 
model and (b) the control model. Bacterial enumeration of total 
anaerobes (black), B. fragilis gp. (red), Clostridium spp. (green), 
Bifidobacterium spp. (purple), and spores (yellow) of the recipient 
model (model R) and the control model (model C). Data shows the 
disruption to the microbiota during clindamycin instillation. Data shown 
are the mean log10 CFU/mL ± standard error from three technical 
replicates on alternate days of the model timeline of one biological 
replicate. Different model stages are separated by vertical broken lines 
(grey; biofilm transplantation – red – model R only). CD – C. difficile, Clind 










Figure 6-7 Enumeration of planktonic facultative anaerobes in (a) the 
recipient model and (b) the control model. Bacterial enumeration of 
total facultative anaerobes (black), lactose fermenting (LF) 
Enterobacteriaceae (red), Enterococcus spp. (green), and Lactobacillus 
spp. (purple) of the recipient model (model R) and the control model 
(model C). Data shows the disruption to the microbiota during clindamycin 
instillation. Data shown are the mean log10 CFU/mL ± standard error from 
three technical replicates on alternate days of the model timeline of one 
biological replicate. Different model stages are separated by vertical 
broken lines (grey; biofilm transplantation – red – model R only). CD – C. 






Figure 6-8 Enumeration of planktonic C. difficile total and spore counts 
in (a) vessel two and (b) vessel three of the recipient model (model 
R). Enumerations of C. difficile spores (red) and total viable counts (blue) 
are represented for vessels two and three in mean log10 CFU/mL ± 
standard error (left axis). C. difficile toxin (black broken line) is 
represented as log reciprocal units (RU, right axis). Data represents C. 
difficile originating from the biofilm re-populating the planktonic phase 
with evidence of spore germination and toxin production in vessel three. 
Data shown are from three technical replicates on alternate days of the 
model timeline from one biological replicate. Different model stages are 
separated by vertical broken lines (grey; biofilm transplantation – red – 








Figure 6-9  Enumeration of planktonic C. difficile total and spore 
counts in (a) vessel two and (b) vessel three of the control 
model (model C). Enumerations of C. difficile spores (red) and 
total viable counts (blue) are represented for vessels two and 
three in mean log10 CFU/mL ± standard error (left axis). C. difficile 
toxin (black broken line) is represented as log reciprocal units (RU, 
right axis). Data represents C. difficile originating from spores 
added to vessel one, with evidence of C. difficile germination and 
toxin production in vessel two and three. Data shown are from 
three technical replicates on alternate days of the model timeline 
from one biological replicate. Different model stages are separated 
by vertical broken lines. CD – C. difficile, Clind – clindamycin, Vanc – 










Biofilms have been implicated in many chronic infections and the persistence of 
microbial pathogens; for example, P. aeruginosa infections in chronic otitis 
media and UTIs from indwelling urinary catheters, Porphyromonas gingivalis in 
periodontal infections and Staphylococcus epidermidis in prosthetic valve 
endocarditis. Increased tolerance to antimicrobial agents plays an important 
role biofilm-associated infections, with treatment failure and disease 
persistence a common occurrence (Stewart, 2015). Current recommendations 
for the treatment of primary CDI include the use metronidazole or vancomycin; 
however, in up 30 % of cases the disease relapses within 8 weeks and this is 
not linked to increased resistance of the infecting strain (Kelly and LaMont, 
2008). Relapse with the initial strain during the primary episode of CDI is 
present in between 65 - 88% of recurrences (Kamboj et al., 2011, Figueroa et 
al., 2012). The risk of further recurrence was found to increase with each 
subsequent episode, (McFarland et al., 1994), suggesting that C. difficile may 
exploit a protective niche in the GI tract where antimicrobial therapy is 
ineffective. We believe that biofilms offer such a niche and may facilitate rCDI. 
Although rCDI displays a number of characteristics normally associated with 
biofilm-mediated infections, the role of biofilms in rCDI has not been 
established.  
C. difficile has been shown to form biofilms in vitro (Dawson et al., 2012, 
Donelli et al., 2012, Dapa and Unnikrishnan, 2013, Semenyuk et al., 2014) and 
in vivo (Buckley et al., 2011, Semenyuk et al., 2015, Soavelomandroso et al., 
2017); however, the ability of sessile C. difficile to contribute towards 
pathogenesis and recurrence has not been demonstrated. The gut model used 
here provides an ideal opportunity to study the contribution of biofilms towards 
CDI. It is clinically relevant and accurately represents the different stages of the 
C. difficile disease process and facilitates the manipulation of the sessile 
populations independent of the planktonic populations. Consistent with findings 
from Crowther et al. (2014a), we demonstrated that treatment with vancomycin 
was ineffective against sessile C. difficile populations that formed part of a 
multispecies biofilm in a continuous flow model system of the human gut. Batch 
culture biofilm experiments support this increased tolerance of sessile C. 
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difficile to vancomycin therapy, with increased resistance rates of 100 times the 
MIC of the hypervirulent R20291 strain seen (Ðapa et al., 2013, Mathur et al., 
2016, James et al., 2017). This increased antimicrobial tolerance extended to 
studies with metronidazole (Semenyuk et al., 2014, James et al., 2017) with 
sub-inhibitory concentrations resulting in an increase in biofilm formation 
(Vuotto et al., 2015). It was found that fidaxomicin displayed increased 
effectiveness against in vitro C. difficile biofilms, resulting in biofilm disruption 
and a reduction in C. difficile numbers (James et al., 2017). The increased 
efficacy of fidaxomicin against sessile C. difficile may, in addition to microbiota 
sparing properties due to its narrow spectrum of activity (Crawford et al., 2012), 
contribute towards the reduced recurrence rates associated with fidaxomicin 
when compared to vancomycin therapy (Cornely et al., 2012b). The ability of 
biofilm-dwelling microorganisms to either actively or passively disperse from a 
biofilm to colonise new niches and spread infection has been demonstrated 
(Boyd and Chakrabarty, 1994, Lee et al., 1996, Kaplan et al., 2003, Kaplan, 
2010); however, dispersal and seeding from C. difficile biofilms has not been 
well studied.   
In previous gut model experiments, C. difficile spores added to the models 
rapidly became associated with the biofilm. The incorporation of the spores into 
the biofilm may involve the presence of a mature exosporium layer, with hair-
like protrusions and hydrophobicity mediating adhesion to matrix components 
(Henriques and Charles P. Moran, 2007, Barra-Carrasco et al., 2013, Mora-
Uribe et al., 2016). This incorporation into the biofilm enabled the survival of 
sessile C. difficile populations during vancomycin dosing, suggesting a 
colonisation niche for C. difficile and a potential reservoir to facilitate rCDI. 
Indeed, disease relapse was demonstrated despite planktonic levels of C. 
difficile falling to below the limit of detection. To further explore the relationship 
of sessile C. difficile and rCDI, we transplanted sessile C. difficile into a naive 
model treated with clindamycin to create a susceptible environment for CDI. At 
the time of donation, planktonic recoveries of C. difficile in the Donor Model 
were below the level of detection, ensuring that the C. difficile transplanted was 
from a sessile origin. Enumeration of the biofilm indicated levels of sessile C. 
difficile of 3.1 log10 CFU/g, which is consistent with results from previous 
models after vancomycin treatment. We monitored the C. difficile recoveries in 
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the planktonic phase seeded from the transplanted biofilm for the duration of 
the experiment. We ran a positive control model alongside this model with the 
addition of a C. difficile spore preparation into vessel one. Levels of clindamycin 
in vessel one were comparable between the models, reaching peak levels on 
day 6 of dosing. Disruption to the microflora was similar and consistent with 
previous and induced CDI was deemed present in Model C when evidence of 
C. difficile spore germination was seen approximately 10 days after clindamycin 
cessation, accompanied by vegetative cell outgrowth and toxin production. In 
Model R, the biofilm was transplanted three days after clindamycin cessation 
into vessel two. This time lag was to ensure levels of clindamycin had dropped 
below the level of detection at the time of biofilm introduction. Transient 
recoveries of planktonic C. difficile was detected in vessel two five days after 
transplantation, with stable C. difficile populations recovered after 15 days in 
vessel two and after 10 days in vessel three. Peak levels of C. difficile 
recovered from vessel three were 4 log10 CFU/mL, with evidence of 
germination and toxin production detected 23 days after transplantation; 
however, the toxin levels detected did not reach levels associated with 
simulated CDI. The biofilm in this experiment was transplanted from a 
recurrence model into a model that had been prepared for acute infection, and 
therefore it should be acknowledged that the end point comparison is not the 
equivalent; however, the overall objective was to re-establish C. difficile 
colonisation from sessile origins, which was clearly demonstrated.  
Although full CDI was not established in this model, there was clear evidence of 
C. difficile seeding from the transplanted biofilm and subsequent colonisation of 
the planktonic phase. In our gut models, biofilms also form on the walls of the 
vessels and the composition of which has been shown to be equivalent to that 
formed on the biofilm support structures. Thus the amount of biofilm 
transplanted here represents a small proportion of the C. difficile-containing 
biofilm that would normally seed the planktonic phase. As we were only able to 
transplant a very small portion of the biofilm in the form of biofilm support 
structures, the number of C. difficile cells seeded from the biofilm were only a 
fraction of what could be seen, which could account for the low levels of cells 
recovered from planktonic populations. It was estimated that approximately 3.8 
log10 CFU C. difficile was transferred to the recipient model. These numbers 
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are significantly lower than the two doses of 7 log10 CFU/mL that was added to 
the Control Model. The effect of different infective doses was seen in mouse 
models where a dose – response relationship was seen between 
environmental spore concentration and the development of CDI (Lawley et al., 
2010).  
In previous models, Clostridium spp. and B. fragilis gp. recoveries increased to 
pre-antibiotic levels just prior to clindamycin cessation, with the rest of the 
microbiota taking approximately 10 – 14 days to recover from clindamycin 
dosing. The delay between clindamycin cessation and biofilm transplantation 
could have allowed the partial recovery of colonisation resistance of the 
microbiota, potentially inhibiting the ability of sessile populations to effectively 
colonise the niche generated by clindamycin. Another factor to consider is the 
transplantation into vessel two where normally C. difficile spores are introduced 
to the model in vessel one. There is an abundance of biofilm formed on the 
walls of vessel one, with previous models demonstrating sessile associated C. 
difficile at levels comparable to those recovered in vessels two and three (data 
not shown). The C. difficile associated with biofilm in vessel one could 
potentially seed the subsequent vessels at a higher rate than our transplant in 
vessel two. As the C. difficile from this model originated from the biofilm, this 
decreased transition time may have had a significant effect on the outcome as 
C. difficile spores from biofilms display reduced germination efficiencies 
compared with conventional spores, and therefore may have required 
increased time to fully germinate and proliferate (Semenyuk et al., 2014).  
Here, we saw clear evidence of C. difficile dispersal from the transplanted 
biofilm that resulted in planktonic seeding and subsequent colonisation. This 
was accompanied by low level spore germination, outgrowth and toxin 
production. The increased survival of C. difficile associated with a biofilm has 
significant repercussions for the development of rCDI. Although simulated CDI 
did not result, the potential of the biofilm to provide a protective niche for C. 
difficile survival during antibiotic therapy, and the subsequent dispersal from the 
biofilm in a susceptible environment to re-establish CDI, was clearly 




Chapter 7 Conclusions  
This research aimed to determine whether multispecies biofilms play a role in 
the recurrence of CDI and to explore the characterisation of C. difficile with 
commensal microorganisms in these structures. The recurrence and 
persistence of CDI, despite appropriate antimicrobial therapy, led us to 
hypothesise that biofilms in the gut may act as a reservoir to C. difficile and 
potentially facilitate rCDI. Currently, there is a lack of knowledge regarding 
intestinal biofilms and their contribution to disease persistence, mainly due to 
the invasive nature of mucosal sampling and the lack of suitable in vitro 
models. Using a combination of continuous flow and batch culture biofilms 
models, we showed that C. difficile was incorporated into a multispecies biofilm, 
which provided a protective niche against antimicrobial and microbiome 
therapies. This facilitated the repopulation of the planktonic phase under 
susceptible conditions, potentially contributing to rCDI.  
Here, a triple stage gut model was used that has been shown to be 
microbiologically and physio-chemically reflective of the human colon 
(Macfarlane et al., 1998) and has been used previously to accurately reflect 
clinical outcomes, in terms of the propensity of drugs to induce and treat 
simulated CDI (Freeman et al., 2003, Baines et al., 2006, Chilton et al., 2014a). 
The ability to longitudinally sample biofilm populations in this model provided a 
valuable opportunity to delineate the contributions of sessile and planktonic 
populations with respect to disease recurrence. With the clinical success of 
FMT and increased interest in microbiome-restoration therapy, we simulated 
FMT in our models to determine whether this could accurately predict clinical 
outcome of microbiome-based therapeutics. In our models, a combination of 
vancomycin treatment followed by FMT instillation successfully prevented rCDI 
for up to 35 days. Vancomycin treatment alone failed to prevent rCDI, with peak 
C. difficile recovered at 6.4 log CFU/ml 28 days post antibiotic treatment, 
accompanied with toxin detection at 3 RU. Antimicrobial therapy was 
associated with a higher ratio of primary bile acids compared with secondary 
bile acids, and this ratio was prolonged in the vancomycin only model. The bile 
acid ratio upon FMT instillation was characterised by a lower ratio of primary to 
secondary bile acids. This demonstrated the microbiome-mediated restoration 
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of bile acid metabolism after FMT therapy. These results were consistent with 
clinical findings (Weingarden et al., 2014, Winston and Theriot, 2016), 
indicating that these models could provide a valuable tool in the development of 
microbiome-based therapies and determining the mechanisms of efficacy. To 
this end, we evaluated two different dosing regimens of the spore-based 
therapeutic SER-109, an undefined spore consortium derived from human 
faeces. In a Phase 2 clinical trial, the relative risk of CDI recurrence for placebo 
compared with SER-109 recipients was not statistically significant. We 
established that a single SER-109 dose was insufficient to prevent rCDI 
whereas a triple dose on sequential days successfully prevented rCDI. These 
results supported one of the conclusions from the Phase 2 post-trial analysis 
regarding under-dosing of SER-109. Using data from Phase 1 clinical studies 
and my results, SER-109 has progressed to Phase 3 clinical trials. 
These models provided the first characterisation of biofilm composition and 
profiling during FMT and microbiome-based therapies. Bacterial culture and 
taxonomic sequencing of the biofilm populations revealed that these sessile 
populations were not affected by antibiotics to the same degree as seen in 
planktonic populations, highlighting the resilience of biofilms towards external 
pressures, such as antimicrobial therapy. A highly significant finding from these 
experiments was the inability of vancomycin or FMT and other microbiome-
based therapies to displace C. difficile from the biofilm in my models. After 
antibiotic treatment, planktonic C. difficile levels dropped to below the level of 
detection, whereas the biofilm populations remained between approximately 3 
– 4 log CFU/g for the duration of the model runs. This suggested that the 
biofilm provided a protective niche for C. difficile during antibiotic treatment 
which, in the vancomycin-only model, potentially facilitated the re-population of 
the planktonic phase and the subsequent development of rCDI. This also 
raised the possibility that patients which undergo FMT and other microbiome-
based therapies could potentially remain at further risk of rCDI with subsequent 
antimicrobial therapy. The biofilm niche we described could be responsible for 
the CDI recurrence in up to 18 % of patients at 18-22 months post-FMT (Mamo 
et al., 2018, Allegretti et al., 2019). The use of antibiotics after successful FMT 
significantly increased the risk of rCDI. Although the gut model has been shown 
to reflect the conditions of the human colon, this model has some limitations, 
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especially with regard to biofilm communities. It has been demonstrated that 
planktonic based culture systems may not be representative of sessile states in 
the colon due to lower cell densities coupled with the washout of less 
competitive or slow growing microorganisms (Lacroix et al., 2015). This can be 
overcome using immobilised faecal microbiota trapped in gel beads or 
colonisation of mucin gels (Macfarlane et al., 2005, Fehlbaum et al., 2015); 
however, these methods were not appropriate for the use in the models here 
and did not facilitate periodic sampling. The use of glass biofilm support 
structures used here facilitated the formation of a multispecies biofilm that 
provided the opportunity for longitudinal sampling and analysis, with 
populations distinct from that of the planktonic phase (Crowther et al., 2014a, 
Crowther et al., 2014b). Due to inaccessibility of mucosal populations in the 
gut, comparisons between these and the sessile populations formed in the 
model are difficult. It is likely that, as the microbiota is unique on an individual 
basis, the same will ring true for the sessile populations.  
As C. difficile has been demonstrated to form a biofilm in vitro (Dawson et al., 
2012, Donelli et al., 2012, Ðapa et al., 2013), a set of biofilm batch culture 
experiments were conducted to explore the interactions of C. difficile with 
commensal microorganisms isolated from the gut models. This utilised the 
crystal violet assay for the semi-quantitative analysis of biofilm formation 
together with total viable counts to assess growth in the biofilm. The crystal 
violet assay is an inexpensive, high-throughput assay used here as an initial 
screen to identify potential interactions with C. difficile. It was optimised for C. 
difficile growth and therefore conditions may not have been suitable for all 
microorganisms examined (O'Toole, 2011) and also only a limited number of 
microbial species were assessed in co-culture biofilms, whereas there would be 
a plethora of species in sessile communities interacting in the gut. Therefore 
caution is required when extrapolating results as the simple nature of this assay 
does not encompass the complexity of interactions and biogeography in vivo. 
Members of the genus Lactobacillus, Bifidobacterium and Bacteroides all 
reduced C. difficile biofilm formation in co-culture. This result is noteworthy as, 
during the gut model experiments, we demonstrated a decreased abundance of 
these bacterial families in the biofilm after exposure to clindamycin and 
vancomycin. Thus, these therapeutics may influence commensal bacteria that 
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reduce C. difficile biofilm formation and, despite the ability of FMT and 
microbiome-based therapies to restore diversity of sessile bacteria, they failed 
to displace C. difficile from the biofilm.  
To determine whether the biofilm-associated C. difficile was responsible for the 
recurrence of CDI, we transplanted the biofilm support structures containing 
multispecies biofilm with C. difficile, into a susceptible, C. difficile naïve model. 
Ten days after the transplant, C. difficile was recovered from the planktonic 
populations and evidence of germination/proliferation was seen 18 days post-
transplant, with peak C. difficile levels of 3.9 log10 CFU/mL recovered 
accompanied by toxin levels of 0.25 RU. Although the toxin levels recovered 
were not clinically significant, implications of the re-population of the planktonic 
phase leading to C. difficile germination and proliferation solely derived from 
the biofilm is striking. This demonstrated that biofilm-associated C. difficile was 
capable of dispersing from the biofilm, and upon encountering an environment 
conducive for CDI, facilitated the colonisation of the planktonic phase, with the 
potential to cause CDI. This is the first clear evidence demonstrating the 
influence of biofilms in driving rCDI.  
This thesis presents evidence to the involvement of biofilms in the recurrence 
of CDI. These results highlight the importance of evaluating the efficacy of CDI 
therapeutics and future microbiome therapies to target both planktonic and 
biofilm C. difficile populations. Additionally, it suggests that patients undergoing 




7.1 Study limitations and further work 
In this body of work, the focus was on measuring bacterial populations and 
their potential association with C. difficile in a biofilm. It is important to 
remember that other microorganisms have the potential to affect C. difficile 
levels. Indeed, we observed a positive correlation in C. difficile biofilm formation 
with Candida species. The importance of the enteric virome was demonstrated 
by Zuo et al. (2018b) and Draper et al. (2018) in the context of CDI. They 
established that the enteric virome was altered in CDI when compared with 
healthy controls, resulting in enteric virome dysbiosis. FMT treatment resulted 
in an increase in both bacterial and virome diversity that closely matched the 
donors, indicating that bacteriophages may play a role in the efficacy of FMT in 
CDI cases. Bacteriophages have also been investigated for the use in the 
treatment of CDI with specific combinations of bacteriophages resulting in the 
complete lysis and eradication of C. difficile after 24 hours, leaving the 
commensal microorganisms unaffected (Nale et al., 2016, Nale et al., 2018). 
Using large-scale metagenomics sequencing (MGS) together with the Human 
Virome Protein Cluster Database (HVPC) (Elbehery et al., 2018) and the 
Human Gut Virome Database (GVD)(Gregory et al., 2019), the virome 
potential, including the active and silent virome, could be monitored in the gut 
models. Alongside the virome, the mycobiome has also been implicated in CDI. 
Marked enrichment of fungi were found in CDI patients but not in CDI negative 
controls (Sangster et al., 2016, Lamendella et al., 2018) and an over-
abundance of C. albicans in recipients was associated with FMT failure (Zuo et 
al., 2018a). Fungal sequencing could be performed on the gut model contents 
using primers for the nuclear ribosomal internal transcribed spacer (ITS) and 
the QIIME (Caporaso et al., 2010) and UNITE (Koljalg et al., 2013) 
softwares/databases. Analysing the virome and mycobiome alongside the 
bacteriome could provide valuable information on the dynamics of microbiome 
changes during CDI and CDI therapy and allow a better understanding of 
interspecies dynamics during health and disease.     
To further explore the role of biofilms in rCDI, it would be beneficial to repeat 
the experiment of the biofilm transplantation with an additional transplantation 
of the planktonic phase. This would serve two purposes, namely to replicate 
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these results by transferring the biofilm support structures into a susceptible 
model as well as provide an opportunity to transfer the planktonic phase, after 
vancomycin treatment, to seed a new model in place of a faecal slurry. This 
would remove the influence of the biofilm populations and determine whether 
any residual C. difficile in the planktonic phase is sufficient to cause rCDI. This 
experiment would require a donor model in which simulated CDI was treated 
with vancomycin. The biofilm from vessel 2 and 3 would be transplanted from 
this model into a C. difficile naïve after clindamycin treatment (as seen in 
Chapter 6, with the exception of transferring additional biofilm support 
structures) and the planktonic phase would be transferred from each vessel to 
an empty model to ensure the biofilm on the vessel walls could not contribute 
any biofilm-associated C. difficile. Both models would be monitored for 
evidence of C. difficile germination and outgrowth. A control model would be 
used to ensure successful CDI induction using a C. difficile spore preparation.    
Currently, the biofilm support structures used in the models are composed of 
glass. I believe these structures could be redesigned to be more reflective of 
the in vivo environment. Therefore, we have set out to redesign the biofilm 
support structures to more closely mimic the intestinal environment. This 
includes plans to replace the glass rods with semi-permeable structures linked 
with a mucin reservoir to simulate the action of goblet cells and facilitate the 
secretion of mucin. The structures will be 3D printed using biocompatible 
materials (such as poly lactic acid from corn starch and collagen) and printing 
will include the addition of a textured appearance to mimic microvilli. Although 
the models do not represent interactions with the host, these suggested 
alterations should provide an environment that more closely reflects those 
found in the intestinal tract, and so could provide vital information on the 
formation of biofilm in a more dynamic environment.   
During gut model experiments, the presence of the AI-2 quorum sensing 
molecule was detected in the multispecies biofilm. These levels decreased in 
accordance with antimicrobial therapy and recovered with an increase in 
species abundance and diversity. Recent work by Slater et al. (2019) described 
the effect of a C. difficile AI-2 (luxS mutant strain) deficient strain on biofilm 
formation. They found that this QS mutant was defective for biofilm formation in 
vitro; however, in co-culture, the antagonistic effect of Bacteroides fragilis on C. 
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difficile biofilm formation was alleviated with the luxS mutant. To further explore 
inter-species communication of C. difficile with other commensal 
microorganisms, we successfully created a C. difficile quorum sensing mutant 
using homologous recombination by allele exchange of the luxS gene 
(appendix A6). The use of this mutant in biofilm co-culture biofilm experiments 
could provide valuable insights into the role of quorum sensing in C. difficile 
biofilm formation and interactions with other commensal microorganisms. The 
use of this mutant in gut model experiments has distinct limitations due to the 
production of AI-2 by other biofilm-dwelling microorganisms and therefore an 
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A.3 Constituents of the culture media used to enumerate 
microbial populations 
Agar  Typical formula Amount (g/ L) 
 












































Columbia blood agar base 









Fastidious anaerobe agar with 






Sodium bicarbonate  
Glucose 
Sodium pyruvate  





Sodium succinate  















Kanamycin aesculin azide Tryptone  18.8 
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Ferric ammonium citrate 
Sodium azide 
Starch 















Bile salts No. 3 











MRS Broth (De Man, Rogosa, 
Sharpe, Oxoid) – CM0359 
Peptone 
‘Lab-Lemco’ powder 
Yeast extract  
Glucose 
Sorbitan mono-oleate 
Dipotassium hydrogen phosphate 
Sodium acetate 3H2O 
Triammonium citrate  
Magnesium sulphate 7H2O 











Nutrient agar (Oxoid) – 
PO0155A 
Protease peptone  









Oxytetracycline glucose yeast 
extract agar (Oxoid) – PO0183 

































Enumeration of planktonic populations in the repeat faecal microbiota 
transplant model. (a) Enumeration of total anaerobes (black), B. fragilis gp. 
(red), Clostridium spp. (green), Bifidobacterium spp. (purple), and spores 
(yellow). (b) Enumeration of total facultative anaerobes (black), lactose 
fermenting (LF) Enterobacteriaceae (red), Enterococcus spp. (green), and 
Lactobacillus spp. (purple). Results show bacterial population changes in 
response to antimicrobial and faecal microbiota transplant therapy. Data shown 
are the mean log10 CFU/mL ± standard error from three technical replicates per 
day of the model timeline of a single biological replicate.  Clind – clindamycin, Vanc 





Enumeration of planktonic C. difficile total and spore counts in repeat simulated 
faecal microbiota transplant model. Enumerations of C. difficile spores (red) 
and total viable counts (blue) are represented in mean log10 CFU/mL ± 
standard error (left axis). C. difficile toxin (black broken line) is represented as 
log reciprocal units (RU, right axis). No evidence of C. difficile recurrence is 
seen after the simulated faecal microbiota transplant. Different model stages 
are separated by vertical broken lines (grey; FMT instillation red). Clind – 






























Enumeration of biofilm populations in the repeat faecal microbiota transplant 
model. (a) Enumeration of total anaerobes (black), B. fragilis gp. (red), 
Clostridium spp. (green), Bifidobacterium spp. (purple), and spores (yellow). (b) 
Enumeration of total facultative anaerobes (black), lactose fermenting (LF) 
Enterobacteriaceae (red), Enterococcus spp. (green), and Lactobacillus spp. 
(purple). Results show bacterial population changes in response to 
antimicrobial and faecal microbiota transplant therapy. Data shown are the 
mean log10 CFU/mL ± standard error from three technical replicates at selected 
time points of a single biological replicate.  Clind – clindamycin, Vanc – vancomycin, 






Enumeration of C. difficile total and spore counts recovered from the biofilm in 
the repeat faecal microbiota transplant model. Bacterial enumeration of C. 
difficile total viable counts (TVC - blue) and spore counts (red). Data 
demonstrates the persistence of C. difficile cells in the biofilm through 
antimicrobial and faecal microbiota transplant therapy. Data shown are the 
mean log10 CFU/g biofilm mass ± standard error from three technical replicates 
at selected time points of a single biological replicate, at various stages 
throughout the model timeline. Clind – clindamycin, Vanc – vancomycin, FMT – faecal 












A.5 Models characterising the niche generated by 
clindamycin 
Enumeration of biofilm populations in a C. difficile naïve model during 
clindamycin treatment. (a) Enumeration of total anaerobes (black), B. fragilis 
gp. (red), Clostridium spp. (green), Bifidobacterium spp. (purple), and spores 
(yellow). (b) Enumeration of total facultative anaerobes (black), lactose 
fermenting (LF) Enterobacteriaceae (red), Enterococcus spp. (green), and 
Lactobacillus spp. (purple). Results show bacterial population changes in 
response to clindamycin therapy. Data shown are the mean log10 CFU/mL ± 
standard error from three technical replicates per day of a single biological 





Enumeration of biofilm populations in a C. difficile naïve model during 
clindamycin treatment. (a) Enumeration of total anaerobes (black), B. fragilis 
gp. (red), Clostridium spp. (green), Bifidobacterium spp. (purple), and spores 
(yellow). (b) Enumeration of total facultative anaerobes (black), lactose 
fermenting (LF) Enterobacteriaceae (red), Enterococcus spp. (green), and 
Lactobacillus spp. (purple). Results show bacterial population changes in 
response to clindamycin therapy. Data shown are the mean log10 CFU/g biofilm 
mass ± standard error from three technical replicates at selected time points of 
a single biological replicate, at various stages throughout the model timeline. 






Enumeration of biofilm populations in a simulated C. difficile infection model 
during clindamycin treatment. (a) enumeration of total anaerobes (black), B. 
fragilis gp. (red), Clostridium spp. (green), Bifidobacterium spp. (purple), and 
spores (yellow). (b) Enumeration of total facultative anaerobes (black), lactose 
fermenting (LF) Enterobacteriaceae (red), Enterococcus spp. (green), and 
Lactobacillus spp. (purple). Results show bacterial population changes in 
response to clindamycin therapy. Data shown are the mean log10 CFU/mL ± 
standard error from three technical replicates per day of a single biological 





Enumeration of planktonic C. difficile total and spore counts recovered from the 
simulated C. difficile infection model. Bacterial enumeration of C. difficile total 
viable counts (TVC - blue) and spore counts (red). Data demonstrates 
detection of C. difficile spore germination, vegetative outgrowth and toxin. Data 
shown are the mean log10 CFU/mL ± standard error from three technical 
replicates per day of a single biological replicate.  Clind – clindamycin, CD- C. 






Enumeration of biofilm populations in a simulated C. difficile model during 
clindamycin treatment. (a) Enumeration of total anaerobes (black), B. fragilis 
gp. (red), Clostridium spp. (green), Bifidobacterium spp. (purple), and spores 
(yellow). (b) Enumeration of total facultative anaerobes (black), lactose 
fermenting (LF) Enterobacteriaceae (red), Enterococcus spp. (green), and 
Lactobacillus spp. (purple). Results show bacterial population changes in 
response to clindamycin therapy. Data shown are the mean log10 CFU/g biofilm 
mass ± standard error from three technical replicates at selected time points of 
a single biological replicate, at various stages throughout the model timeline. 





Enumeration of C. difficile total and spore counts recovered from the biofilm in 
the simulated C. difficile infection model. Bacterial enumeration of C. difficile 
total viable counts (TVC - blue) and spore counts (red). Data demonstrates the 
persistence of C. difficile cells in the biofilm through clindamycin therapy. Data 
shown are the mean log10 CFU/g biofilm mass ± standard error from three 
technical replicates at selected time points of a single biological replicate, at 
various stages throughout the model timeline. Clind – clindamycin, CD – C. difficile, 





A.6 C. difficile luxS mutagenesis using homologous 
recombination by allele exchange.  
The following C. difficile mutagenesis was performed using the method 
described in Faulds-Pain and Wren (2013).  
Bacterial strains and growth conditions  
C. difficile PCR ribotype 027 strain R20291 was grown for 48 hours 
anaerobically on CBA.  Chemically competent Escherichia coli TOP10 
(Invitrogen, UK), used as a cloning host, and the conjugal donor E. coli CA434 
(supplied by Dr Anthony Buckley, University of Leeds), were cultured 
aerobically on Luria-Bertani (LB) agar, supplemented with chloramphenicol (15 
µg/mL) and kanamycin (25 µg/mL), where appropriate. Mutated C. difficile was 
routinely grown on BHISC agar plates supplemented with 5% egg yolk and 15 
µg/mL thiamphenicol, 250 µg/ mL D-cycloserine and 8 µg/ mL cefoxitin , where 
appropriate.  
Knockout plasmid construction  
Primers were designed based on the C. difficile R20291 genome sequence 
from the Artemis genome browser (Version 16.0.0, Wellcome Trust Sanger 
Institute) and all primers used are listed in Table 1. CLC Genomics Workbench 
(version 7.5.1) was used for the in silico design of the four primers (2 x 
homology arm 1 primers and 2 x homology arm 2 primers) required to generate 
the knockout (KO) luxS gene (Figures 1 and 2). To increase the frequency of 
recombination events, primers were designed to amplify approximately 1200 bp 
up- and downstream of the luxS gene. Homology arm 1 (HA1) primers were 
designed to amplify 1355 bp in total, including the first 12 bp of the luxS gene to 
incorporate the promoter sequence and start codon. Homology arm 2 (HA2) 
primers were designed to amplify a total of 1414 bp, including 15 bp of the luxS 
gene to incorporate the stop codon and an additional 50 bp of the gene due to 
any potential overlap with a promoter sequence of the adjacent gene to prevent 
downstream polar effects. Both HA1 and HA2 contained sequences to match 
the restriction sites for plasmid integration (green, Figure 2) and an overlapping 
complementary region of 25 bp (red, Figure 2). Additional primers were 
designed to amplify the entire KO construct and the primer binding site located 
outside of the HA regions. Primer binding position is represented in Figure 1. 
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Table 1. Oligonucleotides and respective binding sites and sequences  
Oligonucleotide Binding site  Sequence (5’-3’) 
CDR luxS KO HA1 
F 
Primer set to amplify 
upstream and start of CDR-
luxS –homology arm 1.  
GCGTGACGTCGACTCTAGAGGATCCGTGAGATATCTGTAAT
TAATCAACT 




CDR luxS KO HA2 
F 
Primer set to amplify 
upstream and start of CDR-
luxS –homology arm 2. 
AATGGAGGATTAAATAATGGAAAAAAATATGCAAAAGATG
TTTTA 






Primer set to confirm 






CDR_LuxS F KO confirm primer set(outside 
HA region) 
GCTGTGCTTTAACTTCAATGCTTA 
CDR_LuxS R CTCCTATTGCATCTACACCTAGACC 
CDR_LuxS F KO confirm primer set(inside 
HA region) 
ACAATGTCACACACTTCTTC 







Figure 1. The graphical representation of the C. difficile luxS gene (yellow 
arrow) and the different primer binding sites. Homology arm 1 (HA 1) forward 
and reverse primers (blue) were designed to amply the region approximately 
1200 bp before and including the start codon. Homology arm 2 (HA2) forward 
and reverse primers (purple) were designed to amplify the region approximately 
1200 bp downstream and including the stop codon. Primers located outside of 
the homology regions (luxS confirm 1F- red and luxS confirm 2R- green) were 
designed to amplify the region spanning both homology arms and the luxS 
gene.  
Using the extracted genomic DNA from C. difficile and the primers for HA1 and 
HA2, HA1 and HA2 regions were amplified using PCR (Prime Thermal Cycler, 
5PRIMEG/02, Thechne), see Table 2 for reaction and program parameters. 
PCR products were run on a 1.2 % agarose gel (gel electrophoresis in TBE 
buffer, run at 120V for 1 hour) to confirm the product size and then they were 
purified from PCR reaction mix using the QIAquick PCR Purification kit 
(Qiagen, Germany). HA1 and HA2 fragments were joined using the Gibson 
Assembly ® (New England Biolabs) (2.5 µL each HA purified fragment, 5 µL 
Gibson master mix for 50°C for 1 hour) and the product amplified using primers 
HA1 (F) and HA2 (R) (Table 1). The HA PCR product was run on a 0.8% 
agarose gel (100V for 2 hours) to confirm an approximately 2700 bp size 
product.  
The shuttle vector pMTL82151 was enzyme digested using restriction enzymes 
BamH-HF and Kpn1-HF (New England Biolabs)(1 µL each enzyme, 1 µL 
plasmid, 5 µL NE buffer made up to 50 µL with PCR grade water and kept at 
37°C for 1 hour before the reaction was stopped with the addition of gel loading 
dye). Shuttle vector pMTL83151 was initially used but failed to conjugate into 
C. difficile. The cut pMTL82151 plasmid was then run on a 0.8% agarose gel 
(80V for 2 hours) before extraction with the QIAquick Gel Extraction kit 
(Qiagen, Germany) and eluted in 30 µL PCR grade water. The pMTL82151 
luxS KO construct was assembled using the Gibson Assembly ® kit (2 µL HA 
purified construct, 5 µL Gibson master mix for 50°C for 1 hour) (Figure 2 and 







Figure 2. Graphical representation of the mutagenesis of the C. difficile luxS 
gene. (i) The primer binding sites for homology arm 1 (HA1 forward and 
reverse primers) and the primer binding sites for homology arm 2 (HA2 forward 
and reverse primers). Both sets of primers consist of a region of homology with 
the C. difficile genome (HA1 – blue arrow, HA2 – purple arrow) and either a 
region of homology with the plasmid restriction site (green) or an overlapping 
sequence (red). (ii) Once both homology arms have been amplified, the HA1 
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and HA2 PCR products are purified and assembled into a single construct (iii) 
using the Gibson assay and mediated by the overlapping sequence (red). (iv) 
The shuttle vector pMTL82151 is then enzyme digested at the multiple cloning 
site with restriction enzymes matching the sequence on the KO construct 
(green). The KO construct is then inserted into the cut plasmid using the 
Gibson assay to create a pMTL82151 plasmid carrying a mutated luxS gene.  
 
Figure 3. In silico schematic of the pMTL82151 shuttle vector with the luxS KO 
homology recombination construct inserted into the multiple cloning site. The 
green bars represent the restriction binding sites; the green arrows indicate the 
homology arm binding sites and direction. The red arrow illustrates the mutated 
luxS gene with a 391 bp deletion. Blue arrows represent genes present on the 
plasmid and include the regulatory protein A (repA), the putative plasmid 
replication protein (orf2), chloramphenicol acetyltransferase (catP), the 






The pMTL82151 luxS KO construct was then transformed into E. coli TOP10 
cells and 100 µL plated onto LB agar plates supplemented with 
chloramphenicol (15 µg/ mL) and incubated aerobically at 37°C for 24 hours to 
select for transformed cells. E. coli TOP10 was retained at room temperature 
overnight and was concentrated by centrifugation (16 000g for 3 mins) and 
plated onto fresh LB agar plates supplemented with chloramphenicol (15 µg/ 
mL) and incubated aerobically at 37°C for 24 hours. Putative colonies were 
plated onto fresh supplemented LB agar and after overnight incubation, and 
were then grown in 10 mL LB broth supplemented with chloramphenicol (15 µg/ 
mL) overnight at 37°C. 3 mL of the overnight culture was then centrifuged (16 
000g, 5 mins) and the supernatant discarded. The plasmid was extracted from 
the remaining pellet using the QIAprep Spin Miniprep kit (Qiagen, Germany). 
The homology construct within the plasmid was then amplified using plasmid 
primers flanking the insert region (Table 1). The PCR product was run on a 1% 
gel (120V for 2.5 hours) to confirm the size of an approximately 3000 bp and 
the construct was confirmed by sequencing.  
The plasmid was then transferred to heat-competent E. coli CA434 cells. 3 µL 
of the plasmid was added to E. coli CA434 cells, gently mixed and left on ice for 
20 mins followed by heat shock at 42°C for 30s and then placed at -20°C for 5 
mins. 1 mL of 37°C SOC (Invitrogen, UK) was added and left to gently shake 
for 6 hours. 100 µL of the solution was then plated onto LB agar supplemented 
with chloramphenicol (15 µg/ mL) and kanamycin (25 µg/ mL). Clones were 




Table 2. PCR reaction composition and respective PCR program settings for 
the different PCR amplification steps.  
Description PCR reaction PCR program settings  
HA1 and HA2 amplification 25 µL Phusion® high-fidelity PCR 
master mix 
0.5 µL of each primer, final 
concentration 2.5 µM 
2 µL C. difficile template DNA 
0.5 µL DMSO 
21.5 µL PCR grade water 
Initial denaturation 95°C for 5 mins  
Amplification x 30 cycles  
Denaturation 95°C for 30s 
Anneal  50°C for 30s  
Extension 68°C for 90s  
Elongation 72°C for 10  mins  
Homology arm assembly   25 µL Phusion® high-fidelity PCR 
master mix 
2 µL HA construct from the Gibson 
Assembly 
0.5 µL of HA1 (F) primer 
0.5 µL of HA2 (R) primer 
0.5 µL DMSO 
21.5 µL PCR grade water  
Initial denaturation 95°C for 5 mins  
Amplification x 30 cycles  
Denaturation 95°C for 30s 
Anneal  50°C for 30s  
Extension 68°C for 120s  
Elongation 72°C for 10  mins 
KO construct confirm 10 µL Phusion® high-fidelity PCR 
master mix 
1µL pMTL82151 plasmid 
containing KO construct  
0.3 µL of pMTL forward primer 
0.3 µL of pMTL reverse primer 
0.5 µL DMSO 
7.9 µL PCR grade water 
Initial denaturation 95°C for 5 mins  
Amplification x 30 cycles  
Denaturation 95°C for 30s 
Anneal  50°C for 30s  
Extension 68°C for 170s  
Elongation 72°C for 10  mins 
 
Conjugation  
Wild type C. difficile was grown in BHISC broth for 24 hours anaerobically. 
Overnight cultures of E. coli CA434 harbouring the KO plasmid in LB broth 
supplemented with chloramphenicol and kanamycin (15 µg/ mL and 25 µg/ mL, 
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respectively), were centrifuged at 16 000 g for 2 mins and the pellet gently 
washed in 1 mL PBS before centrifuging again as above, and the supernatant 
discarded. The E. coli pellet was then transferred to the anaerobic cabinet 
where it was gently resuspended in 200 µL of the C. difficile culture. This step 
is best carried put using a 1 mL pipette tip to avoid breaking the conjugation pili 
on the E. coli. The resultant solution was then dotted onto 4 pre-reduced 
BHISC agar plates (supplemented with 5% egg yolk) and incubated 
anaerobically for 24 hours. All growth was scraped off the culture plates and 
resuspended in pre-reduced PBS. This was then plated out neat or 1:10 
dilution on pre-reduced BHISC agar (supplemented with 5% egg yolk, 15 µg/ 
mL thiamphenicol, 250 µg/ mL D-cycloserine and 8 µg/ mL cefoxitin) and 
incubated for 3 days anaerobically. The largest colonies after 3 days growth 
were restreaked onto fresh supplemented BHISC media, as above, and this 
process was repeated three times to allow for the first crossover event to occur. 
The second crossover event was mediated by restreaking the cells from the 
selective plates on to non-selective media (BHISC supplemented with 5% egg 
yolk) and incubated anaerobically for 24 hours. This step was repeated five 
times before colonies were patch plated on non-selective (BHISC 
supplemented with 5% egg yolk) and selective (BHISC supplemented with 5% 
egg yolk and 15 µg/ mL thiamphenicol) media. C. difficile colonies with growth 
on non-selective media and no growth on selective media were indicative of 
double crossovers. These clones were checked by PCR to look for mutants 
and wild type revertants and the former was sent for sequencing to confirm no 
errors at the gene loci. The mutants contained a 391 bp deletion in the luxS 
gene, however, start and stop codons where still present, thus preventing polar 
effects of downstream genes.  
 
 
